|
|
||||||||
Physiological Reviews, Vol. 79, No. 4, October 1999, pp. 1283-1316
Copyright ©1999 by the American Physiological Society
Ludwig Institute for Cancer Research, Biomedical Center, and Department of Pathology, University Hospital, Uppsala, Sweden
I. INTRODUCTION
II. PLATELET-DERIVED GROWTH FACTOR ISOFORMS
A. Structure of PDGF
B. Biosynthesis and Processing of PDGF
C. PDGF Genes
D. Expression of PDGF
E. Retention Sequence in the COOH Terminus of PDGF
F. PDGF Binding Proteins
G. Receptor Binding Epitopes in PDGF
H. Conclusions
III. PLATELET-DERIVED GROWTH FACTOR RECEPTORS
A. Structure of PDGF Receptors
B. Homo- and Heterodimeric Receptor Complexes
C. Cellular Effects Mediated by PDGF Receptors
D. Expression of PDGF Receptors
E. Activation of PDGF Receptors Through Dimerization
F. Conclusions
IV. INTRACELLULAR SIGNAL TRANSDUCTION
A. Autophosphorylation of PDGF Receptors
B. Binding of SH2 Domain Proteins to PDGF Receptors
C. PI 3-Kinase
D. PLC-
E. Src
F. Grb2/Sos
G. SHP-2
H. GAP
I. Stat
J. Adaptors
K. Control of PDGF Signaling
L. Different Signaling Via Homodimeric and Heterodimeric Receptor Complexes
M. Cooperation With Integrin Signaling
N. Conclusions
V. INTERNALIZATION AND DEACTIVATION OF PLATELET-DERIVED GROWTH FACTOR RECEPTORS
VI. NORMAL IN VIVO FUNCTION OF PLATELET-DERIVED GROWTH FACTOR
A. Embryonic Development
B. CNS
C. Vascular System
D. Tissue Homeostasis
E. Wound Healing
F. Conclusions
VII. PLATELET-DERIVED GROWTH FACTOR IN DISEASE
A. PDGF in Autocrine Transformation
B. PDGF in Human Oncogenesis
C. Atherosclerosis
D. Lung Fibrosis
E. Kidney Fibrosis
F. Other Fibrotic Conditions
G. Conclusions
VIII. PLATELET-DERIVED GROWTH FACTOR ANTAGONISTS
IX. FUTURE PERSPECTIVES
| |
ABSTRACT |
|---|
|
|
|---|
Heldin, Carl-Henrik and
Bengt Westermark.
Mechanism of Action and In Vivo Role of Platelet-Derived
Growth Factor. Physiol. Rev. 79: 1283-1316, 1999.
Platelet-derived growth
factor (PDGF) is a major mitogen for connective tissue cells and
certain other cell types. It is a dimeric molecule consisting of
disulfide-bonded, structurally similar A- and B-polypeptide
chains, which combine to homo- and heterodimers. The PDGF isoforms
exert their cellular effects by binding to and activating two
structurally related protein tyrosine kinase receptors, denoted the
-receptor and the
-receptor. Activation of PDGF receptors leads
to stimulation of cell growth, but also to changes in cell shape and
motility; PDGF induces reorganization of the actin filament system and
stimulates chemotaxis, i.e., a directed cell movement toward a gradient
of PDGF. In vivo, PDGF has important roles during the embryonic
development as well as during wound healing. Moreover, overactivity of
PDGF has been implicated in several pathological conditions. The
sis oncogene of simian sarcoma virus (SSV) is related to the
B-chain of PDGF, and SSV transformation involves autocrine
stimulation by a PDGF-like molecule. Similarly, overproduction of
PDGF may be involved in autocrine and paracrine growth stimulation of
human tumors. Overactivity of PDGF has, in addition, been implicated in
nonmalignant conditions characterized by an increased cell
proliferation, such as atherosclerosis and fibrotic conditions. This
review discusses structural and functional properties of PDGF and PDGF
receptors, the mechanism whereby PDGF exerts its cellular effects, and
the role of PDGF in normal and diseased tissues.
| |
I. INTRODUCTION |
|---|
|
|
|---|
Platelet-derived growth factor (PDGF) is a major mitogen for
fibroblasts, smooth muscle cells, and other cells (for reviews, see
Refs. 183, 377). Originally, PDGF was identified as a constituent of
whole blood serum that was absent in cell-free plasma-derived serum
(252, 396, 494); PDGF was
subsequently purified from human platelets (19,
97, 184, 379). Although the
-granules of platelets are a major storage site for PDGF, recent
studies have shown that PDGF can be synthesized by a number of
different cell types.
Studies of PDGF and PDGF receptor gene targeting in mice have shown that PDGF has important functions as paracrine growth factor in development. Moreover, aberrant synthesis of PDGF and concomitant autocrine growth stimulation may be an important step in the neoplastic conversion of PDGF receptor-positive cells. Here, we describe the most important features of PDGF and PDGF receptors with regard to structure, signal transduction, and physiological and pathophysiological role in vivo.
| |
II. PLATELET-DERIVED GROWTH FACTOR ISOFORMS |
|---|
|
|
|---|
A. Structure of PDGF
Platelet-derived growth factor is a family of cationic homo- and heterodimers of disulfide-bonded A- and B-polypeptide chains. The mature parts of the A- and B-chains of PDGF are ~100 amino acid residues long and show ~60% amino acid sequence identity. Eight cysteine residues are perfectly conserved between the two chains; a similar spacing between cysteine residues is seen also in members of the vascular endothelial cell growth factor (VEGF) family (VEGF, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor) (reviewed in Ref. 219). Two of the cysteine residues (the second and the fourth) are involved in cysteine bonds between the two subunits in the PDGF dimer, and the other six are engaged in intrachain disulfide bonds (the first pairs with the sixth, the third with the seventh, and the fifth with the eighth) (166, 167, 340). Mutation of the interchain disulfide bonds is compatible with retained biological activity of PDGF (12, 238), presumably because the molecule still occurs as a dimer (371).
Platelet-derived growth factor-BB has been crystallized and its
three-dimensional structure solved at 3.0 Å resolution
(328). The two subunits in the dimer are arranged in an
antiparallel manner. They consist of a tight knotlike structure in
which one of the intrachain disulfides goes through the hole formed by
the other two and the intervening sequences. From the cystine knot, two
large loops stabilized by
-sheet interactions extend in one direction (loops 1 and 3) and a shorter loop 2 points in the opposite direction. Because of the antiparallel arrangement of the molecule, loops 1 and 3 of one subunit in the dimer will be close to loop 2 of
the other.
The three-dimensional structure of PDGF-BB is not only
similar to that of VEGF, which has a related amino acid sequence
(313), but also shows some resemblance to those of nerve
growth factor and transforming growth factor-
(TGF-
), despite
the fact that the latter factors have no sequence similarity with PDGF
(315). All these factors are dimers and show the
characteristic cystine knot structure.
B. Biosynthesis and Processing of PDGF
Both the A-chain and the B-chain of PDGF are synthesized as precursor molecules that undergo proteolytic processing in the NH2 termini and, in the case of the B-chain, in the COOH terminus (Fig. 1) (337). The mature native PDGF isoforms migrate in SDS-gel electrophoresis as components of ~30 kDa, whereas the reduced chains migrate as 15-kDa components. The A-chain has one potential site for attachment of N-linked carbohydrates, but PDGF is most likely not glycosylated. Recombinant PDGF has been produced in mammalian cells (339), baculovirus-infected cells (142), and yeast cells (236, 338) as well as in bacteria (111, 197).
|
Human platelets and cultures of cell lines naturally expressing both A- and B-chains contain all three PDGF isoforms, suggesting that the assembly of PDGF dimers is a random process (162, 164, 171). This notion is further supported by the observation that cells transfected with both A- and B-chains make all three isoforms (339) and that bacterially made PDGF chains can be assembled in vitro into homo- as well as heterodimers (198).
C. PDGF Genes
The genes for the A- and B-chains for PDGF are located on chromosomes 7 and 22, respectively (43, 89, 460). They are organized in a similar manner with seven exons. In each case exon 1 encodes the signal sequence, exons 2 and 3 encode precursor sequences that are removed during processing, exons 4 and 5 encode most of the mature protein, and exon 7 is mainly noncoding (61, 217, 394). Exon 6 encodes a COOH-terminal sequence that may be removed during the maturation of the B-chain; the A-chain occurs as two different splice forms, with and without the exon 6-encoded sequence.
D. Expression of PDGF
Platelet-derived growth factor is synthesized by many different cell types (Table 1). The synthesis is often increased in response to external stimuli, such as exposure to low oxygen tension (253), thrombin (90, 169), or stimulation with various growth factors and cytokines (reviewed in Ref. 42). Expression of PDGF-A also increases in human uterine smooth muscle cells during the physiological hypertrophy of pregnancy (299). Most cell types expressing PDGF make both A- and B-chains, but the expression of the two chains are independently regulated at the transcriptional as well as posttranscriptional levels (reviewed in Ref. 102).
|
The 3.5-kb PDGF B-chain mRNA has an ~1-kb-long 5'-untranslated sequence that contains stable secondary structures and three small open reading frames, and it therefore acts as a potent translational inhibitor. The 5'-untranslated region contains an internal ribosomal entry site, which becomes more potent in the erythroleukemia cell line K562 upon their differentiation to megakaryocytic cells (38). Moreover, additional PDGF-B transcripts have been described; a 2.8-kb transcript that is present in endothelial cells lacks the long 5'-untranslated sequence and appears to be initiated from within the first exon genomic sequence (118), and a 2.6 kb transcript that is present in JEG-3 cells initiates at an alternative exon located in intron 1 (103). These alternative transcripts thus lack the translational inhibitory effect exerted by the exon 1 sequence of the 3.5-kb transcript. Interestingly, the expression of a 2.6-kb PDGF-B mRNA, lacking the inhibitory 5'-untranslated sequence, was found to correlate with increased PDGF B-chain immunoreactivity during rat brain development (408).
The PDGF-B gene promoter has been found to contain a regulatory
element, called Sis proximal element (SPE), at nucleotides
64 to
45
(104, 211, 212,
240). A CACCC motif within SPE that binds Sp1 and Sp3
transcription factors is important for transcription of the PDGF-B
gene in U-2OS osteosarcoma cells (273) and in K562 cells
(274). Consensus binding sites for AP-1-like and
Ets-like transcription factors were also observed at nucleotides
92 to
85 and
80 to
70, respectively (240).
Elements involved in thrombin-induced PDGF-B transcription in
endothelial cells (412) and in
12-O-tetradecanoylphorbol 13-acetate (TPA)-dependent promoter activation in K562 cells (352), have also been
identified, as well as a shear-stress response element in
endothelial cells (383) that is activated by NF
B
(240, 241). An enhancer-like transcriptional activator region composed of at least two distinct elements that is active in the choriocarcinoma cell line JEG-3 has also
been identified in the first intron of the PDGF-B gene (131). There is also evidence for negative regulation of
the PDGF-B promoter since cultured dermal fibroblasts contain a
transcriptional activator for the PDGF-B promoter but do not
express the protein (101). No silencer could, however, be
identified in a region from
12 to
25 kb relative to the
transcription start site (101); the mechanism for
inhibition of PDGF-B transcription, thus, remains to be elucidated.
Analysis of somatic cell hybrids between PDGF-B expressing melanoma
cells and hamster fibroblasts revealed that the negative regulation of
the B-chain is probably mediated by a trans-acting
factor (269).
Also, the transcription of the PDGF-A gene is regulated by positive
and negative regulatory elements. A GC-rich region located at
nucleotides
115 to
33 has been shown to contribute >80% promoter activity (220). The region contains three consensus Sp1
binding sites and two overlapping Egr-1 sites. In smooth muscle cells, Sp1 and the related Sp3 bind to the region and activate the A-chain promoter independently or additively (431). A variety of
stimuli, including TPA, PDGF, and mechanical injury, induce Egr-1
expression in smooth muscle cells; the induced Egr-1 displaces members
of the Sp family and activates the PDGF-A promoter further
(431). Egr-1 is also involved in activation of a
shear-stress-response element in the A-chain promoter in
endothelial cells (239). In mesangial cells, TPA induces
the synthesis of a nuclear protein, PDGF-A gene binding protein-1,
which binds to the sequence
102 to
82 relative to the transcription
start site (45). Elements located at nucleotides
223 to
135 and
71 to
55 have been shown to be important for
serum-induced and TPA-induced expression of PDGF-A,
respectively (242, 461). Methylation of the
PDGF-A gene promoter in vitro was found to repress its activity
(278).
The expression of PDGF-A is repressed by several stimuli, such as
glucocorticoid treatment of smooth muscle cells (318) and aging of human fibroblasts (226). Several regions involved
in negative regulation of the PDGF-A gene have been identified. The nucleotide sequences located between
1029 and
883 and between
1800 and
1029 exert negative control of the PDGF-A gene in the renal epithelial cell line BSC-1 (221, 282).
Moreover, the Wilms' tumor suppressor gene product (WT1) binds to
several sites in the region
643 to
8, relative to the transcription
start site, and functions as a powerful repressor of the A-chain
(136, 491). Platelet-derived growth
factor-A is overexpressed in certain Wilms' tumors; it is
therefore possible that loss of WT1 may lead to overexpression of
PDGF-A and thereby contribute to the etiology of the tumor. There
is also a negatively acting control element in the first intron that is
active in HeLa cells but not in A172 glioblastoma cells
(326, 492).
E. Retention Sequence in the COOH Terminus of PDGF
In both the A- and B-chains, exon 6 encodes a basic sequence that mediates interaction with components of the extracellular matrix and also may cause retention inside the producer cell (237, 264, 336, 367, 380). Platelet-derived growth factor binds to various types of collagens (440), thrombospondin (193), and BM-40/osteopontin/SPARC (378); however, the major component of the matrix involved in PDGF binding is likely to be heparan sulfate (286). The binding involves an electrostatic interaction between basic residues in the retention motif (14, 286) and negatively charged groups in heparan sulfate, including N-sulfated saccharide domains containing both 2-O- and 6-O-sulfate groups (121).
The precursor of the B-chain may thus be retained in the matrix; after maturation when the COOH-terminal retention sequence has been cleaved off, the molecule may become more diffusible. Moreover, the compartmentalization of the two splice forms of the A-chain of PDGF may be different. The more common short splice form of the A-chain, which lacks the COOH-terminal retention motif, may diffuse more easy through the tissue and affect cells at some distance from the producer cell, whereas the long form with the retention motif will be restricted to stimulate the producer cell and cells in the immediate environment. The availability of matrix-stored PDGF may also be regulated by proteolysis of matrix molecules (122, 251, 446).
F. PDGF Binding Proteins
Platelet-derived growth factor does not only interact with matrix
molecules but also with soluble proteins. Like many other cytokines,
PDGF binds to
2-macroglobulin (reviewed in Ref. 260). This interaction, which involves PDGF-BB but not PDGF-AA
(59), regulates the amount of PDGF available for
interaction with receptors. Another PDGF binding protein was isolated
from a rat neural retina cell line and called PDGF-associated
protein (PAP) (124). PAP binds PDGF with low affinity and
was found to enhance the activity of PDGF-AA but depress the
activity of PDGF-BB. Moreover, the extracellular part of PDGF
-receptor (see sect. III) has been detected in normal human
plasma; it is possible that such circulating soluble receptors can
compete with cell-associated PDGF receptors for ligand binding
(466).
G. Receptor Binding Epitopes in PDGF
With the use of site-directed mutagenesis, the receptor
binding epitopes in PDGF have been localized. The amino acid residues most important for receptor binding are localized in loops 1 and 3, but
loop 2 is also involved (13, 81,
119, 265, 335). Thus each PDGF
molecule contains two symmetric receptor binding epitopes, each one
built up by structures from both chains in PDGF. Platelet-derived
growth factor-BB interacts with
- and
-receptors with similar
affinity. The interaction appears to involve overlapping but not
identical regions in the ligand, since residues in loop 2 are more
important for binding to the
-receptor than to the
-receptor
(13).
H. Conclusions
Platelet-derived growth factor is a family of heterodimeric or homodimeric isoforms of A- and B-polypeptide chains that are synthesized as precursor molecules undergoing proteolytic maturation. The synthesis of PDGF isoforms is carefully regulated, and their action on receptors is modulated by interaction with components in the matrix as well as with soluble binding proteins.
| |
III. PLATELET-DERIVED GROWTH FACTOR RECEPTORS |
|---|
|
|
|---|
A. Structure of PDGF Receptors
Platelet-derived growth factor isoforms exert their effects on
target cells by activating two structurally related protein tyrosine
kinase receptors. The
- and
-receptors have molecular sizes of
~170 and 180 kDa, respectively, after maturation of their carbohydrates. Extracellularly, each receptor contains five
immunoglobulin-like domains, and intracellularly there is a
tyrosine kinase domain that contains a characteristic inserted sequence
without homology to kinases (78, 295,
505). The structures of PDGF receptors are similar to
those of the colony stimulating factor-1 (CSF-1) receptor
(85) and the stem cell factor (SCF) receptor
(506).
The human
-receptor gene is localized on chromosome 4q12, close to
the genes for the SCF receptor and VEGF receptor-2 (448), and the
-receptor gene is on chromosome 5 (505) close
to the CSF-1 receptor gene (390).
B. Homo- and Heterodimeric Receptor Complexes
Because PDGF isoforms are dimeric molecules, they bind two
receptors simultaneously and thus dimerize receptors upon binding (49, 180, 418). The
-receptor
binds both the A- and B-chains of PDGF with high affinity, whereas
the
-receptor binds only the B-chain with high affinity.
Therefore, PDGF-AA induces 
-receptor homodimers, PDGF-AB

-receptor homodimers or 
-receptor heterodimers, and
PDGF-BB all three dimeric combinations of
- and
-receptors (Fig. 1) (163, 223, 418).
C. Cellular Effects Mediated by PDGF Receptors
The three dimeric PDGF receptor combinations transduces
overlapping, but not identical, cellular signals. Whereas the
heterodimeric receptor complex may have unique properties (see sect.
IVL), most information is available
about the functional roles of PDGF receptor homodimers (Table
2). Both
- and
-receptor homodimers
transduce potent mitogenic signals. There is, however, a difference
between the receptors regarding their effects on the actin filament
system. Whereas both receptors stimulate edge ruffling and loss of
stress fibers, only the
-receptor mediates the formation of circular actin structures on the dorsal surface of the cell (113).
Moreover, activation of the
-receptor stimulates chemotaxis; in
contrast, activation of the
-receptors inhibits chemotaxis of
certain cell types including fibroblasts and smooth muscle cells
(255, 429, 513), whereas
chemotaxis of certain other cell types is stimulated (201,
334, 428, 515). Both the
-receptor and the
-receptor mediate an increase in intracellular
Ca2+ concentration, albeit the
-receptor more
efficiently than the
-receptor; pretreatment with PDGF-AA
depressed the Ca2+ mobilization after PDGF-BB
stimulation (100). Platelet-derived growth factor also
inhibits gap junctional communication between cells (202)
and exerts an antiapoptotic effect (504).
|
D. Expression of PDGF Receptors
Because there are differences between
- and
-receptors in
their binding specificity of PDGF isoforms and in the signals they
transduce, the response of a cell to PDGF stimulation will be
determined by which of the two receptor types the cell expresses. The
classical target cells for PDGF, fibroblasts and smooth muscle cells,
express both
- and
-receptors, but generally higher levels of
-receptors (Table 3). Other cell types
express only
-receptors, such as the O-2A glial precursor cells
(174), human platelets (478), and rat liver
endothelial cells (186), whereas other cell types express
only
-receptors, such as mouse capillary endothelial cells
(435).
|
Importantly, the level of PDGF receptor expression on cells is not
constant. For instance, the expression of
-receptors on connective
tissue cells in vivo is low but increases during inflammation (400) or after explantation into tissue culture
(465). Moreover, estrogen treatment increases both
-
and
-receptors and PDGF in mouse uterus and vagina
(151). On the other hand, stimulation with basic
fibroblast growth factor (bFGF) selectively increases the expression of
the
-receptor, but not the
-receptor, in vascular smooth muscular
cells (416) and in bronchial smooth muscle cells (56), and lipopolysaccharide upregulates the
-receptor
but not the
-receptor in rat lung myofibroblasts (83).
Moreover, interleukin (IL)-1
and tumor necrosis factor (TNF)-
induce the
-receptor in osteoblast cultures from fetal rat bone
(75, 468). On the other hand, IL-1
downregulates the
-receptor in human osteoblastic cells
(500). Also, TGF-
stimulation of fibroblasts or
mesothelial cells leads to a decrease in the expression of the
-receptor (57, 154, 262,
349). Protein kinase C (PKC) seems to be involved in
negative regulation of the
-receptor, since overexpression of
PKC-
suppressed the expression of the
-receptor but not the
-receptor (125).
The
-receptor promoter has been isolated (4,
232, 489) and shown to contain a binding site
for the transcription factor GATA-4, which is responsible for parietal
endoderm-specific
-receptor expression (488). A
region between nucleotides
246 and
139, relative to the
transcriptional initiation site, was found to enhance the promoter
activity in spontaneously hypertensive rats, but not normal rats
(248). Also, the mouse
-receptor promoter has been
isolated (24); nuclear factor Y was found to control its
basal transcription activity (209).
E. Activation of PDGF Receptors Through Dimerization
A common theme for activation of tyrosine kinase receptors is ligand-induced receptor dimerization, which juxtaposes the intracellular parts of the receptors and allows autophosphorylation of tyrosine residues in trans between the two receptors in the dimer (reviewed in Ref. 181).
Because PDGF is a dimeric molecule, it can bind two receptors
simultaneously and thus form a bridge between the receptors. The ligand
binding epitopes in PDGF
- and
-receptors are located in the
three outermost Ig domains (177, 516); Ig
domain 2 appears to be most important for ligand binding
(285, 288, 302). The situation
is analogous for VEGF, which binds with high affinity to Ig domain 2 of
VEGF receptor-1, a tyrosine kinase receptor with seven Ig domains
extracellularly; in this case, detailed information of the interaction
is available following the crystallization of VEGF in complex with Ig
domain 2 of the receptor (496).
In addition to the bridging effect of PDGF, the dimeric receptor complex is further stabilized by direct receptor-receptor interactions mediated by Ig domain 4 (285, 331, 426). The corresponding Ig domain in the SCF receptor (53), and in VEGF receptor-1 (27), is also involved in direct receptor-receptor interactions. Moreover, the complex between growth hormone and its receptor, for which the three-dimensional structure is known through crystallization, also involves direct receptor-receptor interactions. Thus, whereas receptor dimerization is driven by ligand binding, ligand-receptor complexes are often stabilized by direct interactions between receptors.
F. Conclusions
Isoforms of PDGF exert their cellular effects by inducing homo- or
heterodimeric complexes of
- and
-tyrosine kinase receptors, resulting in cell growth, chemotaxis, actin reorganization, and prevention of apoptosis. The
- and
-receptors are expressed on
overlapping but distinct cell types; the level of receptors at the cell
surface can be modulated by external stimuli.
| |
IV. INTRACELLULAR SIGNAL TRANSDUCTION |
|---|
|
|
|---|
A. Autophosphorylation of PDGF Receptors
The autophosphorylation induced after dimerization of PDGF
receptors serves two important functions. On one hand, phosphorylation of a conserved tyrosine residue inside the kinase domains (Tyr-849 in
the
-receptor and Tyr-857 in the
-receptor) leads to an increase in the catalytic efficiencies of the kinases, as has been demonstrated for the PDGF
-receptor (116, 234) and the
receptors for insulin (495), hepatocyte growth factor
(319), fibroblast growth factor (303), and
brain-derived neurotrophic factor (158). On the other hand, autophosphorylation of tyrosine residues located outside the
kinase domain creates docking sites for signal transduction molecules
containing SH2 domains.
B. Binding of SH2 Domain Proteins to PDGF Receptors
The SH2 domain is a conserved motif of ~100 amino acid residues that can bind a phosphorylated tyrosine in a specific environment (reviewed in Ref. 350). Recent observations have shown that signal transduction molecules contain several different types of motifs that mediate interactions between different components in signaling pathways. In addition to SH2 domains, also PTB domains recognize phosphorylated tyrosine residues. Moreover, SH3 domains recognize proline-rich sequences, PH domains membrane phospholipids, and PDZ domains COOH-terminal valine residues in specific sequence contexts (350).
A large number of SH2 domain proteins have been shown to bind to PDGF
- and
-receptors (Table 4). Some of
these molecules are themselves enzymes, such as phosphatidylinositol
3'-kinase (PI 3-kinase), phospholipase C (PLC)-
, the Src family of
tyrosine kinases, the tyrosine phosphatase SHP-2, and a GTPase
activating protein (GAP) for Ras. Other molecules such as Grb2, Grb7,
Nck, Shc, and Crk are devoid of enzymatic activity and have adaptor functions, linking the receptor with downstream catalytic molecules. Also, members of the Stat family bind to the PDGF receptors. They are
transcription factors that after phosphorylation on tyrosine dimerize
and translocate into the nucleus where they affect the transcription of
specific genes. Each SH2 domain molecule that binds to the PDGF
receptors initiates a signal transduction pathway. The more important
and well-characterized signaling pathways activated by PDGF
receptors are described below. For a more comprehensive discussion, see
Reference 182.
|
C. PI 3-Kinase
Members of the PI 3-kinase family that bind to and are activated by tyrosine kinase receptors consist of a regulatory subunit, p85, and a catalytic subunit, p110. Their preferred substrate is phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2], which is phosphorylated to phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3].
Phosphatidylinositol 3'-kinase has a central role in intracellular signal transduction; it can be activated by several different signals, it has a number of downstream effector molecules, and it mediates many different cellular responses, including actin reorganization, chemotaxis, cell growth, and antiapoptosis (reviewed in Ref. 476). The precise roles of the different effector molecules in the various responses remain to be elucidated. However, members of the Rho family of small GTPases, and in particular Rac, seem to be important for actin reorganization (175) and chemotaxis (195), and the serine/threonine kinase Akt/PKB for the antiapoptotic effect (106, 231).
D. PLC-
Phospholipase C-
acts on the same substrate as PI 3-kinase,
i.e., PI(4,5)P2; the products, inositol
1,4,5-trisphosphate and diacylglycerol, mobilize intracellular
Ca2+ from internal stores and activate certain members of
the PKC family, respectively (39). The binding of PLC-
to the PDGF receptor leads to its phosphorylation on specific tyrosine
residues, whereby its catalytic activity increases (298,
485). Interestingly, full activation of PLC-
is
dependent on PI 3-kinase; the PI(3,4,5)P3 formed by PI 3-kinase binds the PH domain of PLC-
and may anchor the
enzyme at the membrane (115). Phospholipase C-
appears
not to be of primary importance for the stimulation of cell growth and
motility in most cell types; however, in certain cell types, PLC-
affects these responses (reviewed in Ref. 222).
E. Src
Members of the Src family of tyrosine kinases are characterized by
the presence of one SH3 domain and one SH2 domain in addition to the
catalytic domain. In its inactive configuration, a phosphorylated COOH-terminal tyrosine residue in Src is involved in an
intermolecular interaction (reviewed in Ref. 114). The binding of the
SH2 domain to autophosphorylated PDGF receptors, in conjunction with
dephosphorylation of the COOH-terminal phosphorylated tyrosine and
phosphorylation of other tyrosines in the molecule, activates Src. Src
appears to be important for the mitogenic response of PDGF, since
microinjection of blocking antibodies or a dominant negative Src
molecule inhibit cell growth (reviewed in Ref. 114). However, direct
binding of Src to the PDGF
-receptor is not necessary for mitogenic
signaling via this receptor (196).
F. Grb2/Sos
Grb2 is an adaptor molecule with one SH2 domain and two SH3 domains; the latter domains mediate binding of Sos, a nucleotide exchange factor for Ras which converts inactive Ras·GDP to active Ras·GTP (reviewed in Ref. 414). The SH2 domain of Grb2 can bind directly to autophosphorylated PDGF receptors, or indirectly via other components, such as Shc or SHP-2; after binding to PDGF receptors, these molecules become phosphorylated on tyrosine residues that can be recognized by the SH2 domain of Grb2.
Activation of Ras is of major importance for several cellular responses. Activated Ras binds to the serine/threonine kinase Raf-1 that initiates activation of the mitogen-activated protein (MAP) kinase cascade, a pathway which is implicated in stimulation of cell growth, migration, and differentiation. Interestingly, there is a cross-talk between Ras and PI 3-kinase, which interact physically and can activate each other (203, 392).
G. SHP-2
SHP-2 is a ubiquitously expressed tyrosine phosphatase with two SH2 domains, both of which need to bind to phosphorylated tyrosine residues for full activation of the catalytic activity (366).
Through its ability to dephosphorylate autophosphorylated PDGF receptors (250) and substrates for the PDGF receptors, SHP-2 is a potential negative modulator of signaling from the PDGF receptors. However, SHP-2 may also be involved in positive signaling through its ability to act as an adaptor that binds Grb2/Sos and thus to contribute to Ras activation (272), and through its ability to dephosphorylate the COOH-terminal tyrosine residue of Src and thus to contribute to Src activation (393a, 454).
H. GAP
GTPase activating protein binds to PDGF
-receptors but not to
-receptors (178). It converts Ras · GTP to
Ras · GDP and thus has a modulatory role in Ras activation by PDGF
receptors (475). The magnitude of Ras activation in
PDGF-stimulated cells will thus be dependent on stimulatory as well
as inhibitory signals.
I. Stat
The family of Stat molecules has seven members of which Stat1,
Stat3, Stat5a and -
, and Stat6 have been shown to bind to the
activated PDGF
-receptor and to be phosphorylated after PDGF stimulation; binding also occurs to the
-receptor, albeit only weakly (347, 474, 482). After
phosphorylation on tyrosine, Stats dimerize and translocate to the
nucleus, where they act as transcription factors (reviewed in Ref. 92).
Stat molecules are important for the transduction of signals downstream
of cytokine receptors; however, their importance in PDGF signaling
remains to be elucidated.
J. Adaptors
Adaptors are molecules that are devoid of intrinsic catalytic activity; after binding to the PDGF receptors through their SH2 domains, they connect the receptor with downstream effector molecules. The regulatory subunits of PI 3-kinase and Grb2, which form complexes with the catalytic subunit of PI 3-kinase and Sos, respectively, are examples of adaptor molecules that have been discussed already. Other adaptor molecules that bind to PDGF receptors are Shc, Grb7, Nck, and Crk.
After binding of Shc to the PDGF receptors, it becomes phosphorylated
on Tyr-317, which can be recognized by Grb2/Sos and thus contributes to
Ras activation (398), as well as on Tyr-239 and Tyr-240,
which initiates another signaling pathway leading to induction of
c-myc (148). The SH2 domain of Grb7 has similar binding specificity to that of Grb2 (452,
512); its role in PDGF signaling remains to be determined.
Nck is involved in activation of the JNK/SAPK serine/threonine kinase
through interaction with the serine/threonine kinases PAK1 and NIK
(55, 456). Crk, which is the only SH2 protein
known that binds with significantly higher affinity to the
-receptor
than to the
-receptor (511), forms a complex with the
docking protein Cas and the nucleotide exchange protein C3G, which has
been linked to the activation of JNK/SAPK (462).
K. Control of PDGF Signaling
Several mechanisms for modulation of signaling via PDGF receptors have been elucidated. For instance, MAP kinase, which is activated by Ras, phosphorylates and inactivates Sos, which thereby leads to a decreased Ras activation (369). Another negative-feedback mechanism involves cAMP-dependent protein kinase, which is activated by PDGF through induction of prostaglandin synthesis and activation of adenylyl cyclase (150); the cAMP-dependent protein kinase inhibits several of the pathways that are activated in PDGF-stimulated cells through phosphorylation of components in these pathways. Moreover, angiotensin II has been shown to delay PDGF-BB-induced DNA synthesis in vascular smooth muscle cells; the mechanism behind the effect remains to be elucidated (88).
A striking feature of PDGF signaling is that the strength of signals is modulated by the simultaneous activation of stimulatory and inhibitory signals. Thus the tyrosine phosphorylation induced by the PDGF receptors is balanced by activation of tyrosine phosphatases by PDGF. SHP-2 is one example that has been discussed above, but also other tyrosine phosphatases may be involved (40, 305). Another example is the binding of GAP to the receptor, which will counteract the Ras activation induced by Grb2/Sos binding to the receptor.
L. Different Signaling Via Homodimeric and Heterodimeric Receptor Complexes
Homodimeric 
- and 
-receptor complexes give overlapping
but distinctly different effects on target cells (Table 2), which can
be explained by differential interactions with various SH2 domain
proteins (Table 4). The finding that PDGF-AB gives stronger mitogenic and chemotactic effects on cells expressing both
- and
-receptors (179, 401) suggests that the
heterodimeric 
-receptor complex may have unique properties. One
mechanism for such a difference would be if receptors in a
heterodimeric complex were autophosphorylated on different tyrosine
residues compared with in the homodimeric receptor complexes. This
possibility was substantiated by the findings that Tyr-754 in the
-receptor was phosphorylated to a higher degree in the heterodimer
compared with the homodimer (401) and that Tyr-771 in the
-receptor was phosphorylated to a higher degree in the homodimer
compared with the heterodimer (111a).
M. Cooperation With Integrin Signaling
Most of the cell types that are responsive to PDGF are anchorage dependent, i.e., they are dependent for their growth on contacts with matrix molecules surrounding the cell. Such contacts are mediated by integrins, which are transmembrane receptors for matrix molecules. Binding of integrins to their specific extracellular matrix molecules leads to the formation of focal adhesions with the assembly of a large complex of signaling molecules around the cytoplasmic tails of integrins, including Src, PI 3-kinase, and Ras (reviewed in Ref. 79). Integrin signaling enhances growth factor-mediated cell proliferation and cell migration and is necessary to prevent apoptosis (20, 133). On the other hand, fibrillar collagen suppresses PDGF-induced DNA synthesis in arterial smooth muscle cells (256). This effect is likely to be mediated by an integrin-dependent suppression of cyclin E-Cdk2 activity.
A molecular basis for a cooperation between integrins and PDGF was
unravelled by the demonstration that a highly phosphorylated subfraction of PDGF
-receptors forms a complex with
v
3-integrins (415).
Moreover, engagement of
1-integrins by plating of
fibroblasts on collagen or fibronectin caused a transient tyrosine
phosphorylation of PDGF receptors in the absence of PDGF
(459). On the other hand, PDGF simulates the synthesis of
the collagen binding integrin
2
1
(5, 246). A specificity in the cooperation
between PDGF and integrins has been observed since PDGF was found to
stimulate
2-integrin mRNA accumulation when cells were
grown on collagen, but
3- and
5-integrin
mRNA accumulation when cells were grown on fibronectin
(501).
N. Conclusions
Ligand-induced PDGF receptor activation causes autophosphorylation of the receptors, which leads to increased catalytic activity of the kinases and to the formation of docking sites for downstream signal transduction molecules containing SH2 domains. Therefore, a number of signaling pathways are initiated, leading to different cellular responses. Signaling is modulated positively and negatively, extracellularly through interaction with matrix molecules and intracellularly through cross-talk with different signaling pathways.
| |
V. INTERNALIZATION AND DEACTIVATION OF PLATELET-DERIVED GROWTH FACTOR RECEPTORS |
|---|
|
|
|---|
Platelet-derived growth factor receptors are not uniformly
distributed in the cell membrane, but rather concentrated in caveolae, distinct membrane invaginations which are involved in endocytosis (284). Ligand binding induces internalization of the
ligand-receptor complex into endosomes (443). The
PDGF-receptor complex then dissociates, and the receptor recycles
to the cell membrane, or, alternatively, the ligand-receptor
complex is degraded upon fusion of the endosomes with lysosomes. The
latter pathway appears to dominate in the cell types studied. In
addition to degradation in lysosomes, PDGF receptors also undergo
cytoplasmic degradation in proteasomes after ubiquitination
(306, 309). The PDGF
-receptor mutants
with a decreased ability to undergo ubiquitination were found to
have a longer half-life and to mediate a stronger mitogenic effect
than wild-type receptors (307). This observation
illustrates that the rate of deactivation of PDGF receptors is an
important parameter in the regulation of the mitogenic response.
The internalization of PDGF receptors is a controlled process that is dependent on the kinase activity of the receptor (443) as well as on the interaction between the receptor and PI 3-kinase (218) and possibly other molecules (308).
| |
VI. NORMAL IN VIVO FUNCTION OF PLATELET-DERIVED GROWTH FACTOR |
|---|
|
|
|---|
A. Embryonic Development
The recent inactivation of the genes for PDGF A-chain
(63) and B-chain (270) as well as PDGF
-receptor (442) and
-receptor (441) in
mice has provided insight into the in vivo function of PDGF. The notion
that PDGF and PDGF receptors have important roles during embryonic
development is supported by the findings that in each case the mice
died during embryogenesis or perinatally.
Targeting of the B-chain or the
-receptor gave similar
phenotypes. In both types of mice, kidney development was severely affected with a total absence of mesangial cell development
(270, 441). This leads to a poor filtration
in the glomeruli. There was also a defective development of blood
vessels, with a dilated aorta and characteristic bleeding at about the
time of birth. The bleeding was likely to be because of an inability of
the newly formed blood vessels of the knock-out animals to attract
pericytes (279). In contrast to the
-receptor
knock-out mice, however, the B-chain knock-out mice also showed
heart defects with an increased size and trabeculation of the
myocardium. The fact that this defect is not seen in the
-receptor
knock-out animals suggests that during normal development
PDGF-BB may act via
-receptors in the heart.
Knock-out of the A-chain gene led to defect development of the alveoli of the lung, giving an emphysema-like phenotype and leading to death of the mice at ~3 wk of age (63). The failure of alveoli to form was coupled to lack of distal spreading of alveolar smooth muscle cell progenitors during lung development (280).
Inactivation of the
-receptor led to a phenotype that was more
severe than the A-chain knock-out, including cranial malformations and deficiency of myotome formation (442). This is
consistent with the possibility that PDGF-BB is the natural ligand
for the
-receptor in some tissues. The spontaneous mouse mutant
Patch involves a deletion of the
-receptor gene (453).
The Patch mice have a phenotype similar to the
-receptor
knock-out mice but have, in addition, a coat color defect that
possibly is due to a perturbed expression of the neighboring gene for
SCF receptor.
Studies of the expression of PDGF A- and B-chains and PDGF
receptors in different tissues during the development have revealed examples of expression of ligand and receptors in the same cells, suggesting autocrine stimulation, as well as in adjacent cell layers,
suggesting paracrine stimulation (reviewed in Ref. 21). Maternal
A-chain and
-receptor transcripts have been detected in embryos
of several species (300, 343,
382), suggesting autocrine stimulation of growth of early
blastomeres. The notion that PDGF A-chain has an important role in
the early embryo is supported by the observations that about
one-half of embryos lacking the A-chain gene die before
embryonic day 10.5 (E10.5) (63) and that the
Xenopus embryos injected with a dominant negative
-receptor mRNA stop cleaving and subsequently die (22).
At later stages of development, PDGF receptors are often expressed in
mesenchymal structures and the corresponding ligands in adjacent
epithelial layers. For example, at E7.5, the
-receptor is expressed
in the mesoderm, with the exception of the primitive streak
(333), and the A-chain is expressed in the nearby
ectodermal and endodermal layers (332, 333,
344). The A-chain is expressed in the epidermal
ectoderm, and the
-receptor is present in the dermis
(333, 413). The A- and B-chains are
expressed in lung epithelium and the
- and
-receptors in
mesenchyme (63, 444). The A-chain is
expressed in the mouse limb ectoderm and the
-receptor in the limb
bud mesenchyme (332, 413). The B-chain is
expressed in glomerular epithelium and the
-receptor in the
metanephric blastoma (10). The PDGF A- and B-chains
are expressed in Sertoli cells of the testis and PDGF
- and
-receptors in the adjacent peritubular myoid cells
(143). These expression patterns suggest important roles
for PDGF in paracrine stimulation of mesenchymal cells.
The PDGF receptors are also expressed in cells of nonmesodermal origin.
The
-receptor is expressed in the ectodermally derived neural crest
(192, 311, 332,
333, 343, 413), and the
-receptor is expressed on mammary epithelial cells
(464); both receptors are expressed on retinal pigmented
epithelial cells (70) and in the central nervous system
(CNS) (see Table 3 and sect. VIB).
With the consideration of the elaborate expression of PDGF A- and
B-chains and
- and
-receptors in the embryo, it may be somewhat surprising that embryos with the genes for either of the
ligands or receptors inactivated survive as long as they do. Part of
the explanation is likely to be that
- and
-receptors, which
mediate similar intracellular signals, can compensate for each other,
since both receptors bind PDGF-BB with high affinity. There may
also be a redundancy between the ligands; both PDGF-AA and
PDGF-BB bind the
-receptor with high affinity.
B. CNS
Analyses of the temporal-spatial expression of PDGF ligands and receptors provide evidence for a role of PDGF in the development of the CNS through paracrine and autocrine stimulation. In mice, PDGF A-chain mRNA is found in neurons in spinal cord and dorsal root ganglia on E12, whereas it occurs in brain on E15 and continues to be expressed in most adult neurons (507). Analyses of the monkey Macaca nemestrina confirm these findings (409). Platelet-derived growth factor A-chain expression in neurons precedes that of astrocytes and may therefore constitute an earlier signal for oligodendrocyte development than astrocyte-derived PDGF (see also below).
Evidence for the expression of PDGF B-chain in the CNS was initially derived from in situ mRNA analysis and by the use of a transgenic mouse expressing a reporter gene under the transcriptional control of a putative B-chain promoter (409). The distribution of PDGF B-chain immunoreactivity confirms these findings; B-chain protein is found in neurons in several CNS regions of the embryo and in the adult (407). The earliest and strongest expression is recorded in the olfactory system, notably in olfactory nerve fibers and accessory olfactory nerve fibers. The PDGF B-chain content stays at a high level in the adult olfactory system. Because the primary sensory neurons of the olfactory system retain their capacity to regenerate in the adult, this finding is in accordance with the suggested role of PDGF as a neurotrophic factor.
Expression of the PDGF
-receptor is found in glial precursors in
various regions of the developing CNS. There is a transient expression
of the
-receptor in the neuronal tube at E9 in the mouse
(332, 413), whereas it occurs in the brain,
brain stem, and spinal cord on E13.5. After E16, PDGF
-receptor
expression is distinctly found in the O-2A
oligodendroglial-astroglial precursors (372). This
finding adds to the notion that the PDGF
-receptor is a critical
determinant for the development of the oligodendrocyte compartment of
the brain. Whereas the expression of PDGF
-receptor initially was
thought to be restricted to the glial lineage (e.g., Refs. 508, 509),
there is recent evidence that also this PDGF receptor type is expressed
on postnatal neurons (342).
The distribution of PDGF receptors and the cognate ligands in the CNS suggests a functional role in the development and functional properties of the brain and spinal cord. With a few exceptions, however, information on the contribution of PDGF to the development and function of the CNS is as yet very scarce.
Studies of the growth and differentiation of the bipotential O-2A cells in vitro suggested an important role for PDGF in these processes. In their pioneering work, Raff and Noble (reviewed in 374, 376) defined the O-2A cell as a progenitor cell capable of differentiating into either type 2 astrocytes or oligodendrocytes. Although the O-2A cell was initially identified in the rat optic nerve, there is accumulating evidence that analogous cells are present in the entire CNS. In culture, the O-2A cells undergo premature differentiation to oligodendrocytes when deprived of growth factors; among these, PDGF is a critical factor. The mitogenic activity in astrocyte-conditioned medium was shown to be identical to PDGF-AA (386), and several studies have indicated that the presence of PDGF is obligatory for the proper timing of differentiation of the O-2A cells (173, 174, 375). Interestingly, the combined action of PDGF and bFGF leads to a complete block of differentiation and functional immortalization of the O-2A-cells (68). Moreover, PDGF added together with bFGF converts slowly proliferating adult O-2A progenitor cells to rapidly dividing cells with a phenotype similar to that of perinatal O-2A cells (498).
O-2A cells express PDGF
-receptors (173,
174) and will therefore respond to all isoforms of PDGF.
Although astrocytes were initially supposed to be the single or main
source of PDGF, several cell types in the CNS, including neurons,
synthesize PDGF (see above).
Using the expression of the PDGF
-receptor as a marker in
wild-type mice, Pringle and Richardson (373)
identified a subset of neuroepithelial cells in the ventral half of the
E14 rat spinal cord. These cells were seen to proliferate and migrate
to populate the entire spinal cord. In vitro, all cells of the PDGF
-receptor phenotype derived from the ventral E14 spinal cord were
found to differentiate into oligodendrocytes. No such cells were found in other regions (161). These data indicate that PDGF
-receptor-positive cells in the developing spinal cord are
oligodendrocyte precursors (O-2A cells) and that most or all mature
oligodendrocytes are derived from these cells. Although the PDGF
-receptor was used as a marker for the precursor cell, the actual
role of PDGF in the development of oligodendrocytes in vivo has not yet
been determined.
Probably because of the partial redundancy in the PDGF-PDGF-receptor pathway, analyses of the PDGF A- and B-chain knock-out mice have so far provided only limited information on the role of PDGF in the development of the O-2A lineage. Other in vivo data, however, suggest that PDGF is involved in the production of myelinating cells. Overproduction of PDGF in the rat CNS afforded by transplantation of PDGF-producing cells was found to lead to an expansion of the oligodendrocyte compartment, as a result of a reduced rate of apoptosis (29). Furthermore, PDGF has been found to reduce chemically induced rat oligodendrocyte death and enhance myelination in vitro (132). In conclusion, there is accumulating evidence that PDGF has a critical role in the development of the myelinating cells of the CNS. This finding has obvious therapeutical implications, particularly if PDGF can be used to induce remyelination.
Schwann cells, the myelinating cells in the peripheral nervous system,
express PDGF
-receptors and respond to PDGF-BB with an enhanced
proliferation in vitro (93, 108). In these
cells, PDGF acts synergistically with agents that stimulate the
formation of cAMP. The major effect of cAMP is to increase the
expression of
-receptors (493). These observations
suggest that PDGF might play a role in the development and maintenance
of the peripheral neuronal system (109).
A neuroprotective and neurotrophic effect of PDGF has been recorded in
cultures of rat dopaminergic neurons (341,
361). Thus addition of PDGF-BB to rat as well as human
dopaminergic cells resulted in an increase in survival and neurite
formation of tyrosine hydroxylase-positive cells
(341). The presence of PDGF
-receptors on these cells
was confirmed by immunohistochemistry. The effect of PDGF on cell
survival was as marked as that of brain-derived neurotrophic
factor, although PDGF was less efficient in promoting neurite
outgrowth. The in vivo expression of PDGF was examined in
6-hydroxydopamine-induced lesions of dopaminergic neurons in the
substantia nigra of rats (135). Expression of both the A- and B-chain was increased after injury, suggesting a role in
compensatory neuroprotection and repair processes. The finding that
PDGF exerts a neuroprotective effect on rat dopaminergic neurons
exposed to 6-hydroxydopamine in culture (361) supports
this notion. As suggested by Othberg et al. (341), PDGF
agonists may be potential therapeutic agents for patients with
Parkinson's disease. Platelet-derived growth factor and PDGF
receptors are upregulated in infarcted human brain tissue, suggesting a
role in neuroprotection and regeneration. An upregulation of PDGF and
PDGF receptors was also found in facial nuclei in rats after axotomi
(190). Neurons were found to have an increased expression
of A- and B-chain mRNA as well as an increased expression of PDGF
-receptor. The density of PDGF
-receptor-positive astrocytes
increased as well as their content of PDGF immunoreactivity.
C. Vascular System
The PDGF receptors are expressed on capillary endothelial cells (26, 35, 294, 425, 435), and PDGF has been shown to have an angiogenic effect (30, 321, 388, 410). The effect is, however, weaker than that of fibroblast growth factors or VEGF, and PDGF does not appear to be of importance for the initial formation of blood vessels, since no apparent vascular abnormality was observed during early embryogenesis in mice with genes for PDGF or PDGF receptors inactivated. However, in specific organs, the effect of PDGF on angiogenesis may be significant. Thus stimulation of PDGF-AB production in cardiac microvascular cells leads to induction of both von Willebrand factor and VEGF and VEGF receptor-2, suggesting an important role of PDGF in cardiac angiogenesis (110). Administration of PDGF-BB has been shown to induce functional anastomoses in vivo (65, 293). Moreover, PDGF B-chain produced by capillaries may have a generally important role to recruit pericytes that is likely to be required to promote the structural integrity of the vessels (86, 279, 458).
Platelet-derived growth factor has also been implicated in the regulation of the tonus of blood vessels. On one hand, PDGF induces constriction of different types of blood vessels (37, 405). On the other hand, PDGF-BB stimulation of endothelial cells induces a nitric oxide-mediated relaxation of rat aorta (87), and intravenous injection of PDGF-BB in rats was found to lower the systolic blood pressure through increased macrovascular compliance (206).
Another effect of PDGF that is of importance in the vascular system is
its feedback control effect on platelet aggregation. Platelet-derived growth factor stimulation leads to decreased platelet aggregation (66). Human platelets, which are a
rich source of PDGF, have PDGF
-receptors but not
-receptors
(478), and PDGF receptors have also been demonstrated on
megakaryocytes, the precursors of platelets (503). After
thrombin-induced platelet aggregation, the content of the
-granulae, including PDGF, is released. The fact that
thrombin-induced platelet aggregation is accompanied by activation
of platelet PDGF
-receptors, and that this effect can be inhibited
by PDGF antibodies, indicates that the PDGF released from platelets
serves an autocrine feedback role in control of platelet aggregation
(478).
D. Tissue Homeostasis
The interstitial tissue pressure, which is generally slightly negative, is carefully controlled to allow appropriate exchange of fluid and macromolecules between the extracellular compartment and the circulatory system. Platelet-derived growth factor has an important role to maintain the interstitial fluid pressure (393), probably through its ability to stimulate interactions between connective tissue cells and molecules the extracellular matrix.
E. Wound Healing
The healing of soft tissues involves reepithelialization, angiogenesis, and extracellular matrix deposition. Different types of growth factors regulate the different steps in the healing process. Three lines of studies support a role for PDGF in wound healing, i.e., investigations of the effects in vitro of PDGF on cell types of importance for wound healing, analyses of the expression of PDGF and PDGF receptors during the wound-healing process, and studies of the effect of topical application of PDGF to healing wounds.
Platelet-derived growth factor acts on several cell types involved in wound healing. It stimulates mitogenicity and chemotaxis of fibroblasts and smooth muscle cells and chemotaxis of neutrophils and macrophages (reviewed in Ref. 183). It also stimulates macrophages to produce and secrete other growth factors of importance for various phases in the healing process. Moreover, PDGF has been shown to stimulate production of several matrix molecules, like fibronectin (52), collagen (72), proteoglycans (417), and hyaluronic acid (185). Platelet-derived growth factor may also be of importance at later stages of wound healing, since it stimulates contraction of collagen matrices in vitro (80, 159), implicating a role in wound contraction in vivo. Moreover, PDGF stimulates the production and secretion of collagenase by fibroblasts (32), suggesting a role in the remodeling phase of wound healing.
For PDGF to affect wound healing in vivo it has to be present at the site of the wound. Early observations revealed that PDGF is released by platelets and secreted by activated macrophages (424), thrombin-stimulated endothelial cells (169), smooth muscle cells of damaged arteries (486), activated fibroblasts (348), as well as by epidermal keratinocytes (16), suggesting that PDGF is present in the wounded area. More recent studies have revealed that PDGF is present in wound fluid from soft tissue (230, 439) and in tear fluid produced in conjunction with corneal wound healing (481). Interestingly, with the use of isoform-specific monoclonal antibodies, a markedly upregulated level of the long form of PDGF-AA was observed in capillaries and fibroblasts of acute wounds and in chronic wounds treated with PDGF-BB, whereas in maturing granulation tissue, the short form of PDGF-AA was prevalent; in contrast, normal skin and nonhealing dermal ulcers did not contain PDGF (360). It remains to be elucidated why the matrix binding long form of PDGF-AA is more prevalent early during the healing process and the more efficiently diffusible short form is more prevalent during the later phase.
Another prerequisite for a role of PDGF in wound healing is that cells
in the wounded area express PDGF receptors. Immunohistochemical staining for PDGF receptors has revealed that fibroblasts and smooth
muscle cells of resting tissues contain low levels of receptors. However, the
-receptor is upregulated, e.g., during inflammation (384, 400, 465). Expression of
-receptors has also been observed in epithelial cells after
cutaneous injury (18), although this remains controversial
(360).
-Receptors have also been shown to be
upregulated in human gingival wounds (153) and in
growth-activated skin from chronic wounds and psoriatic lesions
(258). Impaired wound healing in diabetic mice was found
to correlate with reduced expression of PDGF A-chain and
-receptor (34).
Early in vivo studies showed that direct application of PDGF in chambers implanted into rats led to increased formation of granulation tissue (155, 449). Subsequent studies showed increased healing after local application of PDGF-BB to incisional wounds in rat skin (358), excisional wounds in rabbit ear (316) and guinea pig (267), full and partial thickness burn injuries in pigs (91), periodontal wounds in dogs and monkeys (287, 404), and rat medial collateral ligament injury (31). A single application of PDGF-BB to incisional wounds increased the wound-breaking strength to 150-170% of control wounds and decreased the time of healing (357, 358). Wounds treated with PDGF showed an increase of granulation tissue rich in fibroblasts and glycosaminoglycans and an increased rate of reepithelization and of neovascularization (316, 355, 356). Thus PDGF does not alter the normal sequence of repair but increases its rate.
Clinical trials have revealed that PDGF-BB increases the healing of decubitus ulcers (391). Analyses of sections from healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation (359). Importantly, PDGF-BB was found to increase healing also in patients with decreased healing capacity, such as diabetics (451).
To have a maximum effect on wound healing, PDGF-BB has to be given at a high concentration. Alternative modes of administration could therefore be advantageous, such as retroviral-mediated gene transfer into keratinocytes (112). Alternatively, nonreplicating and noncytopathic recombinant vaccinia virus encoding PDGF could be used (327).
Overactivity of PDGF may be involved in the overhealing response of
keloids, since keloid fibroblasts were found to have four to five times
more PDGF
-receptors compared with fibroblasts of normal skin
(160).
Whereas PDGF has a significant stimulatory effect on healing of soft tissues, the effect on fracture healing is less clear. Both PDGF and PDGF receptors are present in healing human fractures (15, 199), and stimulatory effects of topically added PDGF-BB on fracture healing have been noticed in different experimental models (301, 320, 484). However, PDGF has also been seen to inhibit the bone regeneration induced by osteogenin and instead induced a soft tissue repair phenotype and response (290).
F. Conclusions
Platelet-derived growth factor has important functions during the embryogenesis, in particular for the development of the kidneys, blood vessels, lungs, and CNS. In these organs, connective tissue-like cell types are dependent on PDGF, including mesangial cells, pericytes, alveolar fibroblasts, and glial cells. The significant role of PDGF in the formation of connective tissue is also important during wound healing in the adult.
| |
VII. PLATELET-DERIVED GROWTH FACTOR IN DISEASE |
|---|
|
|
|---|
A. PDGF in Autocrine Transformation
The PDGF gene has been transduced as the v-sis oncogene
by two acutely transforming retroviruses: SSV (98) and
Parodi-Irgens feline sarcoma virus (41). The
v-sis product is identical to the PDGF B-chain precursor
and is identically synthesized, assembled, processed, and externalized
(337, 389). Both v-sis and its
cellular counterpart, c-sis, cause transformation by an
autocrine mechanism when expressed by PDGF-responsive cells, i.e.,
cells that express either
- and/or
-receptors (33,
266). Obviously, the PDGF A-chain gene transforms
-receptor-positive cells only (295, 296).
The ligand-receptor interaction in sis-transformed cells
has been studied in detail. The newly synthesized PDGF binds to
immature receptors already in the ER, where it causes PDGF
-receptor
autophosphorylation (126, 235). Several
investigators have argued that the mitogenic and transforming signal is
generated intracellularly (36, 204, 235), as was originally suggested by Betsholtz et al.
(44). Others have argued that the transforming signal is
generated only by receptors located at the cell surface
(126, 168, 473). The latter
hypothesis is strongly supported by the finding that SSV transformation
can be blocked by PDGF antibodies (216). Moreover, Valgeirsdottir et al. (473) could show that the
intracellularly activated and autophosphorylated receptors failed to
bind or activate some of the signal transducers involved in
mitogenesis, such as Grb2, Shc, and Src, in cells in which
transformation was reverted by suramin. Other substrates, i.e.,
PLC-
, the regulatory subunit of PI 3-kinase, and RasGAP, associated
with the receptor even in suramin-treated cells; these signals are
thus not sufficient for cell transformation.
The sis gene not only transforms cells in culture but also causes tumors in experimental animals. Thus injection of SSV intramuscularly or intracerebrally causes fibrosarcoma and glioma, respectively, in marmosets (95). Similarly, a Moloney murine leukemia virus-based PDGF B-chain vector causes fibrosarcoma (351) in mice and glioma (472). Because it is unlikely that an autocrine growth stimulation is sufficient to cause a fully malignant phenotype, it is reasonable to believe that an aberrant activation of PDGF receptors is complemented by additional aberrations of as yet unknown nature in the virally induced tumors.
The transforming potential of the PDGF receptor pathway is further
highlighted by studies of the mechanism of action of the E5 oncoprotein
of bovine papilloma virus type 1. This virus causes fibropapillomas,
i.e., benign skin tumors containing transformed epithelial as well as
fibroblastoid cells. The E5 gene product is a 44-amino acid
homodimeric, hydrophobic membrane protein (200). Several
studies have shown that E5 forms a stable complex with the PDGF
-receptor and activates its intrinsic protein tyrosine kinase
(146, 323, 353,
354); this event probably explains the transforming
activity of E5 in fibroblasts (387). Mutational studies
show that interaction between E5 and the
-receptor occurs via their
hydrophobic membrane-spanning domains (82,
145, 447, 450). One possibility
is that binding of E5 to the receptor causes dimerization and thereby
receptor activation. Retention of the E5 protein in the endoplasmic
reticulum/cis-Golgi has no effect on PDGF
-receptor
autophosphorylation but abrogates transformation. This finding
reinforces the notion that activated PDGF
-receptors are
transformation incompetent when located intracellularly, although it
cannot be formally excluded that the transforming signal of E5/PDGF
-receptor is generated, e.g., in trans-Golgi or in
post-Golgi vesicles.
B. PDGF in Human Oncogenesis
The finding that PDGF causes transformation and malignant tumors in experimental systems raises the question of whether PDGF is involved as an autocrine growth factor in the development of spontaneous tumors in humans. This question has been addressed by several investigators, and a large number of tumor types have been studied with regard to their expression of PDGF and PDGF receptors. As is evident from Table 5, many tumors express PDGF and cognate receptors, and in these an autocrine stimulation of tumor cell growth may prevail. These studies have to be interpreted with some caution, however. First, in most cases, the expression of PDGF and PDGF receptors in the normal tissue from which the tumor is derived is not known. Second, in several tumor cases, only mRNA expression has been studied. Third, all studies have been restricted to the analysis of expression, and no attempts have been made to study receptor activation in terms of constitutive autophosphorylation or substrate binding. Finally, even if an autocrine receptor activation should occur, it is not known if this is a critical or even contributing event in the development of the tumor. With these caveats in mind, we and others argue that an autocrine PDGF receptor activation may be a rate-limiting event in the genesis of some tumor types, e.g., glioma and sarcoma (156, 157, 188, 189, 297, 434).
|
In human glioma, PDGF
-receptor-positive cells are found in all
grades, although they occur at higher densities in high-grade tumors (189). Expression of the cognate ligand, PDGF
A-chain, is dramatically increased from low or undetectable levels
in low grade (I and II) to high levels in high grade (III and IV)
tumors, suggesting a role in tumor progression. High levels of
-receptor expression are particularly found in tumors without
epidermal growth factor (EGF) receptor gene amplification. In virtually all cases of glioblastoma multiform (grade IV tumors), there is a high
expression of either EGF receptors or PDGF
-receptors. Thus
activation of either type of receptor may be of critical importance in
tumor progression.
Compelling evidence for an involvement of PDGF and PDGF receptors in
tumorigenesis is provided by findings of structural aberrations of the
corresponding genes that lead to overexpression or expression of an
abnormal protein. In a few cases of glioblastoma, the PDGF
-receptor
gene is amplified (127, 189,
259), leading to receptor overexpression. In cases of
dermatofibrosarcoma protuberans and giant-cell sarcoma, the PDGF
B-chain gene is rearranged by a chromosomal rearrangement
(432). Reciprocal translocations t(17;22; q22;q13) fuse
the B-chain gene to the COL1A1 gene. This rearrangement
leads to the synthesis of a chimeric protein with transforming activity in culture. In chronic myelomonocytic leukemia, the
-receptor gene
is fused to an ets-like gene, TEL, by a t(5;12; q33;p13) translocation (74, 147). The resulting
chimeric protein is likely to behave as a constitutively active PDGF
-receptor.
The growth of certain human glioma cells in vitro (479) and in vivo (422) can be blocked by PDGF antagonists. Such studies have, however, been restricted to permanent cell lines that have been adapted and selected for growth in culture. Similar studies on xenotransplanted primary tissue are therefore warranted.
In addition to being an autocrine growth factor, PDGF is also involved in paracrine stimulation of stroma cells. In several tumor types, there is a complementary expression of PDGF in tumor cells and cognate receptors in stroma cells. Such tumors include, e.g., mammary carcinoma (11, 46), colorectal cancer (457), and small-cell lung carcinoma (233). Furthermore, the development of myelofibrosis in chronic myeloogenous leukemia has been ascribed to PDGF. The potential role of PDGF in stroma development was demonstrated by Forsberg et al. (130). Xenotransplanted human melanoma cells expressing PDGF-BB formed stroma-rich and highly vascularized tumors that were devoid of necroses. In the absence of PDGF, these cells formed poorly vascularized and necrotizing tumors with no detectable stroma.
C. Atherosclerosis
Whereas PDGF is expressed at low levels in arteries from healthy adults, its expression is increased in conjunction with the inflammatory-fibroproliferative response that characterizes atherosclerosis (reviewed in Ref. 395). Thus studies of balloon catheter-injured arterial tissue (224, 289, 469), naturally occurring atherosclerosis (276, 277, 400, 497), coronary arteries after percutanous transluminal coronary angioplasty (471), and experimentally induced atherosclerosis (144, 397) revealed increased expression of PDGF and PDGF receptors in these lesions. These observations suggest that PDGF, produced by activated macrophages, smooth muscle cells, or endothelial cells, or released from platelets in thrombi, is important for the formation of the lesion. The reason for the increased production of PDGF and PDGF receptors in atherosclerotic lesions may be in response to external stimuli but may also be due to rheological changes; low blood flow leads to an increased production of PDGF by endothelial cells (257, 304).
The involvement of PDGF in the atherosclerosis process has been confirmed experimentally using balloon catheterization of rat carotid arteries as a model. In the denuded artery, an increased amount of activated PDGF receptors is seen in the vessel wall (3, 345). The intimal thickening that follows this treatment was inhibited by administration of neutralizing PDGF antibodies (120). In addition, a low-molecular-weight PDGF receptor kinase inhibitor, AG-1295, was recently shown to inhibit neointima formation in a porcine restenosis model (25). Moreover, infusion of PDGF-BB into rats after carotid injury (210), or expression of recombinant PDGF-BB in porcine arteries (317), caused increased intimal thickening. The role of PDGF in the atherosclerotic lesions may be to stimulate smooth muscle cells to migrate from the media of the vessel to the intima layer and to proliferate and produce matrix molecules at this site (368).
Whereas PDGF-BB is important in the restenosis process, also other mitogens, like FGF, are involved. Antibodies to PDGF inhibited intima thickening by ~50% and FGF antibodies also by ~50%; the combination of PDGF antibodies and FGF antibodies resulted in 84% inhibition (403). However, PDGF-AA appears to be less important, since no appreciable inhibition of intimal hyperplasia was observed after administration of PDGF-AA antiserum (172).
Platelet-derived growth factor is also involved in neointima formation in other model systems including human saphenous vein cultured in vitro (138). It is well known that hypercholesterolemia predisposes for atherosclerosis. Interestingly, PDGF A- and B-chain mRNA levels are increased in mononuclear cells from hypercholesterolemia patients (48). Moreover, the development of aortic lesions in cholesterol-fed rabbits was inhibited by prior immunization of the rabbits with PDGF-BB (402). These observations suggest that PDGF is involved in cholesterol-induced atherosclerosis.
Given the role for PDGF in restenosis, the PDGF
-receptor has been
targeted in attempts to inhibit intimal hyperplasia. Neutralizing mouse
or mouse/human chimeric monoclonal antibodies against the receptor have
been found to inhibit intimal thickening in injured arteries of the
baboon, and a murine monoclonal antibody to inhibit intimal thickening
of rat carotid arteries (172). Moreover, treatment of
balloon-injured vessels in the rat with antisense oligonucleotides to PDGF
-receptor significantly decreased PDGF
-receptor
expression and intimal thickening (433). These
observations suggest that inhibitors of PDGF-BB or PDGF
-receptor may be useful clinically to prevent the restenosis that
occurs at high frequency after coronary angioplasty. Clinical trails
using the rather unspecific PDGF inhibitor Trapidil have already given
encouraging results (291, 330).
D. Lung Fibrosis
Studies of the effects of antisense oligonucleotides on early lung
explants revealed that both
- and
-receptors were of importance
in lung growth, whereas the
-receptor was of specific importance to
induce lung branching (445). There are several observations that support the notion that overactivity of PDGF is
involved in the development of various fibrotic conditions in the lung.
Idiopathic pulmonary fibrosis is an inflammatory and fibrotic condition
in which alveolar macrophages are an important source of PDGF and other
factors (292, 483). Normal alveolar
macrophages express PDGF in vitro, and this expression can be
upregulated by a variety of stimuli (176,
310). However, also the alveolar epithelium of patients
with idiopathic pulmonary fibrosis produce PDGF and other cytokines
(17). Mesenchymal cells have more PDGF
-receptors than
-receptors and thus respond better to PDGF-BB or PDGF-AB
than to PDGF-AA (60, 73). Upregulation of
the
-receptor on rat pulmonary fibroblasts was observed in response
to stimulation with IL-1 (281) or exposure to asbestos
(58).
Overexpression of PDGF has also been seen in other forms of lung fibrosis, including bronchiolitis obliterans-organizing pneumonia (23), obliterative bronchiolitis after transplantation (191), histiocytosis X (470) and coal workers' pneumoconiosis (477), as well as fibrosis following hypoxic pulmonary hypertension (227), breathing of high concentrations of oxygen (165, 370), and exposure to asbestos (283). An increased amount of PDGF is also seen in bronchial lavage of lungs after acute injury (438, 487).
Studies of a genetic form of lung fibrosis, Hermansky-Pudlak syndrome, provided evidence that PDGF has a causal role in lung fibrosis; in this disease, an increased concentration of PDGF was observed in bronchial lavage fluid even before the patients had any symptoms (170).
Experimental evidence for a role of PDGF-BB in lung fibrosis was obtained by the demonstration that intratracheal injection of PDGF-BB causes transient proliferation of pulmonary mesenchymal and epithelial cells accompanied by collagen deposition (510). Moreover, administration of neutralizing PDGF antibodies or anti-sense PDGF oligonucleotides inhibited silica particle-induced pulmonary fibrosis in a mouse model (329).
E. Kidney Fibrosis
As mentioned in section VIA, PDGF is important for the development of mesangial cells of the kidney during embryonic development (10, 270). Recent studies have shown that overactivity of PDGF is involved in the pathogenesis of several glomerular diseases that are characterized by mesangial cell proliferation, including IgA nephropathy, membranoproliferative glomerulonephritis, and lupus nephritis (reviewed in Ref. 1).
Mesangial cells cultured in vitro both produce and respond to PDGF (129, 427, 430). In normal kidney tissue, the expression of PDGF and PDGF receptor is low; the expression is increased in conjunction with glomerulonephritis in patients (140, 322) as well as in animal models (141, 205, 514). Whereas PDGF B-chain is clearly most important, the A-chain can also contribute (275). The anti-Thy-1 model in rats is a much-studied model for glomerulonephritis. It resembles IgA nephropathy, the most common form of glomerulonephritis in humans. Injection of complement-fixing antibodies against the mesangial cell antigen Thy-1 results in mesangiolysis. After infiltration of platelets and monocytes/macrophages, a massive proliferation of mesangial cells is seen after 2-6 days (214). Thereafter, a phase characterized by extracellular matrix deposition ensues, whereafter the lesion is healed. In this model, the expression of PDGF and PDGF receptors correlates with the mesangial cell proliferation (205). The notion that PDGF has a causative role in this process is furthermore supported by the finding that administration of neutralizing PDGF antibodies slows down the proliferation of mesangial cells 4 days after injury (215). The antibodies had no effect on day 2, however, suggesting that the early phase of mesangial proliferation is driven by other factors. Moreover, infusion of PDGF-BB to normal rats induced mild mesangial proliferation and a massive proliferation in rats given subnephritic doses of anti-Thy-1 sera (128).
Platelet-derived growth factor is not the only growth factor or
cytokine involved in the development of glomerulonephritis. Isaka et
al. (208) used an in vivo transfection technique to compare the effects of PDGF and TGF-
on glomerulonephritis; whereas introduction of PDGF B-chain caused increased mesangial cell
proliferation, TGF-
caused primarily extracellular matrix
accumulation. The importance of TGF-
in the development of
glomerulonephritis was underscored by the observation that infusion of
the TGF-
binding proteoglycan decorin inhibits the development of
glomerulonephritis in the anti-Thy-1 model (62).
Platelet-derived growth factor overactivity may be involved also in another fibrotic condition in the kidney, i.e., tubulointerstitial fibrosis, since administration of PDGF-BB induced tubulointerstitial proliferation and increased production of collagen (463). This observation is of importance, since impaired renal function correlates more closely with histological changes in the tubular and interstitial compartments in the kidney than with changes in the glomerular compartment (6).
A role for PDGF in chronic vascular rejection of kidneys has been inferred from the observations that PDGF receptors (117) and PDGF (9) increase in conjunction with renal rejection.
F. Other Fibrotic Conditions
Platelet-derived growth factor has also been implicated in liver cirrosis. In this condition fat-storing cells (Ito cells) dedifferentiate into myofibroblast-like cells that respond to PDGF (186, 362, 363). After liver injury, e.g., after administration of carbon tetrachloride, the amounts of PDGF and PDGF receptors in the liver increase (364, 499). An immunohistochemical analysis revealed that PDGF A- and B-chain are present in infiltrating inflammatory cells and along vascular structures in fibrous septa and PDGF receptors in mesenchymal cells, fibrous septa and around sinuses; the expression of receptors correlated with the severity of the lesion (365).
Another fibrotic condition where PDGF may be involved is palmar fibrosis (Dupuytren's contracture). Both PDGF A- and B-chain were expressed by primary cell cultures from palmar fibromatosis, and the expression increased when the cells were subjected to mechanical strain; neutralizing PDGF antibodies decreased DNA syntheses in fibromatous cultures (7, 8).
There are also other conditions where PDGF may be involved. In chronic
synovial inflammation, PDGF (406) and PDGF receptors (385, 399) are upregulated, suggesting a role
for PDGF in mesenchymal cell proliferation in rheumatoid arthritis. In
scleroderma, an autoimmune disease characterized by progressive
fibrosis in the skin and in visceral organs, PDGF
-receptor
(249) and PDGF (137) are upregulated. In
patients with myelofibrosis of the bone marrow, PDGF levels in serum
and urine have been found to be elevated (139) and the
content of PDGF in platelets correspondingly decreased (229).
G. Conclusions
Overactivity of PDGF has been linked to several different disorders. In progression of glioblastoma and sarcomas, PDGF often causes autocrine stimulation of tumor cell growth. In addition, paracrine stimulation of stroma cells by PDGF made by tumor cells is also important for the balanced growth of different cell types in tumors. Overactivity of PDGF has also been implicated in atherosclerosis and several fibrotic conditions, including lung fibrosis, kidney fibrosis, liver cirrhosis, and myelofibrosis.
| |
VIII. PLATELET-DERIVED GROWTH FACTOR ANTAGONISTS |
|---|
|
|
|---|
As discussed in sections VI and VII, PDGF is implicated in autocrine and paracrine stimulation of cell growth in several different pathological conditions. Potent and specific PDGF antagonists could therefore be clinically useful.
Antagonists that interfere with the binding of PDGF to its receptors have already been shown to have effects in animal models; a PDGF antiserum inhibits neointimal smooth muscle cell accumulation in a restenosis model in the rat (120). Other possibilities to bind and inhibit PDGF include use of soluble extracellular domains of the PDGF receptors (105), PDGF binding DNA aptamers (152), or low-molecular-weight compounds binding PDGF (314). Monoclonal PDGF receptor antibodies that block ligand binding and receptor activation have been described and are also potentially useful as PDGF antagonists (263, 285, 381).
An interesting and potentially useful approach to inhibit PDGF action is by inhibiting the PDGF receptor kinase. Low-molecular-weight compounds, tyrphostins, have been described that efficiently inhibit tyrosine kinases (reviewed in Ref. 271). Some of these compounds show selectivity for inhibition of PDGF receptor kinases (47, 67, 254, 411, 423); however, their precise specificities remain to be determined. A PDGF receptor kinase inhibitor was recently shown to inhibit neointimal thickening in vivo (25).
| |
IX. FUTURE PERSPECTIVES |
|---|
|
|
|---|
During the 25 years since its discovery, PDGF has been one of the most studied growth factors. With the recent knock-out of the genes for PDGF and PDGF receptors, important roles for PDGF during embryonic development have been elucidated. However, because mice with the genes for either of the two ligand chains or the two receptors inactivated die around birth, much work remains to investigate the roles for PDGF after birth. Because PDGF and PDGF receptors are expressed at high amounts in the CNS, it will be of particular interest to explore the possibility that PDGF is of importance for the function of the CNS.
Studies during the recent years have provided an initial insight into the mechanism of signal transduction via tyrosine kinase receptors. Several different signal transduction pathways have been identified and linked to the cellular effects of growth factors. The exact mechanism whereby PDGF and other growth factors stimulate cell growth is, however, still unknown. Different research groups have reported slightly different results, partly because different cell types have been studied. The precise role of individual pathways thus remains to be determined. It is clear, however, that there is an elaborate cross-talk between different signaling pathways and that the ultimate strength of a response is determined by the balance between positive and negative signals.
The observations that PDGF and PDGF receptors are expressed on various cell types in a healing wound and that addition of PDGF increases the rate of wound healing in animal models and patients suggest that PDGF might find clinical utility to enhance wound healing. Platelet-derived growth factor is one of several growth factors that speeds up wound healing, and it remains to be determined which of the factors, or combination of factors, gives the best results in patients with a decreased ability to heal wounds, such as diabetic patients.
There is good evidence that PDGF overactivity is involved in the development of several serious disorders, including certain malignancies, atherosclerosis, and various fibrotic conditions. The development of clinically useful PDGF antagonists is therefore highly warranted. One promising type of antagonist is inhibitors of the PDGF receptor kinases. Several such inhibitors have been described; future studies will aim to identify potent inhibitors that are specific for PDGF receptors and that do not inhibit other kinases.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ingegärd Schiller for valuable help in the preparation of this manuscript.
Address for reprint requests and other correspondence: C.-H. Heldin, Ludwig Institute for Cancer Research, Box 595, Biomedical Center, S-751 24 Uppsala, Sweden (E-mail: C-H.Heldin{at}LICR.uu.se).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | ABBOUD, H. E. Role of platelet-derived growth factor in renal injury. Annu. Rev. Physiol. 57: 297-309, 1995[Medline]. |
| 2. | ABBOUD, H. E., E. POPTIC, AND P. DICORLETO. Production of platelet-derived growth factor-like protein by rat mesangial cells in culture. J. Clin. Invest. 80: 675-683, 1987. |
| 3. |
ABE, J.-I.,
J.-O. DEGUCHI,
T. MATSUMOTO,
N. TAKUWA,
M. NODA,
M. OHNO,
M. MAKUUCHI,
K. KUROKAWA, AND Y. TAKUWA.
Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries. A link between angiotensin II and intimal thickening.
Circulation
96: 1906-1913, 1997 |
| 4. | AFINK, G. B., M. NISTÉR, B. H. G. J. STASSEN, P. H. L. J. JOOSTEN, P. J. H. RADEMAKERS, E. BONGCAM-RUDLOFF, E. J. J. VAN ZOELEN, AND S. MOSSELMAN. Molecular cloning and functional characterization of the human platelet-derived growth factor a receptor gene promoter. Oncogene 10: 1667-1672, 1995[Medline]. |
| 5. |
ÅHLÉN, K., AND K. RUBIN.
Platelet-derived growth factor-BB stimulates synthesis of the integrin 2-subunit in human diploid fibroblasts.
Exp. Cell Res.
215: 347-353, 1994[Medline].
|
| 6. | ALEXOPOULOS, E., D. SERON, R. B. HARTLEY, AND J. S. CAMERON. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int. 37: 100-109, 1990[Medline]. |
| 7. | ALMAN, B. A., D. A. GREEL, L. K. RUBY, M. J. GOLDBERG, AND H. J. WOLFE. Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis (Dupuytren contracture) by mechanical strain. J. Orthop. Res. 14: 722-728, 1996[Medline]. |
| 8. | ALMAN, B. A., S. P. NABER, R. M. TEREK, W. A. JIRANEK, M. J. GOLDBERG, AND H. J. WOLFE. Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J. Orthop. Res. 13: 67-77, 1995[Medline]. |
| 9. | ALPERS, C. E., C. L. DAVIS, D. BARR, C. L. MARSH, AND K. L. HUDKINS. Identification of platelet-derived growth factor A and B chains in human renal vascular rejection. Am. J. Pathol. 148: 439-451, 1996[Abstract]. |
| 10. |
ALPERS, C. E.,
R. A. SEIFERT,
K. L. HUDKINS,
R. J. JOHNSON, AND D. F. BOWEN-POPE.
Developmental patterns of PDGF B-chain, PDGF-receptor, and -actin expression in human glomerulogenesis.
Kidney Int.
42: 390-399, 1992[Medline].
|
| 11. | ANAN, K., T. MORISAKI, M. KATANO, A. IKUBO, H. KITSUKI, A. UCHIYAMA, S. KUROKI, M. TANAKA, AND M. TORISU. Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119: 333-339, 1996[Medline]. |
| 12. |
ANDERSSON, M.,
A. ÖSTMAN,
G. BÄCKSTRÖM,
U. HELLMAN,
C. GEORGE-NASCIMENTO,
B. WESTERMARK, AND C.-H. HELDIN.
Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF.
J. Biol. Chem.
267: 11260-11266, 1992 |
| 13. | ANDERSSON, M., A. ÖSTMAN, J. KREYSING, G. BÄCKSTRÖM, M. VAN DE POLL, AND C.-H. HELDIN. Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. Growth Factors 12: 159-164, 1995[Medline]. |
| 14. |
ANDERSSON, M.,
A. ÖSTMAN,
B. WESTERMARK, AND C.-H. HELDIN.
Characterization of the retention motif in the C-terminal part of the long splice form of platelet-derived growth factor A-chain.
J. Biol. Chem.
269: 926-930, 1994 |
| 15. | ANDREW, J. G., J. A. HOYLAND, A. J. FREEMONT, AND D. R. MARSH. Platelet-derived growth factor expression in normally healing human fractures. Bone 16: 455-460, 1995[Medline]. |
| 16. | ANSEL, J. C., J. P. TIESMAN, J. E. OLERUD, J. G. KRUEGER, J. F. KRANE, D. C. TARA, G. D. SHIPLEY, D. GILBERTSON, M. L. USUI, AND C. E. HART. Human keratinocytes are a major source of cutaneous platelet-derived growth factor. J. Clin. Invest. 92: 671-678, 1993. |
| 17. | ANTONIADES, H. N., M. A. BRAVO, R. E. AVILA, T. GALANOPOULOS, J. NEVILLE-GOLDEN, M. MAXWELL, AND M. SELMAN. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J. Clin. Invest. 86: 1055-1064, 1990. |
| 18. |
ANTONIADES, H. N.,
T. GALANOPOULOS,
J. NEVILLE-GOLDEN,
C. P. KIRITSY, AND S. E. LYNCH.
Injury induces in vivo expression of platelet-derived growth factor (PDGF) and PDGF receptor mRNAs in skin epithelial cells and PDGF mRNA in connective tissue fibroblasts.
Proc. Natl. Acad. Sci. USA
88: 565-569, 1991 |
| 19. |
ANTONIADES, H. N.,
C. D. SCHER, AND C. D. STILES.
Purification of human platelet-derived growth factor.
Proc. Natl. Acad. Sci. USA
76: 1809-1812, 1979 |
| 20. |
ASSOIAN, R. K.
Anchorage-dependent cell cycle progression.
J. Cell Biol.
136: 1-4, 1997 |
| 21. | ATALIOTIS, P., AND M. MERCOLA. Distribution and functions of platelet-derived growth factors and their receptors during embryogenesis. Int. Rev. Cytol. 172: 95-127, 1997[Medline]. |
| 22. | ATALIOTIS, P., K. SYMES, M. M. CHOU, L. HO, AND M. MERCOLA. PDGF signalling is required for gastrulation of Xenopus laevis. Development 121: 3099-3110, 1995[Abstract]. |
| 23. | AUBERT, J.-D., P. D. PARÉ, J. C. HOGG, AND S. HAYASHI. Platelet-derived growth factor in bronchiolitis obliterans-organizing pneumonia. Am. J. Respir. Crit. Care Med. 155: 676-681, 1997[Abstract]. |
| 24. |
BALLAGI, A. E.,
A. ISHIZAKI,
J.-O. NEHLIN, AND K. FUNA.
Isolation and characterization of the mouse PDGF -receptor promoter.
Biochem. Biophys. Res. Commun.
210: 165-173, 1995[Medline].
|
| 25. |
BANAI, S.,
Y. WOLF,
G. GOLOMB,
A. PEARLE,
J. WALTENBERGER,
I. FISHBEIN,
A. SCHNEIDER,
A. GAZIT,
L. PEREZ,
R. HUBER,
G. LAZAROVICHI,
L. RABINOVICH,
A. LEVITZKI, AND S. D. GERTZ.
PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine.
Circulation
97: 1960-1969, 1998 |
| 26. |
BAR, R. S.,
M. BOES,
B. A. BOOTH,
B. L. DAKE,
S. HENLEY, AND M. N. HART.
The effects of platelet-derived growth factor in cultured microvessel endothelial cells.
Endocrinology
124: 1841-1848, 1989 |
| 27. |
BARLEON, B.,
F. TOTZKE,
C. HERZOG,
S. BLANKE,
E. KREMMER,
G. SIEMEISTER,
D. MARMÉ, AND G. MARTINY-BARON.
Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.
J. Biol. Chem.
272: 10382-10388, 1997 |
| 28. | BARNHILL, R. L., M. XIAO, D. GRAVES, AND H. N. ANTONIADES. Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br. J. Dermatol. 135: 898-904, 1996[Medline]. |
| 29. | BARRES, B. A., I. K. HART, H. S. COLES, J. F. BURNE, J. T. VOYVODIC, W. D. RICHARDSON, AND M. C. RAFF. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70: 31-46, 1992[Medline]. |
| 30. |
BATTEGAY, E. J.,
J. RUPP,
L. IRUELA-ARISPE,
E. H. SAGE, AND M. PECH.
PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF -receptors.
J. Cell Biol.
125: 917-928, 1994 |
| 31. | BATTEN, M. L., J. C. HANSEN, AND L. E. DAHNERS. Influence of dosage and timing of application of platelet-derived growth factor on early healing of the rat medial collateral ligament. J. Orthop. Res. 14: 736-741, 1996[Medline]. |
| 32. |
BAUER, E. A.,
T. W. COOPER,
J. S. HUANG,
J. ALTMAN, AND T. F. DEUEL.
Stimulation of in vitro human skin collagenase expression by platelet-derived growth factor.
Proc. Natl. Acad. Sci. USA
82: 4132-4136, 1985 |
| 33. |
BECKMANN, M. P.,
C. BETSHOLTZ,
C.-H. HELDIN,
B. WESTERMARK,
E. DI MARCO,
P. P. DI FIORE,
K. C. ROBBINS, AND S. A. AARONSON.
Comparison of biological properties and transforming potential of human PDGF-A and PDGF-B chains.
Science
241: 1346-1349, 1988 |
| 34. | BEER, H. D., M. T. LONGAKER, AND S. WERNER. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J. Invest. Dermatol. 109: 132-138, 1997[Medline]. |
| 35. |
BEITZ, J. G.,
I.-S. KIM,
P. CALABRESI, AND A. R. FRACKELTON, JR
Human microvascular endothelial cells express receptors for platelet-derived growth factor.
Proc. Natl. Acad. Sci. USA
88: 2021-2025, 1991 |
| 36. |
BEJCEK, B. E.,
D. Y. LI, AND T. F. DEUEL.
Transformation by v-sis occurs by an internal autoactivation mechanism.
Science
245: 1496-1499, 1989 |
| 37. |
BERK, B. C.,
R. W. ALEXANDER,
T. A. BROCK,
M. A. GIMBRONE, JR., AND R. C. WEBB.
Vasoconstriction: a new activity for platelet-derived growth factor.
Science
232: 87-90, 1986 |
| 38. |
BERNSTEIN, J.,
O. SELLA,
S.-Y. LE, AND O. ELROY-STEIN.
PDGF2/c-sis mRNA leader contains a differentiation-linked internal ribosomal entry site (D-IRES).
J. Biol. Chem.
272: 9356-9362, 1997 |
| 39. | BERRIDGE, M. J. Inositol trisphosphate and calcium signalling. Nature 361: 315-325, 1993[Medline]. |
| 40. | BERTI, A., S. RIGACCI, G. RAUGEI, D. DEGL'INNOCENTI, AND G. RAMPONI. Inhibition of cellular response to platelet-derived growth factor by low Mr phosphotyrosine protein phosphatase overexpression. FEBS Lett. 349: 7-12, 1994[Medline]. |
| 41. |
BESMER, P.,
H. W. SNYDER, JR.,
J. E. MURPHY,
W. D. HARDY, JR., AND A. PARODI.
The Parodi-Irgens feline sarcoma virus and simian sarcoma virus have homologous oncogenes, but in different contexts of the viral genomes.
J. Virol.
46: 606-613, 1983 |
| 42. | BETSHOLTZ, C. In: The PDGF Genes and Their Regulation, edited by B. Westermark, and C. Sorg. Basel: Karger, 1993, vol. 5, p. 11-30. |
| 43. | BETSHOLTZ, C., A. JOHNSSON, C.-H. HELDIN, B. WESTERMARK, P. LIND, M. S. URDEA, R. EDDY, T. B. SHOWS, K. PHILPOTT, A. L. MELLOR, T. J. KNOTT, AND J. SCOTT. cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature 320: 695-699, 1986[Medline]. |
| 44. | BETSHOLTZ, C., B. WESTERMARK, B. EK, AND C.-H. HELDIN. Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation. Cell 39: 447-457, 1984[Medline]. |
| 45. |
BHANDARI, B.,
U. O. WENZEL,
F. MARRA, AND H. E. ABBOUD.
A nuclear protein in mesangial cells that binds to the promoter region of the platelet-derived growth factor-A chain gene. Induction by phorbol ester.
J. Biol. Chem.
270: 5541-5548, 1995 |
| 46. |
BHARDWAJ, B.,
J. KLASSEN,
N. COSSETTE,
E. STERNS,
A. TUCK,
R. DEELEY,
S. SENGUPTA, AND B. ELLIOTT.
Localization of platelet-derived growth factor receptor expression in the periepithelial stroma of human breast carcinoma.
Clin. Cancer Res.
2: 773-782, 1996[Abstract].
|
| 47. | BILDER, G. E., AND C. J. ROJAS. Inhibitors of the platelet-derived growth factor receptor tyrosine kinase. Cardiovasc. Drug Rev. 14: 380-399, 1996. |
| 48. |
BILLETT, M. A.,
I. S. ADBEISH,
S. A. H. ALROKAYAN,
A. J. BENNETT,
C. B. MARENAH, AND D. A. WHITE.
Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients.
Arterioscler. Thromb. Vasc. Biol.
16: 399-406, 1996 |
| 49. |
BISHAYEE, S.,
S. MAJUMDAR,
J. KHIRE, AND M. DAS.
Ligand-induced dimerization of the platelet-derived growth factor receptor. Monomer-dimer interconversion occurs independent of receptor phosphorylation.
J. Biol. Chem.
264: 11699-11705, 1989 |
| 50. | BLACK, P., R. CARROLL, AND D. GLOWACKA. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. Pediatr. Neurosurg. 24: 74-78, 1996[Medline]. |
| 51. | BLACK, P. M., R. CARROLL, D. GLOWACKA, K. RILEY, AND K. DASHNER. Platelet-derived growth factor expression and stimulation in human meningiomas. J. Neurosurg. 81: 388-393, 1994[Medline]. |
| 52. |
BLATTI, S. P.,
D. N. FOSTER,
G. RANGANATHAN,
H. L. MOSES, AND M. J. GETZ.
Induction of fibronectin gene transcription and mRNA is a primary response to growth-factor stimulation of AKR-2B cells.
Proc. Natl. Acad. Sci. USA
85: 1119-1123, 1988 |
| 53. | BLECHMAN, J. M., S. LEV, J. BARG, M. EISENSTEIN, B. VAKS, Z. VOGEL, D. GIVOL, AND Y. YARDEN. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80: 105-115, 1995. |
| 54. | BOEHM, K. D., M. DAIMON, I. G. GORODESKI, L. A. SHEEAN, W. H. UTIAN, AND J. ILAN. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol. Reprod. Dev. 27: 93-101, 1990[Medline]. |
| 55. |
BOKOCH, G. M.,
Y. WANG,
B. P. BOHL,
M. A. SELLS,
L. A. QUILLIAM, AND U. G. KNAUS.
Interaction of the Nck adapter protein with p21-activated kinase (PAK1).
J. Biol. Chem.
271: 25746-25749, 1996 |
| 56. |
BONNER, J. C.,
A. BADGETT,
P. M. LINDROOS, AND P. G. COIN.
Basic fibroblast growth factor induces expression of the PDGF receptor- on human bronchial smooth muscle cells.
Am. J. Physiol.
271 (Lung Cell. Mol. Physiol. 15): L880-L888, 1996 |
| 57. |
BONNER, J. C.,
A. BADGETT,
P. M. LINDROOS, AND A. R. OSORNIO-VARGAS.
Transforming growth factor 1 downregulates the platelet-derived growth factor -receptor subtype on human lung fibroblasts in vitro.
Am. J. Respir. Cell Mol. Biol.
13: 496-505, 1995[Abstract].
|
| 58. |
BONNER, J. C.,
A. L. GOODELL,
P. G. COIN, AND A. R. BRODY.
Chrysotile asbestos upregulates gene expression and production of -receptors for platelet-derived growth factor (PDGF-AA) on rat lung fibroblasts.
J. Clin. Invest.
92: 425-430, 1993.
|
| 59. |
BONNER, J. C., AND A. R. OSORNIO-VARGAS.
Differential binding and regulation of platelet-derived growth factor A and B chain isoforms by 2-macroglobulin.
J. Biol. Chem.
270: 16236-16242, 1995 |
| 60. | BONNER, J. C., A. R. OSORNIO-VARGAS, A. BADGETT, AND A. R. BRODY. Differential proliferation of rat lung fibroblasts induced by the platelet-derived growth factor-AA, -AB, and -BB isoforms secreted by rat alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 5: 539-547, 1991. |
| 61. |
BONTHRON, D. T.,
C. C. MORTON,
S. H. ORKIN, AND T. COLLINS.
Platelet-derived growth factor A chain: gene structure, chromosomal location, and basis for alternative mRNA splicing.
Proc. Natl. Acad. Sci. USA
85: 1492-1496, 1988 |
| 62. |
BORDER, W. A.,
S. OKUDA,
L. R. LANGUINO,
M. B. SPORN, AND E. RUOSLAHTI.
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor 1.
Nature
346: 371-374, 1990[Medline].
|
| 63. | BOSTRÖM, H., K. WILLETTS, M. PEKNY, P. LEVÉEN, P. LINDAHL, H. HEDSTRAND, M. PEKNA, M. HELLSTRÖM, S. GEBRE-MEDHIN, M. SCHALLING, M. NILSSON, S. KURLAND, J. TÖRNELL, J. K. HEATH, AND C. BETSHOLTZ. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85: 863-873, 1996[Medline]. |
| 64. |
BRONZERT, D. A.,
S. E. BATES,
J. P. SHERIDAN,
R. LINDSEY,
E. M. VALVERIUS,
M. R. STAMPFER,
M. E. LIPPMAN, AND R. B. DICKSON.
Transforming growth factor- induces platelet-derived growth factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells.
Mol. Endocrinol.
4: 981-989, 1990 |
| 65. |
BROWN, D. M.,
S. P. HONG,
C. L. FARRELL,
G. F. PIERCE, AND R. K. KHOURI.
Platelet-derived growth factor BB induces functional vascular anastomoses in vivo.
Proc. Natl. Acad. Sci. USA
92: 5920-5924, 1995 |
| 66. |
BRYCKAERT, M. C.,
F. RENDU,
G. TOBELEM, AND Å. WASTESON.
Collagen-induced binding to human platelets of platelet-derived growth factor leading to inhibition of P43 and P20 phosphorylation.
J. Biol. Chem.
264: 4336-4341, 1989 |
| 67. |
BUCHDUNGER, E.,
J. ZIMMERMANN,
H. METT,
T. MEYER,
M. MÜLLER,
U. REGENASS, AND N. B. LYDON.
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Proc. Natl. Acad. Sci. USA
92: 2558-2562, 1995 |
| 68. |
BÖGLER, O.,
D. WREN,
S. C. BARNETT,
H. LAND, AND M. NOBLE.
Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells.
Proc. Natl. Acad. Sci. USA
87: 6368-6372, 1990 |
| 69. | BÖHLING, T., E. HATVA, M. KUJALA, L. CLAESSON-WELSH, K. ALITALO, AND M. HALTIA. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J. Neuropathol. Exp. Neurol. 55: 522-527, 1996[Medline]. |
| 70. | CAMPOCHIARO, P. A., S. F. HACKETT, S. A. VINORES, J. FREUND, C. CSAKY, W. LAROCHELLE, J. HENDERER, M. JOHNSON, I. R. RODRIGUEZ, Z. FRIEDMAN, N. DEREVJANIK, AND J. DOONER. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J. Cell Sci. 107: 2459-2469, 1994[Abstract]. |
| 71. | CAMPOCHIARO, P. A., R. SUGG, G. GROTENDORST, AND L. M. HJELMELAND. Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp. Eye Res. 49: 217-227, 1989[Medline]. |
| 72. | CANALIS, E. Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat calvaria. Metabolism 30: 970-975, 1981[Medline]. |
| 73. | CANIGGIA, I., J. LIU, R. HAN, S. BUCH, K. FUNA, K. TANSWELL, AND M. POST. Fetal lung epithelial cells express receptors for platelet-derived growth factor. Am. J. Respir. Cell Mol. Biol. 9: 54-63, 1993. |
| 74. |
CARROLL, M.,
M. H. TOMASSON,
G. F. BARKER,
T. R. GOLUB, AND D. G. GILLILAND.
The TEL/platelet-derived growth factor receptor (PDGF R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF R kinase-dependent signaling pathways.
Proc. Natl. Acad. Sci. USA
93: 14845-14850, 1996 |
| 75. | CENTRELLA, M. I., T. L. McCARTHY, W. F. KUSMIK, AND E. CANALIS. Isoform-specific regulation of platelet-derived growth factor activity and binding in osteoblast-enriched cultures from fetal rat bone. J. Clin. Invest. 89: 1076-1084, 1992. |
| 76. |
CHAUDHRY, A.,
V. PAPANICOLAOU,
K. BERG,
C.-H. HELDIN, AND K. FUNA.
Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.
Cancer Res.
52: 1006-1012, 1992 |
| 77. |
CHUNG, C. K., AND H. N. ANTONIADES.
Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor a messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry.
Cancer Res.
52: 3453-3459, 1992 |
| 78. |
CLAESSON-WELSH, L.,
A. ERIKSSON,
B. WESTERMARK, AND C.-H. HELDIN.
cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor.
Proc. Natl. Acad. Sci. USA
86: 4917-4921, 1989 |
| 79. |
CLARK, E. A., AND J. S. BRUGGE.
Integrins and signal transduction pathways: the road taken.
Science
268: 233-239, 1995 |
| 80. | CLARK, R. A. F., J. M. FOLKVORD, C. E. HART, M. J. MURRAY, AND J. M. McPHERSON. Platelet isoforms of platelet-derived growth factor stimulate fibroblasts to contract collagen matrices. J. Clin. Invest. 84: 1036-1040, 1989. |
| 81. | CLEMENTS, J. M., L. J. BAWDEN, R. E. BLOXIDGE, G. CATLIN, A. L. COOK, S. CRAIG, A. H. DRUMMOND, R. M. EDWARDS, A. FALLON, D. R. GREEN, P. G. HELLEWELL, P. M. KIRWIN, P. D. NAYEE, S. J. RICHARDSON, D. BROWN, S. B. CHAHWALA, M. SNAREY, AND D. WINSLOW. Two PDGF-B chain residues, arginine 27 and isoleucine 30, mediate receptor binding and activation. EMBO J. 10: 4113-4120, 1991[Medline]. |
| 82. |
COHEN, B. D.,
D. J. GOLDSTEIN,
L. RUTLEDGE,
W. C. VASS,
D. R. LOWY,
R. SCHLEGEL, AND J. T. SCHILLER.
Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain.
J. Virol.
67: 5303-5311, 1993 |
| 83. |
COIN, P. G.,
P. M. LINDROOS,
G. S. J. BIRD,
A. R. OSORNIO-VARGAS,
V. L. ROGGLI, AND J. C. BONNER.
Lipopolysaccharide upregulates platelet-derived growth factor (PDGF) -receptor expression in rat lung myofibroblasts and enhances response to all PDGF isoforms.
J. Immunol.
156: 4797-4806, 1996[Abstract].
|
| 84. |
COLTRERA, M. D.,
J. WANG,
P. L. PORTER, AND A. M. GOWN.
Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma.
Cancer Res
55: 2703-2708, 1995 |
| 85. | COUSSENS, L., C. VAN BEVEREN, D. SMITH, E. CHEN, R. L. MITCHELL, C. ISACKE, I. A. VERMA, AND A. ULLRICH. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature 320: 277-280, 1986[Medline]. |
| 86. | CROSBY, J. R., R. A. SEIFERT, P. SORIANO, AND D. F. BOWEN-POPE. Chimaeric analysis reveals role of PDGF receptors in all muscle lineages. Nature Genet. 18: 385-388, 1998[Medline]. |
| 87. | CUNNINGHAM, L. D., P. BRECHER, AND R. A. COHEN. Platelet-derived growth factor receptors on macrovascular endothelial cells mediate relaxation via nitric oxide in rat aorta. J. Clin. Invest. 89: 878-882, 1992. |
| 88. |
DAHLFORS, G.,
Y. CHEN,
M. WASTESON, AND H. J. ARNQVIST.
PDGF-BB-induced DNA synthesis is delayed by angiotensin II in vascular smooth muscle cells.
Am. J. Physiol.
274 (Heart Circ. Physiol. 43): H1742-H1748, 1998 |
| 89. |
DALLA FAVERA, R.,
R. C. GALLO,
A. GIALLONGO, AND C. M. CROCE.
Chromosomal localization of the human homolog (c-sis) of the simian sarcoma virus oncogene.
Science
218: 686-688, 1982 |
| 90. |
DANIEL, T. O.,
V. C. GIBBS,
D. F. MILFAY,
M. R. GAROVOY, AND L. T. WILLIAMS.
Thrombin stimulates c-sis gene expression in microvascular endothelial cells.
J. Biol. Chem.
261: 9579-9582, 1986 |
| 91. | DANILENKO, D. M., B. D. RING, J. E. TARPLEY, B. MORRIS, G. Y. VAN, A. MORAWIECKI, W. CALLAHAN, M. GOLDENBERG, S. HERSHENSON, AND G. F. PIERCE. Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor. Am. J. Pathol. 147: 1261-1277, 1995[Abstract]. |
| 92. |
DARNELL, J. E., JR
STATs and gene regulation.
Science
277: 1630-1635, 1997 |
| 93. |
DAVIS, J. B., AND P. STROOBANT.
Platelet-derived growth factors and fibroblast growth factors are mitogens for rat Schwann cells.
J. Cell Biol.
110: 1353-1360, 1990 |
| 94. |
DAYNES, R. A.,
T. DOWELL, AND B. A. ARANEO.
Platelet-derived growth factor is a potent biologic response modifier of T cells.
J. Exp. Med.
174: 1323-1333, 1991 |
| 95. | DEINHARDT, F. In: The Biology of Primate Retrovirus, edited by G. Klein. New York: Raven, 1980, p. 359-398. |
| 96. |
DE PARSEVAL, N.,
S. FICHELSON,
P. MAYEUX,
S. GISSELBRECHT, AND B. SOLA.
Expression of functional -platelet-derived growth factor receptors on hematopoietic cell lines.
Cytokine
5: 8-15, 1993[Medline].
|
| 97. |
DEUEL, T. F.,
J. S. HUANG,
R. T. PROFFITT,
J. U. BAENZIGER,
D. CHANG, AND B. B. KENNEDY.
Human platelet-derived growth factor: purification and resolution into two active protein fractions.
J. Biol. Chem.
256: 8896-8899, 1981 |
| 98. |
DEVARE, S. G.,
E. P. REDDY,
J. D. LAW,
K. C. ROBBINS, AND S. A. AARONSON.
Nucleotide sequence of the simian sarcoma virus genome: demonstration that its acquired cellular sequences encode the transforming gene product p28sis.
Proc. Natl. Acad. Sci. USA
80: 731-735, 1983 |
| 99. |
DICORLETO, P. E., AND D. F. BOWEN-POPE.
Cultured endothelial cells produce a platelet-derived growth factor-like protein.
Proc. Natl. Acad. Sci. USA
80: 1919-1923, 1983 |
| 100. |
DILIBERTO, P. A.,
G. W. GORDON,
C.-L. YU,
H. S. EARP, AND B. HERMAN.
Platelet-derived growth factor (PDGF) receptor activation modulates the calcium mobilizing activity of the PDGF receptor in Balb/c3T3 fibroblasts.
J. Biol. Chem.
267: 11888-11897, 1992 |
| 101. | DIRKS, R. P., H. J. JANSEN, C. ONNEKINK, R. J. DE JONGE, AND H. P. BLOEMERS. DNase-I-hypersensitive sites located far upstream of the human c-sis/PDGF-B gene comap with transcriptional enhancers and a silencer and are preceded by (part of) a new transcription unit. Eur. J. Biochem. 216: 487-495, 1993[Medline]. |
| 102. | DIRKS, R. P. H., AND H. P. J. BLOEMERS. Signals controlling the expression of PDGF. Mol. Biol. Rep. 22: 1-24, 1996. |
| 103. |
DIRKS, R. P. H.,
H. J. JANSEN,
B. VAN GERVEN,
C. ONNEKINK, AND H. P. J. BLOEMERS.
In vivo footprinting and functional analysis of the human c-sis/PDGF B gene promoter provides evidence for two binding sites for transcriptional activators.
Nucleic Acids Res.
23: 1119-1126, 1995 |
| 104. |
DIRKS, R. P. H.,
C. ONNEKINK,
H. J. JANSEN,
A. DE JONG, AND H. P. J. BLOEMERS.
A novel human c-sis mRNA species is transcribed from a promoter in c-sis intron 1 and contains the code for an alternative PDGF B-like protein.
Nucleic Acids Res.
23: 2815-2822, 1995 |
| 105. |
DUAN, D.-S. R.,
M. J. PAZIN,
L. J. FRETTO, AND L. T. WILLIAMS.
A functional soluble extracellular region of the platelet-derived growth factor (PDGF) -receptor antagonizes PDGF-stimulated responses.
J. Biol. Chem.
266: 413-418, 1991 |
| 106. |
DUDEK, H.,
S. R. DATTA,
T. F. FRANKE,
M. J. BIRNBAUM,
R. YAO,
G. M. COOPER,
R. A. SEGAL,
D. R. KAPLAN, AND M. E. GREENBERG.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275: 661-665, 1997 |
| 107. | EBERT, M., M. YOKOYAMA, H. FRIESS, M. S. KOBRIN, M. W. BÖCHLER, AND M. KORC. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer 62: 529-535, 1995[Medline]. |
| 108. | ECCLESTON, P. A., E. J. COLLARINI, K. R. JESSEN, R. MIRSKY, AND W. D. RICHARDSON. Schwann cells secrete a PDGF-like factor: evidence for an autocrine growth mechanism involving PDGF. Eur. J. Neurosci. 2: 985-992, 1990[Medline]. |
| 109. |
ECCLESTON, P. A.,
K. FUNA, AND C.-H. HELDIN.
Expression of platelet-derived growth factor (PDGF) and PDGF - and -receptors in the peripheral nervous system: an analysis of sciatic nerve and dorsal root ganglia.
Dev. Biol.
155: 459-470, 1993[Medline].
|
| 110. | EDELBERG, J. M., W. C. AIRD, W. WU, H. RAYBURN, W. S. MAMUYA, M. MERCOLA, AND R. D. ROSENBERG. PDGF mediates cardiac microvascular communication. J. Clin. Invest. 102: 837-843, 1998[Medline]. |
| 111. | EICHNER, W., V. JÄGER, D. HERBST, H. HAUSER, AND J. HOPPE. Large-scale preparation of recombinant platelet-derived growth factor AA secreted from recombinant baby hamster kidney cells. Eur. J. Biochem. 185: 135-140, 1989[Medline]. |
| 111a. |
EKMAN, S.,
E. RUPP THURESSON,
C.-H. HELDIN, AND L. RÖNN-STRAND.
Increased mitogenicity of an ![]() heterodimeric PDGF receptor complex correlates with lack of RasGAP binding.
Oncogene
18: 2481-2488, 1999[Medline].
|
| 112. | EMING, S. A., J. LEE, R. G. SNOW, R. G. TOMPKINS, M. L. YARMUSH, AND J. R. MORGAN. Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice: implications for the use of genetically modified keratinocytes to modulate dermal regeneration. J. Invest. Dermatol. 105: 756-763, 1995[Medline]. |
| 113. |
ERIKSSON, A.,
A. SIEGBAHN,
B. WESTERMARK,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
PDGF - and -receptors activate unique and common signal transduction pathways.
EMBO J.
11: 543-550, 1992[Medline].
|
| 114. | ERPEL, T., AND S. A. COURTNEIDGE. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr. Opin. Cell Biol. 7: 176-182, 1995[Medline]. |
| 115. |
FALASCA, M.,
S. K. LOGAN,
V. P. LEHTO,
G. BACCANTE,
M. A. LEMMON, AND J. SCHLESSINGER.
Activation of phospholipase C by PI3-kinase-induced PH domain-mediated membrane targeting.
EMBO J.
17: 414-422, 1998[Medline].
|
| 116. |
FANTL, W. J.,
J. A. ESCOBEDO, AND L. T. WILLIAMS.
Mutations of the platelet-derived growth factor receptor that cause a loss of ligand-induced conformational change, subtle changes in kinase activity, and impaired ability to stimulate DNA synthesis.
Mol. Cell. Biol.
9: 4473-4478, 1989 |
| 117. | FELLSTRÖM, B., L. KLARESKOG, C.-H. HELDIN, E. LARSSON, L. RÖNNSTRAND, L. TERRACIO, G. TUFVESON, J. WAHLBERG, AND K. RUBIN. Platelet-derived growth factor receptors in the kidney: upregulated expression in inflammation. Kidney Int. 36: 1099-1102, 1989[Medline]. |
| 118. | FEN, Z., AND T. O. DANIEL. 5'-Untranslated sequences determine degradative pathway for alternate PDGF B/c-sis mRNAs. Oncogene 6: 953-959, 1991[Medline]. |
| 119. |
FENSTERMAKER, R. A.,
E. POPTIC,
T. L. BONFIELD,
T. C. KNAUSS,
L. CORSILLO,
J. F. PISKURICH,
C. S. KAETZEL,
J. E. JENTOFT,
C. GELFAND,
P. E. DICORLETO, AND J. KAETZEL.
A cationic region of the platelet-derived growth factor (PDGF) A-chain (Arg159-Lys160-Lys161) is required for receptor binding and mitogenic activity of the PDGF-AA homodimer.
J. Biol. Chem.
268: 10482-10489, 1993 |
| 120. |
FERNS, G. A. A.,
E. W. RAINES,
K. H. SPRUGEL,
A. S. MOTANI,
M. A. REIDY, AND R. ROSS.
Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF.
Science
253: 1129-1132, 1991 |
| 121. |
FEYZI, E.,
F. LUSTIG,
G. FAGER,
D. SPILLMANN,
U. LINDAHL, AND M. SALMIVIRTA.
Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain.
J. Biol. Chem.
272: 5518-5524, 1997 |
| 122. | FIELD, S. L., L. M. KHACHIGIAN, M. J. SLEIGH, G. YANG, S. E. VANDERMARK, P. J. HOGG, AND C. N. CHESTERMAN. Extracellular matrix is a source of mitogenically active platelet-derived growth factor. J. Cell. Physiol. 168: 322-332, 1996[Medline]. |
| 123. | FIGARELLA-BRANGER, D., A. M. VAGNER-CAPODANO, P. BOUILLOT, N. GRAZIANI, D. GAMBARELLI, B. DEVICTOR, H. ZATTARA-CANNONI, N. BIANCO, F. GRISOLI, AND J. F. PELLISSIER. Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis. Neuropathol. Appl. Neurobiol. 20: 439-447, 1994[Medline]. |
| 124. | FISCHER, W. H., AND D. SCHUBERT. Characterization of a novel platelet-derived growth factor-associated protein. J. Neurochem. 66: 2213-2216, 1996[Medline]. |
| 125. |
FITZER-ATTAS, C.,
H. ELDAR,
L. EISENBACH, AND E. LIVNEH.
The expression of PDGF- but not PDGF- receptors is suppressed in Swiss/3T3 fibroblasts over-expressing protein kinase C- .
FEBS Lett.
342: 165-170, 1994[Medline].
|
| 126. |
FLEMING, T. P.,
T. MATSUI,
C. J. MOLLOY,
K. C. ROBBINS, AND S. A. AARONSON.
Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.
Proc. Natl. Acad. Sci. USA
86: 8063-8067, 1989 |
| 127. |
FLEMING, T. P.,
A. SAXENA,
W. C. CLARK,
J. T. ROBERTSON,
E. H. OLDFIELD,
S. A. AARONSON, AND I. U. ALI.
Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.
Cancer Res.
52: 4550-4553, 1992 |
| 128. | FLOEGE, J., E. ENG, B. A. YOUNG, C. E. ALPERS, T. B. BARRETT, D. F. BOWEN-POPE, AND R. J. JOHNSON. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J. Clin. Invest. 92: 2952-2962, 1993. |
| 129. | FLOEGE, J., N. TOPLEY, J. HOPPE, T. B. BARRETT, AND K. RESCH. Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokines. Clin. Exp. Immunol. 86: 334-341, 1991[Medline]. |
| 130. |
FORSBERG, K.,
I. VALYI-NAGY,
C.-H. HELDIN,
M. HERLYN, AND B. WESTERMARK.
Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB.
Proc. Natl. Acad. Sci. USA
90: 393-397, 1993 |
| 131. | FRANKLIN, G. C., M. DONOVAN, G. I. R. ADAM, L. HOLMGREN, S. PFEIFER-OHLSSON, AND R. OHLSSON. Expression of the human PDGF-B gene is regulated by both positively and negatively acting cell type-specific regulatory elements located in the first intron. EMBO J. 10: 1365-1373, 1991[Medline]. |
| 132. | FRESSINAUD, C., J. M. VALLAT, AND A. POUPLARD-BARTHELAIX. Platelet-derived growth factor partly prevents chemically induced oligodendrocyte death and improves myelin-like membranes repair in vitro. Glia 16: 40-50, 1996[Medline]. |
| 133. | FRISCH, S. M., AND E. RUOSLAHTI. Integrins and anoikis. Curr. Opin. Cell Biol. 9: 701-706, 1997[Medline]. |
| 134. | FUDGE, K., D. G. BOSTWICK, AND M. E. STEARNS. Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 29: 282-286, 1996[Medline]. |
| 135. | FUNA, K., N. YAMADA, G. BRODIN, K. PIETZ, A. ÅHGREN, K. WICTORIN, O. LINDVALL, AND P. ODIN. Enhanced synthesis of platelet-derived growth factor following injury induced by 6-hydroxydopamine in rat brain. Neuroscience 74: 825-833, 1996[Medline]. |
| 136. |
GASHLER, A. L.,
D. T. BONTHRON,
S. L. MADDEN,
F. J. RAUSCHER III,
T. COLLINS, AND V. P. SUKHATME.
Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.
Proc. Natl. Acad. Sci. USA
89: 10984-10988, 1992 |
| 137. | GAY, S., R. E. J. JONES, G. Q. HUANG, AND R. E. GAY. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J. Invest. Dermatol. 92: 301-303, 1989[Medline]. |
| 138. | GEORGE, S. J., A. WILLIAMS, AND A. C. NEWBY. An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis 120: 227-240, 1996[Medline]. |
| 139. |
GERSUK, G. M.,
R. CARMEL, AND P. K. PATTENGALE.
Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Blood
74: 2330-2334, 1989 |
| 140. | GESUALDO, L., S. DI PAOLO, S. MILANI, M. PINZANI, C. GRAPPONE, E. RANIERI, G. PANNARALE, AND F. P. SCHENA. Expression of platelet-derived growth factor receptors in normal and diseased human kidney. An immunohistochemistry and in situ hybridization study. J. Clin. Invest. 94: 50-58, 1994. |
| 141. | GESUALDO, L., M. PINZANI, J. J. FLORIANO, M. O. HASSAN, N. U. NAGY, F. P. SCHENA, S. N. EMANCIPATOR, AND H. E. ABBOUD. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab. Invest. 65: 160-167, 1991[Medline]. |
| 142. |
GIESE, N.,
M. MAY-SIROFF,
W. J. LAROCHELLE,
K. VAN WYKE COELINGH, AND S. A. AARONSON.
Expression and purification of biologically active v-sis/platelet-derived growth factor B protein by using a baculovirus vector system.
J. Virol.
63: 3080-3086, 1989 |
| 143. |
GNESSI, L.,
A. EMIDI,
E. A. JANNINI,
E. CAROSA,
M. MARODER,
M. ARIZZI,
S. ULISSE, AND G. SPERA.
Testicular development involves the spatiotemporal control of PDGFs and PDGF receptors gene expression and action.
J. Cell Biol.
131: 1105-1121, 1995 |
| 144. | GOLDEN, M. A. Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons: association in vivo of platelet-derived growth factor mRNA and protein with cellular proliferation. J. Clin. Invest. 87: 406-414, 1991. |
| 145. | GOLDSTEIN, D. J., T. ANDRESSON, J. J. SPARKOWSKI, AND R. SCHLEGEL. The BPV-1 E5 protein, the 16 kDa membrane pore-forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. EMBO J. 11: 4851-4859, 1992[Medline]. |
| 146. |
GOLDSTEIN, D. J.,
W. LI,
L. M. WANG,
M. A. HEIDARAN,
S. AARONSON,
R. SHINN,
R. SCHLEGEL, AND J. H. PIERCE.
The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the beta-type receptor for the platelet-derived growth factor but not other related tyrosine kinase-containing receptors to induce cellular transformation.
J. Virol.
68: 4432-4441, 1994 |
| 147. |
GOLUB, T. R.,
G. F. BARKER,
M. LOVETT, AND D. G. GILLILAND.
Fusion of PDGF receptor to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.
Cell
77: 307-316, 1994[Medline].
|
| 148. | GOTOH, N., M. TOYODA, AND M. SHIBUYA. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol. Cell. Biol. 17: 1824-1831, 1997[Abstract]. |
| 149. | GOUSTIN, A. S., C. BETSHOLTZ, S. PFEIFER-OHLSSON, H. PERSSON, J. RYDNERT, M. BYWATER, G. HOLMGREN, C.-H. HELDIN, B. WESTERMARK, AND R. OHLSSON. Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. Cell 41: 301-312, 1985[Medline]. |
| 150. |
GRAVES, L. M.,
K. E. BORNFELDT,
J. S. SIDHU,
G. M. ARGAST,
E. W. RAINES,
R. ROSS,
C. C. LESLIE, AND E. G. KREBS.
Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells.
J. Biol. Chem.
271: 505-511, 1996 |
| 151. |
GRAY, K.,
B. EITZMAN,
K. RASZMANN,
T. STEED,
A. GEBOFF,
J. McLACHLAN, AND M. BIDWELL.
Coordinate regulation by diethylstilbestrol of the platelet-derived growth factor-A (PDGF-A) and -B chains and the PDGF receptor - and -subunits in the mouse uterus and vagina: potential mediators of estrogen action.
Endocrinology
136: 2325-2340, 1995[Abstract].
|
| 152. | GREEN, L. S., D. JELLINEK, R. JENISON, A. ÖSTMAN, C.-H. HELDIN, AND N. JANJIC. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35: 14413-14424, 1996[Medline]. |
| 153. |
GREEN, R. J.,
M. L. USUI,
C. E. HART,
W. F. AMMONS, AND A. S. NARAYANAN.
Immunolocalization of platelet-derived growth factor A and B chains and PDGF- and receptors in human gingival wounds.
J. Periodont. Res.
32: 209-214, 1997[Medline].
|
| 154. |
GRONWALD, R. G. K.,
R. A. SEIFERT, AND D. F. BOWEN-POPE.
Differential regulation of expression of two platelet-derived growth factor receptor subunits by transforming growth factor- .
J. Biol. Chem.
264: 8120-8125, 1989 |
| 155. | GROTENDORST, G. R., G. R. MARTIN, D. PANCEV, J. SODEK, AND A. K. HARVEY. Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats. J. Clin. Invest. 76: 2323-2339, 1985. |
| 156. | GUHA, A., K. DASHNER, P. M. BLACK, J. A. WAGNER, AND C. D. STILES. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int. J. Cancer 60: 168-173, 1995[Medline]. |
| 157. |
GUHA, A.,
D. GLOWACKA,
R. CARROLL,
K. DASHNER,
P. M. BLACK, AND C. D. STILES.
Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome.
J. Neurol. Neurosurg. Psychiatry
58: 711-714, 1995 |
| 158. |
GUITON, M.,
F. J. GUNN-MOORE,
T. N. STITT,
G. D. YANCOPOULOS, AND J. M. TAVARE.
Identification of in vivo brain-derived neurotrophic factor-stimulated autophosphorylation sites on the TrkB receptor tyrosine kinase by site-directed mutagenesis.
J. Biol. Chem.
269: 30370-30377, 1994 |
| 159. |
GULLBERG, D.,
A. TINGSTRÖM,
A.-C. THURESSON,
L. OLSSON,
L. TERRACIO,
T. K. BORG, AND K. RUBIN.
1 Integrin-mediated collagen gel contraction is stimulated by PDGF.
Exp. Cell Res.
186: 264-272, 1990[Medline].
|
| 160. |
HAISA, M.,
H. OKOCHI, AND G. R. GROTENDORST.
Elevated levels of PDGF receptors in keloid fibroblasts contribute to an enhanced response to PDGF.
J. Invest. Dermatol.
103: 560-563, 1994[Medline].
|
| 161. | HALL, A., N. A. GIESE, AND W. D. RICHARDSON. Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development 122: 4085-4094, 1996[Abstract]. |
| 162. |
HAMMACHER, A.,
U. HELLMAN,
A. JOHNSSON,
A. ÖSTMAN,
K. GUNNARSON,
B. WESTERMARK,
Å. WASTESON, AND C.-H. HELDIN.
A major part of platelet-derived growth factor purified from human platelets is a heterodimer of one A and one B chain.
J. Biol. Chem.
263: 16493-16498, 1988 |
| 163. | HAMMACHER, A., K. MELLSTRÖM, C.-H. HELDIN, AND B. WESTERMARK. Isoform-specific induction of actin reorganization by platelet-derived growth factor suggests that the functionally active receptor is a dimer. EMBO J. 8: 2489-2495, 1989[Medline]. |
| 164. | HAMMACHER, A., M. NISTÉR, B. WESTERMARK, AND C.-H. HELDIN. A human glioma cell line secretes three structurally and functionally different dimeric forms of platelet-derived growth factor. Eur. J. Biochem. 176: 179-186, 1988[Medline]. |
| 165. |
HAN, R. N.,
S. BUCH,
B. A. FREEMAN,
M. POST, AND A. K. TANSWELL.
Platelet-derived growth factor and growth-related genes in rat lung. II. Effect of exposure to 85% O2.
Am. J. Physiol.
262 (Lung Cell. Mol. Physiol. 6): L140-L146, 1992 |
| 166. | HANIU, M., P. HSIEH, M. F. ROHDE, AND W. C. KENNEY. Characterization of disulfide linkages in platelet-derived growth factor AA. Arch. Biochem. Biophys. 310: 433-439, 1994[Medline]. |
| 167. | HANIU, M., M. F. ROHDE, AND W. C. KENNEY. Disulfide bonds in recombinant human platelet-derived growth factor BB dimer: characterization of intermolecular and intramolecular disulfide linkages. Biochemistry 32: 2431-2437, 1993[Medline]. |
| 168. |
HANNINK, M., AND D. J. DONOGHUE.
Autocrine stimulation by the v-sis gene product requires a ligand-receptor interaction at the cell surface.
J. Cell Biol.
107: 287-298, 1988 |
| 169. |
HARLAN, J. M.,
P. J. THOMPSON,
R. ROSS, AND D. F. BOWEN-POPE.
-Thrombin induces release of platelet-derived growth factor-like molecule(s) by cultured human endothelial cells.
J. Cell Biol.
103: 1129-1133, 1986 |
| 170. | HARMON, K. R., C. J. WITKOP, J. G. WHITE, R. A. KING, M. PETERSON, D. MOORE, J. TASHJIAN, W. A. MARINELLI, AND P. B. BITTERMAN. Pathogenesis of pulmonary fibrosis: platelet-derived growth factor precedes structural alterations in the Hermansky-Pudlak syndrome. J. Lab. Clin. Med. 123: 617-627, 1994[Medline]. |
| 171. | HART, C. E., M. BAILEY, D. A. CURTIS, S. OSBORN, E. RAINES, R. ROSS, AND J. W. FORSTROM. Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry 29: 166-172, 1990[Medline]. |
| 172. |
HART, C. E., AND A. W. CLOWES.
Platelet-derived growth factor and arterial response to injury.
Circulation
95: 555-556, 1997 |
| 173. |
HART, I. K.,
W. D. RICHARDSON,
S. R. BOLSOVER, AND M. C. RAFF.
PDGF and intracellular signaling in the timing of oligodendrocyte differentiation.
J. Cell Biol.
109: 3411-3417, 1989 |
| 174. |
HART, I. K.,
W. D. RICHARDSON,
C.-H. HELDIN,
B. WESTERMARK, AND M. C. RAFF.
PDGF receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage.
Development
105: 595-603, 1989 |
| 175. | HAWKINS, P. T., A. EGUINOA, R.-G. QIU, D. STOKOE, F. T. COOKE, R. WALTERS, S. WENNSTRÖM, L. CLAESSON-WELSH, T. EVANS, M. SYMONS, AND L. STEPHENS. PDGF stimulates an increase in GTP-Rac via activation of phosphoinositide 3-kinase. Curr. Biol. 5: 393-403, 1995[Medline]. |
| 176. | HAYNES, A. R., AND R. J. SHAW. Dexamethasone-induced increase in platelet-derived growth factor (B) mRNA in human alveolar macropahges and myelomonocytic HL60 marcrophage-like cells. Am. J. Respir. Cell Mol. Biol. 7: 198-206, 1992. |
| 177. |
HEIDARAN, M. A.,
J. H. PIERCE,
R. A. JENSEN,
T. MATSUI, AND S. A. AARONSON.
Chimeric - and -platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the -PDGF receptor that determine PDGF-AA binding specificity.
J. Biol. Chem.
265: 18741-18744, 1990 |
| 178. |
HEIDARAN, M. A.,
J. F. BEELER,
J.-C. YU,
T. ISHIBASHI,
W. J. LAROCHELLE,
J. H. PIERCE, AND S. A. AARONSON.
Differences in substrate specificities of and platelet-derived growth factor (PDGF) receptors.
J. Biol. Chem.
268: 9287-9295, 1993 |
| 179. |
HEIDARAN, M. A.,
J. H. PIERCE,
J.-C. YU,
D. LOMBARDI,
J. E. ARTRIP,
T. P. FLEMING,
A. THOMASON, AND S. A. AARONSON.
Role of ![]() receptor heterodimer formation in platelet-derived growth factor (PDGF) receptor activation by PDGF-AB.
J. Biol. Chem.
266: 20232-20237, 1991 |
| 180. |
HELDIN, C.-H.,
A. ERNLUND,
C. RORSMAN, AND L. RÖNNSTRAND.
Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation.
J. Biol. Chem.
264: 8905-8912, 1989 |
| 181. | HELDIN, C.-H., AND A. ÖSTMAN. Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokines Growth Factor Rev. 7: 3-10, 1996[Medline]. |
| 182. | HELDIN, C.-H., A. ÖSTMAN, AND L. RÖNNSTRAND. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1378: 79-113, 1998. |
| 183. | HELDIN, C.-H., AND B. WESTERMARK. In: Role of Platelet-Derived Growth Factor In Vivo (2nd ed.), edited by R. A. F. Clark. New York: Plenum, 1996, p. 249-273. |
| 184. |
HELDIN, C.-H.,
B. WESTERMARK, AND Å. WASTESON.
Platelet-derived growth factor: purification and partial characterization.
Proc. Natl. Acad. Sci. USA
76: 3722-3726, 1979 |
| 185. | HELDIN, P., T. C. LAURENT, AND C.-H. HELDIN. Effect of growth factors on hyaluronan synthesis in cultured human fibroblasts. Biochem. J. 258: 919-922, 1989[Medline]. |
| 186. |
HELDIN, P.,
H. PERTOFT,
H. NORDLINDER,
C.-H. HELDIN, AND T. C. LAURENT.
Differential expression of platelet-derived growth factor - and -receptors on fat-storing cells and endothelial cells of rat liver.
Exp. Cell Res.
193: 364-369, 1991[Medline].
|
| 187. |
HENRIKSEN, R.,
K. FUNA,
E. WILANDER,
T. BÄCKSTRÖM,
M. RIDDERHEIM, AND K. BERG.
Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
Cancer Res.
53: 4550-4554, 1993 |
| 188. |
HERMANSON, M.,
K. FUNA,
M. HARTMAN,
L. CLAESSON-WELSH,
C.-H. HELDIN,
B. WESTERMARK, AND M. NISTÉR.
Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
Cancer Res.
52: 3213-3219, 1992 |
| 189. |
HERMANSON, M.,
K. FUNA,
J. KOOPMANN,
D. MAINTZ,
A. WAHA,
B. WESTERMARK,
C.-H. HELDIN,
O. D. WIESTLER,
D. N. LOUIS,
A. VON DEIMLING, AND M. NISTÉR.
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor receptor expression in human malignant gliomas.
Cancer Res.
56: 164-171, 1996 |
| 190. | HERMANSON, M., T. OLSSON, B. WESTERMARK, AND K. FUNA. PDGF and its receptors following facial nerve axotomy in rats: expression in neurons and surrounding glia. Exp. Brain Res. 102: 415-422, 1995[Medline]. |
| 191. |
HERTZ, M. I.,
C. A. HENKE,
R. E. NAKHLEH,
K. R. HARMON,
W. A. MARINELLI,
J. M. K. FOX,
S. H. KUBO,
S. J. SHUMWAY,
R. M. BOLMAN III, AND P. B. BITTERMAN.
Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor.
Proc. Natl. Acad. Sci. USA
89: 10385-10389, 1992 |
| 192. | HO, L., K. SYMES, C. YORDÁN, L. J. GUDAS, AND M. MERCOLA. Localization of PDGF A and PDGFRalpha mRNA in Xenopus embryos suggests signalling from neural ectoderm and pharyngeal endoderm to neural crest cells. Mech. Dev. 48: 165-174, 1994[Medline]. |
| 193. | HOGG, P. J., K. A. HOTCHKISS, B. M. JIMÉNEZ, P. STATHAKIS, AND C. N. CHESTERMAN. Interaction of platelet-derived growth factor with thrombospondin 1. Biochem. J. 326: 709-716, 1997. |
| 194. |
HOLMGREN, L.,
F. FLAM,
E. LARSSON, AND R. OHLSSON.
Successive activation of the platelet-derived growth factor receptor and platelet-derived growth factor B genes correlates with the genesis of human choriocarcinoma.
Cancer Res.
53: 2927-2931, 1993 |
| 195. | HOOSHMAND-RAD, R., L. CLAESSON-WELSH, S. WENNSTRÖM, K. YOKOTE, A. SIEGBAHN, AND C.-H. HELDIN. Involvement of phosphatidylinositide 3'-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis. Exp. Cell Res. 234: 434-441, 1997[Medline]. |
| 196. |
HOOSHMAND-RAD, R.,
K. YOKOTE,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
PDGF -receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells.
J. Cell Sci.
111: 607-614, 1998[Abstract].
|
| 197. | HOPPE, J., H. A. WEICH, AND W. EICHNER. Preparation of biologically active platelet-derived growth factor type BB from a fusion protein expressed in Escherichia coli. Biochemistry 28: 2956-2960, 1989[Medline]. |
| 198. | HOPPE, J., H. A. WEICH, W. EICHNER, AND D. TATJE. Preparation of biologically active platelet-derived growth factor isoforms AA and AB. Preferential formation of AB heterodimers. Eur. J. Biochem. 187: 207-214, 1990[Medline]. |
| 199. | HORNER, A., S. BORD, P. KEMP, D. GRAINGER, AND J. E. COMPSTON. Distribution of platelet-derived growth factor (PDGF) A chain mRNA, protein, and PDGF-a receptor in rapidly forming human bone. Bone 19: 353-362, 1996[Medline]. |
| 200. |
HORWITZ, B. H.,
A. L. BURKHARDT,
R. SCHLEGEL, AND D. DIMAIO.
44-Amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids.
Mol. Cell. Biol.
8: 4071-4078, 1988 |
| 201. | HOSANG, M., M. ROUGE, B. WIPF, B. EGGIMANN, F. KAUFMANN, AND W. HUNZIKER. Both homodimeric isoforms of PDGF (AA and BB) have mitogenic and chemotactic activity and stimulate phosphoinositol turnover. J. Cell. Physiol. 140: 558-564, 1989[Medline]. |
| 202. | HOSSAIN, M. Z., P. AO, AND A. L. BOYNTON. Rapid disruption of gap junctional communication and phosphorylation of connexin43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J. Cell. Physiol. 174: 66-77, 1998[Medline]. |
| 203. |
HU, Q.,
A. KLIPPEL,
A. J. MUSLIN,
W. J. FANTL, AND L. T. WILLIAMS.
Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase.
Science
268: 100-102, 1995 |
| 204. |
HUANG, S. S., AND J. S. HUANG.
Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation.
J. Biol. Chem.
263: 12608-12618, 1988 |
| 205. |
IIDA, H.,
R. SEIFERT,
C. E. ALPERS,
R. G. K. GRONWALD,
P. E. PHILLIPS,
P. PRITZL,
K. GORDON,
A. M. GOWN,
R. ROSS,
D. F. BOWEN-POPE, AND R. J. JOHNSON.
Platelet-derived growth factor (PDGF) and PDGF receptor are induced in mesangial proliferative nephritis in the rat.
Proc. Natl. Acad. Sci. USA
88: 6560-6564, 1991 |
| 206. |
IKEDA, M.,
C. MORITA,
M. MIZUNO,
T. SADA,
H. KOIKE, AND K. KUROKAWA.
PDGF-BB decreases systolic blood pressure through an increase in macrovascular compliance in rats.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42): H1719-H1726, 1997 |
| 207. |
INABA, T.,
H. SHIMANO,
T. GOTODA,
K. HARADA,
M. SHIMADA,
J.-I. OHSUGA,
Y. WATANABE,
M. KAWAMURA,
Y. YAZAKI, AND N. YAMADA.
Expression of platelet-derived growth factor receptor on human monocyte-derived macrophages and effects of platelet-derived growth factor BB dimer on the cellular function.
J. Biol. Chem.
268: 24353-24360, 1993 |
| 208. |
ISAKA, Y.,
Y. FUJIWARA,
N. UEDA,
Y. KANEDA,
T. KAMADA, AND E. IMAI.
Glomerulosclerosis induced by in vivo transfection of transforming growth factor- or platelet-derived growth factor gene into the rat kidney.
J. Clin. Invest.
92: 2597-2601, 1993.
|
| 209. |
ISHISAKI, A.,
T. MURAYAMA,
A. E. BALLAGI, AND K. FUNA.
Nuclear factor Y controls the basal transcription activity of the mouse platelet-derived-growth-factor -receptor gene.
Eur. J. Biochem.
246: 142-146, 1997[Medline].
|
| 210. | JAWIEN, A., D. F. BOWEN-POPE, V. LINDNER, S. M. SCHWARTZ, AND A. W. CLOWES. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89: 507-511, 1992. |
| 211. |
JIN, H.-M.,
M. L. BRADY, AND W. E. FAHL.
Identification and characterization of an essential, activating regulatory element of the human SIS/PDGFB promoter in human megakaryocytes.
Proc. Natl. Acad. Sci. USA
90: 7563-7567, 1993 |
| 212. |
JIN, H.-M.,
D. F. ROBINSON,
Y. LIANG, AND W. E. FAHL.
SIS/PDGF-B promoter isolation and characterization of regulatory elements necessary for basal expression of the SIS/PDGF-B gene in U2-OS osteosarcoma cells.
J. Biol. Chem.
269: 28648-28654, 1994 |
| 213. |
JIN, P.,
M. RAHM,
L. CLAESSON-WELSH,
C.-H. HELDIN, AND T. SEJERSEN.
Expression of PDGF A-chain and -receptor genes during rat myoblast differentiation.
J. Cell Biol.
110: 1665-1672, 1990 |
| 214. | JOHNSON, R. J., H. IIDA, C. E. ALPERS, M. W. MAJESKY, S. M. SCHWARTZ, P. PRITZL, K. GORDON, AND A. M. GOWN. Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. J. Clin. Invest. 87: 847-858, 1991. |
| 215. |
JOHNSON, R. J.,
E. W. RAINES,
J. FLOEGE,
A. YOSHIMURA,
P. PRITZL,
C. ALPERS, AND R. ROSS.
Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor.
J. Exp. Med.
175: 1413-1416, 1992 |
| 216. | JOHNSSON, A., C. BETSHOLTZ, C.-H. HELDIN, AND B. WESTERMARK. Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. Nature 317: 438-440, 1985[Medline]. |
| 217. | JOHNSSON, A., C.-H. HELDIN, Å. WASTESON, B. WESTERMARK, T. F. DEUEL, J. S. HUANG, P. H. SEEBURG, A. GRAY, A. ULLRICH, G. SCRACE, P. STROOBANT, AND M. D. WATERFIELD. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EMBO J. 3: 921-928, 1984[Medline]. |
| 218. |
JOLY, M.,
A. KAZLAUSKAS,
F. S. FAY, AND S. CORVERA.
Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase binding sites.
Science
263: 684-687, 1994 |
| 219. | JOUKOV, V., A. KAIPAINEN, M. JELTSCH, K. PAJUSOLA, B. OLOFSSON, V. KUMAR, U. ERIKSSON, AND K. ALITALO. Vascular endothelial growth factors VEGF-B and VEGF-C. J. Cell. Physiol. 173: 211-215, 1997[Medline]. |
| 220. | KAETZEL, D. M., D. W. COYNE, AND R. A. FENSTERMAKER. Transcriptional control of the platelet-derived growth factor subunit genes. Biofactors 4: 71-81, 1993[Medline]. |
| 221. | KAETZEL, D. M., JR., R. S. MAUL, B. LIU, D. BONTHRON, R. A. FENSTERMAKER, AND D. W. COYNE. Platelet-derived growth factor A-chain gene transcription is mediated by positive and negative regulatory regions in the promoter. Biochem. J. 301: 321-327, 1994. |
| 222. |
KAMAT, A., AND G. CARPENTER.
Phospholipase C- 1: regulation of enzyme function and role in growth factor-dependent signal transduction.
Cytokine Growth Factor Rev.
8: 109-117, 1997[Medline].
|
| 223. |
KANAKARAJ, P.,
S. RAJ,
S. A. KHAN, AND S. BISHAYEE.
Ligand-induced interaction between - and -type platelet derived growth factor (PDGF) receptors: role of receptor heterodimers in kinase activation.
Biochemistry
30: 1761-1767, 1991[Medline].
|
| 224. |
KANZAKI, T.,
M. SHINOMIYA,
S. UEDA,
N. MORISAKI,
Y. SAITO, AND S. YOSHIDA.
Enhanced arterial intimal thickening after balloon catheter injury in diabetic animals accompanied by PDGF -receptor overexpression of aortic media.
Eur. J. Clin. Invest.
24: 377-381, 1994[Medline].
|
| 225. |
KAPLAN, D. R.,
F. C. CHAO,
C. D. STILES,
H. N. ANTONIADES, AND C. D. SCHER.
Platelet -granules contain a growth factor for fibroblasts.
Blood
53: 1043-1052, 1979 |
| 226. | KARLSSON, C., AND Y. PAULSSON. Age related induction of platelet-derived growth factor A-chain mRNA in normal human fibroblasts. J. Cell. Physiol. 158: 256-262, 1994[Medline]. |
| 227. |
KATAYOSE, D.,
M. OHE,
K. YAMAUCHI,
M. OGATA,
K. SHIRATO,
H. FUJITA,
S. SHIBAHARA, AND T. TAKISHIMA.
Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension.
Am. J. Physiol.
264 (Lung Cell. Mol. Physiol. 8): L100-L106, 1993 |
| 228. | KATOH, O., A. KIMURA, T. ITOH, AND A. KURAMOTO. Platelet- derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders. Am. J. Hematol. 35: 145-150, 1990[Medline]. |
| 229. | KATOH, O., A. KIMURA, AND A. KURAMOTO. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders. Am. J. Hematol. 27: 276-280, 1988[Medline]. |
| 230. | KATZ, M. H., A. F. ALVAREZ, R. S. KIRSNER, W. H. EAGLSTEIN, AND V. FALANGA. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J. Am. Acad. Dermatol. 25: 1054-1058, 1991[Medline]. |
| 231. | KAUFFMANN-ZEH, A., P. RODRIGUEZ-VICIANA, E. ULRICH, C. GILBERT, P. COFFER, J. DOWNWARD, AND G. EVAN. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-548, 1997[Medline]. |
| 232. |
KAWAGISHI, J.,
T. KUMABE,
T. YOSHIMOTO, AND T. YAMAMOTO.
Structure, organization, and transcription units of the human -platelet-derived growth factor receptor gene, PDGFRA.
Genomics
30: 224-232, 1995[Medline].
|
| 233. | KAWAI, T., S. HIROI, AND C. TORIKATA. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab. Invest. 77: 431-436, 1997[Medline]. |
| 234. | KAZLAUSKAS, A., AND J. A. COOPER. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 58: 1121-1133, 1989[Medline]. |
| 235. |
KEATING, M. T., AND L. T. WILLIAMS.
Autocrine stimulation of intracellular PDGF receptors in v-sis transformed cells.
Science
239: 914-916, 1988 |
| 236. | KELLY, J. D., E. W. RAINES, R. ROSS, AND M. J. MURRAY. The B chain of PDGF alone is sufficient for mitogenesis. EMBO J. 4: 3399-3405, 1985[Medline]. |
| 237. |
KELLY, J. L.,
A. SÁNCHEZ,
G. S. BROWN,
C. N. CHESTERMAN, AND M. J. SLEIGH.
Accumulation of PDGF B and cell-binding forms of PDGF A in the extracellular matrix.
J. Cell Biol.
121: 1153-1163, 1993 |
| 238. |
KENNEY, W. C.,
M. HANIU,
A. C. HERMAN,
T. ARAKAWA,
V. J. COSTIGAN,
J. LARY,
D. A. YPHANTIS, AND A. R. THOMASON.
Formation of mitogenically active PDGF-B dimer does not require interchain disulfide bonds.
J. Biol. Chem.
269: 12351-12359, 1994 |
| 239. |
KHACHIGIAN, L. M.,
K. R. ANDERSON,
N. J. HALNON,
M. A. GIMBRONE, JR.,
N. RESNICK, AND T. COLLINS.
Egr-1 is activated in endothelial cells exposed to fluid shear stress and interacts with a novel shear-stress-response element in the PDGF A-chain promoter.
Arterioscler. Thromb. Vasc. Biol.
17: 2280-2286, 1997 |
| 240. |
KHACHIGIAN, L. M.,
J. W. U. FRIES,
M. W. BENZ,
D. T. BONTHRON, AND T. COLLINS.
Novel cis-acting elements in the human platelet-derived growth factor B-chain core promoter that mediate gene expression in cultured vascular endothelial cells.
J. Biol. Chem.
269: 22647-22656, 1994 |
| 241. | KHACHIGIAN, L. M., E. M. MANN, M. A. GIMBRONE, JR., AND T. COLLINS. Nuclear factor-kappaB interacts functionally with the platelet-derived growth factor B-chain shear-stress response element in vascular endothelial cells exposed to fluid shear stress. J. Clin. Invest. 96: 1169-1175, 1995. |
| 242. |
KHACHIGIAN, L. M.,
A. J. WILLIAMS, AND T. COLLINS.
Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells.
J. Biol. Chem.
270: 27679-27686, 1995 |
| 243. | KIMURA, A., O. KATOH, H. HYODO, A. KURAMOTO, AND Y. SATOW. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk. Lymphoma 18: 237-242, 1995[Medline]. |
| 244. | KIMURA, A., Y. NAKATA, H. HYODO, A. KURAMOTO, AND Y. SATOW. Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br. J. Haematol. 86: 303-307, 1994[Medline]. |
| 245. |
KIMURA, K.,
S. HATTORI,
Y. KABUYAMA,
Y. SHIZAWA,
J. TAKAYANAGI,
S. NAKAMURA,
S. TOKI,
Y. MATSUDA,
K. ONODERA, AND Y. FUKUI.
Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase.
J. Biol. Chem.
269: 18961-18967, 1994 |
| 246. |
KIRCHBERG, K.,
T. S. LANGE,
E. C. KLEIN,
H. JUNGTÄUBL,
G. HEINEN,
W. MEYER-INGOLD, AND K. SCHARFFETTER-KOCHANEK.
Induction of 1 integrin synthesis by recombinant platelet-derived growth factor (PDGF-AB) correlates with an enhanced migratory response of human dermal fibroblasts to various extracellular matrix proteins.
Exp. Cell Res.
220: 29-35, 1995[Medline].
|
| 247. |
KITAGAWA, M.,
S. YOSHIDA,
I. ISHIGE,
J. MINAMI,
T. KUWATA,
T. TANIZAWA, AND R. KAMIYAMA.
Immunolocalization of platelet-derived growth factor, transforming growth factor- , and fibronectin in acute megakaryoblastic leukemia manifesting tumor formation.
Hum. Pathol.
25: 723-726, 1994[Medline].
|
| 248. |
KITAMI, Y.,
H. INUI,
S. UNO, AND T. INAGAMI.
Molecular structure and transcriptional regulation of the gene for the platelet-derived growth factor receptor in cultured vascular smooth muscle cells.
J. Clin. Invest.
96: 558-567, 1995.
|
| 249. | KLARESKOG, L., R. GUSTAFSSON, A. SCHEYNIUS, AND R. HÄLLGREN. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum. 33: 1534-1541, 1990[Medline]. |
| 250. |
KLINGHOFFER, R. A., AND A. KAZLAUSKAS.
Identification of a putative Syp substrate, the PDGF receptor.
J. Biol. Chem.
270: 22208-22217, 1995 |
| 251. | KO, F. N., Y. C. YANG, S. C. HUANG, AND J. T. OU. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J. Clin. Invest. 98: 1493-1501, 1996[Medline]. |
| 252. | KOHLER, N., AND A. LIPTON. Platelet as a source of fibroblast growth-promoting activity. Exp. Cell Res. 87: 297-301, 1974[Medline]. |
| 253. | KOUREMBANAS, S., T. MORITA, Y. LIU, AND H. CHRISTOU. Mechanisms by which oxygen regulates gene expression and cell-cell interaction in the vasculature. Kidney Int. 51: 438-443, 1997[Medline]. |
| 254. |
KOVALENKO, M.,
A. GAZIT,
A. BÖHMER,
C. RORSMAN,
L. RÖNNSTRAND,
C.-H. HELDIN,
J. WALTENBERGER,
F.-D. BÖHMER, AND A. LEVITZKI.
Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Cancer Res.
54: 6106-6114, 1994 |
| 255. |
KOYAMA, H.,
Y. NISHIZAWA,
M. HOSOI,
S. FUKUMOTO,
K. KOGAWA,
A. SHIOI, AND H. MORII.
The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I: possible involvement of cyclin-dependent kinase 2.
Circ. Res.
79: 757-764, 1996 |
| 256. | KOYAMA, H., E. W. RAINES, K. E. BORNFELDT, J. M. ROBERTS, AND R. ROSS. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87: 1069-1078, 1996[Medline]. |
| 257. |
KRAISS, L. W.,
R. L. GEARY,
E. J. R. MATTSSON,
S. VERGEL,
Y. P. T. AU, AND A. W. CLOWES.
Acute reductions in blood flow and shear stress induce platelet-derived growth factor-A expression in baboon prosthetic grafts.
Circ. Res.
79: 45-53, 1996 |
| 258. | KRANE, J. F., D. P. MURPHY, A. B. GOTTLIEB, D. M. CARTER, C. E. HART, AND J. G. KRUEGER. Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. J. Invest. Dermatol. 96: 983-986, 1991[Medline]. |
| 259. |
KUMABE, T.,
Y. SOHMA,
T. KAYAMA,
T. YOSHIMOTO, AND T. YAMAMOTO.
Amplification of -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin.
Oncogene
7: 627-633, 1992[Medline].
|
| 260. |
LAMARRE, J.,
M. A. HAYES,
G. K. WOLLENBERG,
I. HUSSAINI,
S. W. HALL, AND S. L. GONIAS.
An 2-macroglobulin receptor-dependent mechanism for the plasma clearance of transforming growth factor- 1 in mice.
J. Clin. Invest.
87: 39-44, 1991.
|
| 261. | LANGERAK, A. W., P. DE LAAT, C. A. J. VAN DER LINDEN-VAN BEURDEN, M. DELAHAYE, T. H. VAN DER KWAST, H. C. HOOGSTEDEN, R. BENNER, AND M. A. VERSNEL. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J. Pathol. 178: 151-160, 1996[Medline]. |
| 262. |
LANGERAK, A. W.,
C. A. J. VAN DER LINDEN-VAN BEURDEN, AND M. A. VERSNEL.
Regulation of differential expression of platelet-derived growth factor - and -receptor mRNA in normal and malignant human mesothelial cell lines.
Biochim. Biophys. Acta
1305: 63-70, 1996[Medline].
|
| 263. | LAROCHELLE, W. J., R. A. JENSEN, M. A. HEIDARAN, M. MAY-SIROFF, L.-M. WANG, S. A. AARONSON, AND J. H. PIERCE. Inhibition of platelet-derived growth factor autocrine growth stimulation by a monoclonal antibody to the human a platelet-derived growth factor receptor. Cell Growth Differ. 4: 547-553, 1993[Abstract]. |
| 264. |
LAROCHELLE, W. J.,
M. MAY-SIROFF,
K. C. ROBBINS, AND S. A. AARONSON.
A novel mechanism regulating growth factor association with the cell surface: identification of a PDGF retention domain.
Genes Dev.
5: 1191-1199, 1991 |
| 265. |
LAROCHELLE, W. J.,
J. H. PIERCE,
M. MAY-SIROFF,
N. GIESE, AND S. A. AARONSON.
Five PDGF B amino acid substitutions convert PDGF A to a PDGF B-like transforming molecule.
J. Biol. Chem.
267: 17074-17077, 1992 |
| 266. |
LEAL, F.,
L. T. WILLIAMS,
K. C. ROBBINS, AND S. A. AARONSON.
Evidence that the v-sis gene product transforms by interaction with the receptor for platelet-derived growth factor.
Science
230: 327-330, 1985 |
| 267. | LEGRAND, E. K., J. F. BURKE, D. E. COSTA, AND T. C. KIORPES. Dose responsive effects of PDGF-BB, PDGF-AA, EGF, and bFGF on granulation tissue in a guinea pig partial thickness skin excision model. Growth Factors 8: 307-314, 1993[Medline]. |
| 268. | LEON, S. P., R. S. CARROLL, K. DASHNER, D. GLOWACKA, AND P. M. BLACK. Messenger ribonucleic acid expression of platelet-derived growth factor subunits and receptors in pituitary adenomas. J. Clin. Endocrinol. Metab. 79: 51-55, 1994[Abstract]. |
| 269. | LEVÉEN, P., C. BETSHOLTZ, AND B. WESTERMARK. Negative trans-acting mechanisms controlling expression of platelet-derived growth factor A and B mRNA in somatic cell hybrids. Exp. Cell Res. 207: 283-289, 1993[Medline]. |
| 270. |
LEVÉEN, P.,
M. PEKNY,
S. GEBRE-MEDHIN,
B. SWOLIN,
E. LARSSON, AND C. BETSHOLTZ.
Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities.
Genes Dev.
8: 1875-1887, 1994 |
| 271. |
LEVITZKI, A., AND A. GAZIT.
Tyrosine kinase inhibition: an approach to drug development.
Science
267: 1782-1788, 1995 |
| 272. |
LI, W.,
R. NISHIMURA,
A. KASHISHIAN,
A. G. BATZER,
W. J. H. KIM,
J. A. COOPER, AND J. SCHLESSINGER.
A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase.
Mol. Cell. Biol.
14: 509-517, 1994 |
| 273. |
LIANG, Y.,
D. F. ROBINSON,
J. DENNIG,
G. SUSKE, AND W. E. FAHL.
Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors.
J. Biol. Chem.
271: 11792-11797, 1996 |
| 274. | LIANG, Y., D. F. ROBINSON, G. C. KUJOTH, AND W. E. FAHL. Functional analysis of the SIS proximal element and its activating factors: regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells. Oncogene 13: 863-871, 1996[Medline]. |
| 275. | LIAPIS, H., H. YU, A. FLATH, AND G. F. STEINHARDT. Increased expression of platelet-derived growth factor A and collagenous matrix proteins in congenital multicystic renal dysplasia. Nephron 76: 161-170, 1997[Medline]. |
| 276. | LIBBY, P., R. N. SALOMON, D. D. PAYNE, F. J. SCHOEN, AND J. S. POBER. Functions of vascular vessel wall cells related to the development of transplantation-associated coronary arteriosclerosis. Transplant. Proc. 21: 3677-3684, 1989[Medline]. |
| 277. | LIBBY, P., S. J. WARNER, R. N. SALOMON, AND L. K. BIRINYI. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N. Engl. J. Med. 318: 1493-1498, 1988[Abstract]. |
| 278. |
LIN, X.-H.,
C. GUO,
L. J. GU, AND T. F. DEUEL.
Site-specific methylation inhibits transcriptional activity of platelet-derived growth factor A-chain promoter.
J. Biol. Chem.
268: 17334-17340, 1993 |
| 279. |
LINDAHL, P.,
B. R. JOHANSSON,
P. LEVÉEN, AND C. BETSHOLTZ.
Pericyte loss and microaneurysm formation in PDGF-B-deficient mice.
Science
277: 242-245, 1997 |
| 280. | LINDAHL, P., L. KARLSSON, M. HELLSTRÖM, S. GEBRE-MEDHIN, K. WILLETTS, J. K. HEATH, AND C. BETSHOLTZ. Alveogenesis failure in PDGF-A-deficient mice is coupled to lack of distal spreading of alveolar smooth muscle cell progenitors during lung development. Development 124: 3943-3953, 1997[Abstract]. |
| 281. |
LINDROOS, P. M.,
P. G. COIN,
A. R. OSORNIO-VARGAS, AND J. C. BONNER.
Interleukin 1 (IL-1 ) and the IL-1 - 2-macroglobulin complex upregulate the platelet-derived growth factor -receptor on rat pulmonary fibroblasts.
Am. J. Respir. Cell Mol. Biol.
13: 455-465, 1995[Abstract].
|
| 282. |
LIU, B.,
R. S. MAUL, AND D. M. KAETZEL, JR
Repression of platelet-derived growth factor A-chain gene transcription by an upstream silencer element. Participation by sequence-specific single-stranded DNA-binding proteins.
J. Biol. Chem.
271: 26281-26290, 1996 |
| 283. |
LIU, J.-Y.,
G. F. MORRIS,
W.-H. LEI,
C. E. HART,
J. A. LASKY, AND A. R. BRODY.
Rapid activation of PDGF-A and -B expression at sites of lung injury in asbestos-exposed rats.
Am. J. Respir. Cell Mol. Biol.
17: 129-140, 1997 |
| 284. |
LIU, P.,
Y. YING,
Y.-G. KO, AND R. G. W. ANDERSON.
Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae.
J. Biol. Chem.
271: 10299-10303, 1996 |
| 285. |
LOKKER, N. A.,
J. P. O'HARE,
A. BARSOUMIAN,
J. E. TOMLINSON,
V. RAMAKRISHNAN,
L. J. FRETTO, AND N. A. GIESE.
Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies.
J. Biol. Chem.
272: 33037-33044, 1997 |
| 286. | LUSTIG, F., J. HOEBEKE, G. STERGREN-LUNDÈN, F. VELGE-ROUSSEL, G. BONDJERS, U. OLSSON, U. RÜETSCHI, AND G. FAGER. Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans. Biochemistry 35: 12077-12085, 1996[Medline]. |
| 287. | LYNCH, S. E., G. R. DE CASTILLA, R. C. WILLIAMS, C. P. KIRITSY, T. H. HOWELL, M. S. REDDY, AND H. N. ANTONIADES. The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. J. Periodontol. 62: 458-467, 1991[Medline]. |
| 288. |
MAHADEVAN, D.,
J.-C. YU,
J. W. SALDANHA,
N. THANKI,
P. McPHIE,
A. UREN,
W. J. LAROCHELLE, AND M. A. HEIDARAN.
Structural role of extracellular domain 1 of -platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding.
J. Biol. Chem.
270: 27595-27600, 1995 |
| 289. |
MAJESKY, M. W.,
M. A. REIDY,
D. F. BOWEN-POPE,
C. E. HART,
J. N. WILCOX, AND S. M. SCHWARTZ.
PDGF ligand and receptor gene expression during repair of arterial injury.
J. Cell Biol.
111: 2149-2158, 1990 |
| 290. | MARDEN, L. J., R. S. P. FAN, G. F. PIERCE, A. H. REDDI, AND J. O. HOLLINGER. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J. Clin. Invest. 92: 2897-2905, 1993. |
| 291. |
MARESTA, A.,
M. BALDUCELLI,
L. CANTINI,
A. CASARI,
R. CHIOIN,
M. FABBRI,
A. FONTANELLI,
P. A. MONICI PRETI,
S. REPETTO,
S. DE SERVI, AND E. VARANI.
Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study.
Circulation
90: 2710-2715, 1994 |
| 292. | MARTINET, Y., P. B. BITTERMAN, J.-F. MORNEX, G. R. GROTENDORST, G. R. MARTIN, AND R. G. CRYSTAL. Activated human monocytes express the c-sis proto-oncogene and release a mediator showing PDGF-like activity. Nature 319: 158-160, 1986[Medline]. |
| 293. | MARTINS, R. N., J. O. CHLEBOUN, P. SELLERS, M. SLEIGH, AND J. MUIR. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors 10: 299-306, 1994[Medline]. |
| 294. | MARX, M., R. A. PERLMUTTER, AND J. A. MADRI. Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J. Clin. Invest. 93: 131-139, 1994. |
| 295. |
MATSUI, T.,
M. HEIDARAN,
T. MIKI,
M. TORU,
N. POPESCU,
W. LA ROCHELLE,
M. KRAUS,
J. PIERCE, AND S. A. AARONSON.
Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes.
Science
243: 800-803, 1989 |
| 296. |
MATSUI, T.,
J. H. PIERCE,
T. P. FLEMING,
J. S. GREENBERGER,
W. J. LAROCHELLE,
M. RUGGIERO, AND S. A. AARONSON.
Independent expression of human or platelet-derived growth factor receptor cDNAs in a naive hematopoietic cell leads to functional coupling with mitogenic and chemotactic signaling pathways.
Proc. Natl. Acad. Sci. USA
86: 8314-8318, 1989 |
| 297. | MAXWELL, M., S. P. NABER, H. J. WOLFE, T. GALANOPOULOS, E. T. HEDLEY-WHYTE, P. M. BLACK, AND H. N. ANTONIADES. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J. Clin. Invest. 86: 131-140, 1990. |
| 298. |
MEISENHELDER, J.,
P.-G. SUH,
S. G. RHEE, AND T. HUNTER.
Phospholipase C- is a substrate for the PDGF and EGF receptor protein tyrosine kinases in vivo and in vitro.
Cell
57: 1109-1122, 1989[Medline].
|
| 299. |
MENDOZA, A. E.,
R. YOUNG,
S. H. ORKIN, AND T. COLLINS.
Increased platelet-derived growth factor A-chain expression in human uterine smooth muscle cells during the physiologic hypertrophy of pregnancy.
Proc. Natl. Acad. Sci. USA
87: 2177-2181, 1990 |
| 300. |
MERCOLA, M.,
D. A. MELTON, AND C. D. STILES.
Platelet-derived growth factor A chain is maternally encoded in Xenopus embryos.
Science
241: 1223-1225, 1988 |
| 301. | MITLAK, B. H., R. D. FINKELMAN, E. L. HILL, J. LI, B. MARTIN, T. SMITH, M. D'ANDREA, H. N. ANTONIADES, AND S. E. LYNCH. The effect of systemically administered PDGF-BB on the rodent skeleton. J. Bone Miner. Res. 11: 238-247, 1996[Medline]. |
| 302. |
MIYAZAWA, K.,
G. BÄCKSTRÖM,
O. LEPPÄNEN,
C. PERSSON,
C. WERNSTEDT,
U. HELLMAN,
C.-H. HELDIN, AND A. ÖSTMAN.
Role of immunoglobulin-like domains 2-4 of the platelet-derived growth factor -receptor in ligand-receptor complex assembly.
J. Biol. Chem.
273: 25495-25502, 1998 |
| 303. | MOHAMMADI, M., I. DIKIC, A. SOROKIN, W. H. BURGESS, M. JAYE, AND J. SCHLESSINGER. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16: 977-989, 1996[Abstract]. |
| 304. |
MONDY, J. S.,
V. LINDNER,
J. K. MIYASHIRO,
B. C. BERK,
R. H. DEAN, AND R. L. GEARY.
Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo.
Circ. Res.
81: 320-327, 1997 |
| 305. |
MOONEY, R. A.,
G. G. FREUND,
B. A. WAY, AND K. L. BORDWELL.
Expression of a transmembrane phosphotyrosine phosphatase inhibits cellular response to platelet-derived growh factor and insulin-like growth factor-1.
J. Biol. Chem.
267: 23443-23446, 1992 |
| 306. |
MORI, S.,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Ligand-induced polyubiquitination of the platelet-derived growth factor -receptor.
J. Biol. Chem.
267: 6429-6434, 1992 |
| 307. |
MORI, S.,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Ligand-induced ubiquitination of the platelet-derived growth factor -receptor plays a negative regulatory role in its mitogenic signaling.
J. Biol. Chem.
268: 577-583, 1993 |
| 308. |
MORI, S.,
L. RÖNNSTRAND,
L. CLAESSON-WELSH, AND C.-H. HELDIN.
A tyrosine residue in the juxtamembrane segment of the platelet-derived growth factor -receptor is critical for ligand-mediated endocytosis.
J. Biol. Chem.
269: 4917-4921, 1994 |
| 309. |
MORI, S.,
K. TANAKA,
S. OMURA, AND Y. SAITO.
Degradation process of ligand-stimulated platelet-derived growth factor -receptor involves ubiquitin-proteasome proteolytic pathway.
J. Biol. Chem.
270: 29447-29452, 1995 |
| 310. | MORNEX, J.-F., Y. MARTINET, K. YAMAUCHI, P. B. BITTERMAN, G. R. GROTENDORST, A. CHYTIL-WEIR, G. R. MARTIN, AND R. G. CRYSTAL. Spontaneous expression of the c-sis gene and release of a platelet-derived growth factor-like molecule by human alveolar macrophages. J. Clin. Invest. 78: 61-66, 1986. |
| 311. | MORRISON-GRAHAM, K., G. C. SCHATTEMAN, T. BORK, D. F. BOWEN-POPE, AND J. A. WESTON. A PDGF receptor mutant in the mouse (Patch) perturbs the development of a non-neuronal subset of neural crest-derived cells. Development 115: 133-142, 1992[Abstract]. |
| 312. |
MOSSELMAN, S.,
L. H. LOOIJENGA,
A. J. GILLIS,
M. A. VAN ROOIJEN,
H. J. KRAFT,
E. J. VAN ZOELEN, AND J. W. OOSTERHUIS.
Aberrant platelet-derived growth factor -receptor transcript as a diagnostic marker for early human germ cell tumors of the adult testis.
Proc. Natl. Acad. Sci. USA
93: 2884-2888, 1996 |
| 313. |
MULLER, Y. A.,
B. LI,
H. W. CHRISTINGER,
J. A. WELLS,
B. C. CUNNINGHAM, AND A. M. DE VOS.
Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.
Proc. Natl. Acad. Sci. USA
94: 7192-7197, 1997 |
| 314. |
MULLINS, D. E.,
F. HAMUD,
R. REIM, AND H. R. DAVIS.
Inhibition of PDGF receptor binding and PDGF-stimulated biological activity in vitro and of intimal lesion formation in vivo by 2-bromomethyl-5-chlorobenzene sulfonylphthalimide.
Arterioscler. Thromb.
14: 1047-1055, 1994 |
| 315. |
MURRAY-RUST, J.,
N. Q. McDONALD,
T. L. BLUNDELL,
M. HOSANG,
C. OEFNER,
F. WINKLER, AND R. A. BRADSHAW.
Topological similarities in TGF- 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors.
Structure
1: 153-159, 1993[Medline].
|
| 316. | MUSTOE, T. A., G. F. PIERCE, C. MORISHIMA, AND T. F. DEUEL. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest. 87: 694-703, 1991. |
| 317. |
NABEL, E. G.,
L. SHUM,
V. J. POMPILI,
Z. YANG,
H. SAN,
H. B. SHU,
S. LIPTAY,
L. GOLD,
D. GORDON,
R. DERYNCK, AND G. J. NABEL.
Direct transfer of transforming growth factor 1 gene into arteries stimulates fibrocellular hyperplasia.
Proc. Natl. Acad. Sci. USA
90: 10759-10763, 1993 |
| 318. |
NAKANO, T.,
E. W. RAINES,
J. A. ABRAHAM,
F. G. WENZEL IV,
S. HIGASHIYAMA,
M. KLAGSBRUN, AND R. ROSS.
Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells.
J. Biol. Chem.
268: 22941-22947, 1993 |
| 319. |
NALDINI, L.,
E. VIGNA,
R. FERRACINI,
P. LONGATI,
L. GANDINO,
M. PRAT, AND P. M. COMOGLIO.
The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation.
Mol. Cell. Biol.
11: 1793-1803, 1991 |
| 320. | NASH, T. J., C. R. HOWLETT, C. MARTIN, J. STEELE, K. A. JOHNSON, AND D. J. HICKLIN. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 15: 203-208, 1994[Medline]. |
| 321. | NICOSIA, R. F., S. V. NICOSIA, AND M. SMITH. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-I promote rat aortic angiogenesis in vitro. Am. J. Pathol. 145: 1023-1029, 1994[Abstract]. |
| 322. |
NIEMIR, Z. I.,
H. STEIN,
I. L. NORONHA,
C. KRÜGER,
K. ANDRASSY,
E. RITZ, AND R. WALDHERR.
PDGF and TGF- contribute to the natural course of human IgA glomerulonephritis.
Kidney Int.
48: 1530-1541, 1995[Medline].
|
| 323. |
NILSON, L. A., AND D. DIMAIO.
Platelet-derived growth factor receptor can mediate tumorigenic transformation by the bovine papillomavirus E5 protein.
Mol. Cell. Biol.
13: 4137-4145, 1993 |
| 324. |
NILSSON, J.,
M. SJÖLUND,
L. PALMBERG,
J. THYBERG, AND C.-H. HELDIN.
Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein.
Proc. Natl. Acad. Sci. USA
82: 4418-4422, 1985 |
| 325. | NOBLE, M., K. MURRAY, P. STROOBANT, M. D. WATERFIELD, AND P. RIDDLE. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 333: 560-562, 1988[Medline]. |
| 326. | NOBUYOSHI, M., X.-H. LIN, Y. TAKIMOTO, T. F. DEUEL, AND Z.-Y. WANG. Transcription regulation of the PDGF A-chain gene by first intron elements. Biochem. Biophys. Res. Commun. 230: 569-572, 1997[Medline]. |
| 327. | NORTON, J. A., G. R. PEPLINSKI, AND K. TSUNG. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccinia virus. Ann. Surg. 224: 555-562, 1996[Medline]. |
| 328. | OEFNER, C., A. D'ARCY, F. K. WINKLER, B. EGGIMANN, AND M. HOSANG. Crystal structure of human platelet-derived growth factor BB. EMBO J. 11: 3921-3926, 1992[Medline]. |
| 329. |
OHTA, K.,
J. NAKANO,
M. NISHIZAWA,
M. KANETA,
K. NAKAGOME,
K. MAKINO,
N. SUZUKI,
M. NAKAJIMA,
R. KAWASHIMA,
K. MANO, AND H. MIYASHITA.
Suppressive effect of antisense DNA of platelet-derived growth factor on murine pulmonary fibrosis with silica particles.
Chest
111, Suppl.: 105S-105S, 1997 |
| 330. | OKAMOTO, S., M. INDEN, M. SETSUDA, T. KONISHI, AND T. NAKANO. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am. Heart J. 123: 1439-1444, 1992[Medline]. |
| 331. |
OMURA, T.,
C.-H. HELDIN, AND A. ÖSTMAN.
Immunoglobulin-like domain 4-mediated receptor-receptor interactions contribute to platelet-derived growth factor-induced receptor dimerization.
J. Biol. Chem.
272: 12676-12682, 1997 |
| 332. |
ORR-URTREGER, A.,
M. T. BEDFORD,
M.-S. DO,
L. EISENBACH, AND P. LONAI.
Developmental expression of the receptor for platelet-derived growth factor, which is deleted in the embryonic lethal Patch mutation.
Development
115: 289-303, 1992[Abstract].
|
| 333. | ORR-URTREGER, A., AND P. LONAI. Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo. Development 115: 1045-1058, 1992[Abstract]. |
| 334. |
OSORNIO-VARGAS, A. R.,
P. M. LINDROOS,
P. G. COIN,
A. BADGETT,
N. A. HERNANDEZ-RODRIGUEZ, AND J. C. BONNER.
Maximal PDGF-induced lung fibroblast chemotaxis requires PDGF receptor- .
Am. J. Physiol.
271 (Lung Cell. Mol. Physiol. 15): L93-L99, 1996 |
| 335. |
ÖSTMAN, A.,
M. ANDERSSON,
G. BÄCKSTRÖM, AND C.-H. HELDIN.
Assignment of intrachain disulfide bonds in platelet-derived growth factor B-chain.
J. Biol. Chem.
268: 13372-13377, 1993 |
| 336. | ÖSTMAN, A., M. ANDERSSON, C. BETSHOLTZ, B. WESTERMARK, AND C.-H. HELDIN. Identification of a cell retention signal in the B-chain of platelet-derived growth factor and in the long splice version of the A-chain. Cell Regul. 2: 503-512, 1991[Medline]. |
| 337. |
ÖSTMAN, A.,
M. ANDERSSON,
U. HELLMAN, AND C.-H. HELDIN.
Identification of three amino acids in the platelet-derived growth factor (PDGF) B-chain that are important for binding to the PDGF -receptor.
J. Biol. Chem.
266: 10073-10077, 1991 |
| 338. | ÖSTMAN, A., G. BÄCKSTRÖM, N. FONG, C. BETSHOLTZ, C. WERNSTEDT, U. HELLMAN, B. WESTERMARK, P. VALENZUELA, AND C.-H. HELDIN. Expression of three recombinant homodimeric isoforms of PDGF in Saccharomyces cerevisiae: evidence for difference in receptor binding and functional activities. Growth Factors 1: 271-281, 1989[Medline]. |
| 339. |
ÖSTMAN, A.,
L. RALL,
A. HAMMACHER,
M. A. WORMSTEAD,
D. COIT,
P. VALENZUELA,
C. BETSHOLTZ,
B. WESTERMARK, AND C.-H. HELDIN.
Synthesis and assembly of a functionally active recombinant platelet-derived growth factor AB heterodimer.
J. Biol. Chem.
263: 16202-16208, 1988 |
| 340. |
ÖSTMAN, A.,
J. THYBERG,
B. WESTERMARK, AND C.-H. HELDIN.
PDGF-AA and PDGF-BB biosynthesis: proprotein processing in the Golgi complex and lysosomal degradation of PDGF-BB retained intracellularly.
J. Cell Biol.
118: 509-519, 1992 |
| 341. | OTHBERG, A., P. ODIN, A. BALLAGI, A. ÅHGREN, K. FUNA, AND O. LINDVALL. Specific effects of platelet derived growth factor (PDGF) on fetal rat and human dopaminergic neurons in vitro. Exp. Brain Res. 105: 111-122, 1995[Medline]. |
| 342. |
OUMESMAR, B. N.,
L. VIGNAIS, AND A. BARON-VAN EVERCOOREN.
Developmental expression of platelet-derived growth factor -receptor in neurons and glial cells of the mouse CNS.
J. Neurosci.
17: 125-139, 1997 |
| 343. | PALMIERI, S. L., J. PAYNE, C. D. STILES, J. D. BIGGERS, AND M. MERCOLA. Expression of mouse PDGF-A and PDGF alpha-receptor genes during pre- and post-implantation development: evidence for a developmental shift from an autocrine to a paracrine mode of action. Mech. Dev. 39: 181-191, 1992[Medline]. |
| 344. | PALMIERI, S. L., C. D. STILES, AND M. MERCOLA. In: PDGF in the Developing Embryo, edited by B. Westermark, and C. Sorg. Basel: Karger, 1993, vol. 5, p. 115-128. |
| 345. |
PANEK, R. L.,
T. K. DAHRING,
B. J. OLSZEWSKI, AND J. A. KEISER.
PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery.
Arterioscler. Thromb. Vasc. Biol.
17: 1283-1288, 1997 |
| 346. |
PANTAZIS, P.,
S. KHARBANDA,
A. S. GOUSTIN,
T. GALANOPOULOS, AND D. KUFE.
Coexpression of the genes for platelet-derived growth factor B-chain receptor and macrophage colony-stimulating factor 1 receptor during monocytic differentiation.
Proc. Natl. Acad. Sci. USA
88: 2481-2485, 1991 |
| 347. |
PATEL, B. K. R.,
L.-M. WANG,
C.-C. LEE,
W. G. TAYLOR,
J. H. PIERCE, AND W. J. LAROCHELLE.
Stat6 and Jak1 are common elements in platelet-derived growth factor and interleukin-4 signal transduction pathways in NIH 3T3 fibroblasts.
J. Biol. Chem.
271: 22175-22182, 1996 |
| 348. | PAULSSON, Y., A. HAMMACHER, C.-H. HELDIN, AND B. WESTERMARK. Possible positive autocrine feedback in the prereplicative phase of human fibroblasts. Nature 328: 715-717, 1987[Medline]. |
| 349. |
PAULSSON, Y.,
C. KARLSSON,
C.-H. HELDIN, AND B. WESTERMARK.
Density-dependent inhibitory effect of transforming growth factor- 1 on human fibroblasts involves the down-regulation of platelet-derived growth factor -receptors.
J. Cell. Physiol.
157: 97-103, 1993[Medline].
|
| 350. |
PAWSON, T., AND J. D. SCOTT.
Signaling through scaffold, anchoring, and adaptor proteins.
Science
278: 2075-2080, 1997 |
| 351. |
PECH, M.,
A. GAZIT,
P. ARNSTEIN, AND S. A. AARONSON.
Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene.
Proc. Natl. Acad. Sci. USA
86: 2693-2697, 1989 |
| 352. |
PECH, M.,
C. D. RAO,
K. C. ROBBINS, AND S. A. AARONSON.
Functional identification of regulatory elements within the promoter region of platelet-derived growth factor 2.
Mol. Cell. Biol.
9: 396-405, 1989 |
| 353. |
PETTI, L., AND D. DIMAIO.
Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells.
Proc. Natl. Acad. Sci. USA
89: 6736-6740, 1992 |
| 354. | PETTI, L., L. A. NILSON, AND D. DIMAIO. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J. 10: 845-855, 1991[Medline]. |
| 355. | PIERCE, G. F., J. V. BERG, R. RUDOLPH, J. TARPLEY, AND T. A. MUSTOE. Platelet-derived growth factor-BB and transforming growth factor beta1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am. J. Pathol. 138: 629-646, 1991[Abstract]. |
| 356. | PIERCE, G. F., T. A. MUSTOE, B. W. ALTROCK, T. F. DEUEL, AND A. THOMASON. Role of platelet-derived growth factor in wound healing. J. Cell. Biochem. 45: 319-326, 1991[Medline]. |
| 357. |
PIERCE, G. F.,
T. A. MUSTOE,
J. LINGELBACH,
V. R. MASAKOWSKI,
G. L. GRIFFIN,
R. M. SENIOR, AND T. F. DEUEL.
Platelet-derived growth factor and transforming growth factor- enhance tissue repair activities by unique mechanisms.
J. Cell Biol.
109: 429-440, 1989 |
| 358. |
PIERCE, G. F.,
T. A. MUSTOE,
R. M. SENIOR,
J. REED,
G. L. GRIFFIN,
A. THOMASON, AND T. F. DEUEL.
In vivo incisional wound healing augmented by platelet-derived growth factor and recombinant c-sis gene homodimeric proteins.
J. Exp. Med.
167: 974-987, 1988 |
| 359. | PIERCE, G. F., J. E. TARPLEY, R. M. ALLMAN, P. S. GOODE, C. M. SERDAR, B. MORRIS, T. A. MUSTOE, AND J. VANDE BERG. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am. J. Pathol. 145: 1399-1410, 1994[Abstract]. |
| 360. | PIERCE, G. F., J. E. TARPLEY, J. TSENG, J. BREADY, D. CHANG, W. C. KENNEY, R. RUDOLPH, M. C. ROBSON, J. VANDE BERG, P. REID, S. KAUFMAN, AND C. L. FARRELL. Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. J. Clin. Invest. 96: 1336-1350, 1995. |
| 361. | PIETZ, K., P. ODIN, K. FUNA, AND O. LINDVALL. Protective effect of platelet-derived growth factor against 6-hydroxydopamine-induced lesion of rat dopaminergic neurons in culture. Neurosci. Lett. 204: 101-104, 1996[Medline]. |
| 362. | PINZANI, M., L. GESUALDO, G. M. SABBAH, AND H. E. ABBOUD. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest. 84: 1786-1793, 1989. |
| 363. |
PINZANI, M.,
T. C. KNAUSS,
G. F. PIERCE,
P. HSIEH,
W. KENNEY,
G. R. DUBYAK, AND H. E. ABBOUD.
Mitogenic signals for platelet-derived growth factor isoforms in liver fat-storing cells.
Am. J. Physiol.
260 (Cell Physiol. 29): C485-C491, 1991 |
| 364. | PINZANI, M., S. MILANI, C. GRAPPONE, F. L. WEBER, JR., P. GENTILINI, AND H. E. ABBOUD. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 19: 701-707, 1994[Medline]. |
| 365. | PINZANI, M., S. MILANI, H. HERBST, R. DEFRANCO, C. GRAPPONE, A. GENTILINI, A. CALIGIURI, G. PELLEGRINI, D. V. NGO, R. G. ROMANELLI, AND P. GENTILINI. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol. 148: 785-800, 1996[Abstract]. |
| 366. |
PLUSKEY, S.,
T. J. WANDLESS,
C. T. WALSH, AND S. E. SHOELSON.
Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains.
J. Biol. Chem.
270: 2897-2900, 1995 |
| 367. | POLLOCK, R. A., AND W. D. RICHARDSON. The alternative-splice isoforms of the PDGF A-chain differ in their ability to associate with the extracellular matrix and to bind heparin in vitro. Growth Factors 7: 267-277, 1992[Medline]. |
| 368. |
POMPILI, V. J.,
D. GORDON,
H. SAN,
Z. YANG,
D. W. M. MULLER,
G. J. NABEL, AND E. G. NABEL.
Expression and function of a recombinant PDGF B gene in porcine arteries.
Arterioscler. Thromb. Vasc. Biol.
15: 2254-2264, 1995 |
| 369. |
PORFIRI, E., AND F. McCORMICK.
Regulation of epidermal growth factor receptor signaling by phosphorylation of the Ras exchange factor hSOS1.
J. Biol. Chem.
271: 5871-5877, 1996 |
| 370. | POWELL, P. P., C. C. WANG, AND R. JONES. Differential regulation of the genes encoding platelet-derived growth factor receptor and its ligand in rat lung during microvascular and alveolar wall remodeling in hyperoxia. Am. J. Respir. Cell Mol. Biol. 7: 278-285, 1992. |
| 371. | PRESTRELSKI, S. J., T. ARAKAWA, K. DUKER, W. C. KENNEY, AND L. O. NARHI. The conformational stability of a non-covalent dimer of a platelet-derived growth factor-B mutant lacking the two cysteines involved in interchain disulfide bonds. Int. J. Pept. Protein Res. 44: 357-363, 1994[Medline]. |
| 372. | PRINGLE, N. P., H. S. MUDHAR, E. J. COLLARINI, AND W. D. RICHARDSON. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development 115: 535-551, 1992[Abstract]. |
| 373. |
PRINGLE, N. P., AND W. D. RICHARDSON.
A singularity of PDGF -receptor expression in the dorsoventral axis of the neural tube may define the origin of the oligodendrocyte lineage.
Development
117: 525-533, 1993[Abstract].
|
| 374. |
RAFF, M. C.
Glial cell diversification in the rat optic nerve.
Science
243: 1450-1455, 1989 |
| 375. | RAFF, M. C., L. E. LILLIEN, W. D. RICHARDSON, J. F. BURNE, AND M. D. NOBLE. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 333: 562-565, 1988[Medline]. |
| 376. | RAFF, M. C., R. H. MILLER, AND M. NOBLE. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303: 390-396, 1983[Medline]. |
| 377. | RAINES, E. W., D. F. BOWEN-POPE, AND R. ROSS. In: Platelet-Derived Growth Factor, edited by M. B. Sporn, and A. B. Roberts. Heidelberg: Springer-Verlag, 1990, vol. 95, pt. I, p. 173-262. |
| 378. |
RAINES, E. W.,
T. F. LANE,
M.-L. IRUELA-ARISPE,
R. ROSS, AND E. H. SAGE.
The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptor.
Proc. Natl. Acad. Sci. USA
89: 1281-1285, 1992 |
| 379. |
RAINES, E. W., AND R. ROSS.
Platelet-derived growth factor. I. High yield purification and evidence for multiple forms.
J. Biol. Chem.
257: 5154-5160, 1982 |
| 380. |
RAINES, E. W., AND R. ROSS.
Compartmentalization of PDGF on extracellular binding sites dependent on exon-6-encoded sequences.
J. Cell Biol.
116: 533-543, 1992 |
| 381. | RAMAKRISHNAN, V., M.-A. ESCOBEDO, L. J. FRETTO, J. J. SEROOGY, J. E. TOMLINSON, AND D. L. WOLF. A novel monoclonal antibody dependent on domain 5 of the platelet-derived growth factor beta receptor inhibits ligand binding and receptor activation. Growth Factors 8: 253-265, 1993[Medline]. |
| 382. |
RAPPOLEE, D. A.,
C. A. BRENNER,
R. SCHULTZ,
D. MARK, AND Z. WERB.
Developmental expression of PDGF, TGF- , and TGF- genes in preimplantation mouse embryos.
Science
241: 1823-1825, 1988 |
| 383. |
RESNICK, N.,
T. COLLINS,
W. ATKINSON,
D. T. BONTHRON,
C. F. DEWEY, JR., AND M. A. GIMBRONE, JR
Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element.
Proc. Natl. Acad. Sci. USA
90: 4591-4595, 1993 |
| 384. |
REUTERDAHL, C.,
C. SUNDBERG,
K. RUBIN,
K. FUNA, AND B. GERDIN.
Tissue localization of receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans.
J. Clin. Invest.
91: 2065-2075, 1993.
|
| 385. |
REUTERDAHL, C.,
A. TINGSTRÖM,
L. TERRACIO,
K. FUNA,
C.-H. HELDIN, AND K. RUBIN.
Characterization of platelet-derived growth factor -receptor expressing cells in the vasculature of human rheumatoid synovium.
Lab. Invest.
64: 321-329, 1991[Medline].
|
| 386. | RICHARDSON, W. D., N. PRINGLE, M. J. MOSLEY, B. WESTERMARK, AND M. DUBOIS-DALCQ. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell 53: 309-319, 1988[Medline]. |
| 387. | RIESE, D. J., II, AND D. DIMAIO. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 10: 1431-1439, 1995[Medline]. |
| 388. | RISAU, W., H. DREXLER, V. MIRONOV, A. SMITS, A. SIEGBAHN, K. FUNA, AND C.-H. HELDIN. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7: 261-266, 1992[Medline]. |
| 389. | ROBBINS, K. C., H. N. ANTONIADES, S. G. DEVARE, M. W. HUNKAPILLER, AND S. A. AARONSON. Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor. Nature 305: 605-609, 1983[Medline]. |
| 390. | ROBERTS, W. M., A. T. LOOK, M. F. ROUSSEL, AND C. J. SHERR. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell 55: 655-661, 1988[Medline]. |
| 391. | ROBSON, M. C., L. G. PHILLIPS, A. THOMASON, L. E. ROBSON, AND G. F. PIERCE. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339: 23-25, 1992[Medline]. |
| 392. | RODRIGUEZ-VICIANA, P., P. H. WARNE, R. DHAND, B. VANHAESEBROECK, I. GOUT, M. J. FRY, M. D. WATERFIELD, AND J. DOWNWARD. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994[Medline]. |
| 393. |
RODT, S. Å.,
K. ÅHLÉN,
A. BERG,
K. RUBIN, AND R. K. REED.
A novel physiological function for platelet-derived growth factor-BB in rat dermis.
J. Physiol. (Lond.)
495: 193-200, 1996 |
| 393a. |
RÖNNSTRAND, L.,
A.-K. ARVIDSSON,
A. KALLIN,
C. RORSMAN,
U. HELLMAN,
U. ENGSTRÖM,
C. WERNSTEDT, AND C.-H. HELDIN.
SHP-2 binds to Tyr703 and Tyr1009 in the PDGF -receptor and mediates PDGF-induced activation of the Ras/MAP kinase pathway and chemotaxis.
Oncogene
18: 3696-3702, 1999[Medline].
|
| 394. |
RORSMAN, F.,
M. BYWATER,
T. J. KNOTT,
J. SCOTT, AND C. BETSHOLTZ.
Structural characterization of the human platelet-derived growth factor A-chain cDNA and gene: alternative exon usage predicts two different precursor proteins.
Mol. Cell. Biol.
8: 571-577, 1988 |
| 395. | ROSS, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993[Medline]. |
| 396. |
ROSS, R.,
J. GLOMSET,
B. KARIYA, AND L. HARKER.
A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro.
Proc. Natl. Acad. Sci. USA
71: 1207-1210, 1974 |
| 397. |
ROSS, R.,
J. MASUDA,
E. W. RAINES,
A. M. GOWN,
S. KATSUDA,
M. SASAHARA,
L. T. MALDEN,
H. MASUKO, AND H. SATO.
Localization of PDGF-B protein in macrophages in all phases of atherogenesis.
Science
248: 1009-1012, 1990 |
| 398. | ROZAKIS-ADCOCK, M., J. McGLADE, G. MBAMALU, G. PELICCI, R. DALY, W. LI, A. BATZER, S. THOMAS, J. BRUGGE, P. G. PELICCI, J. SCHLESSINGER, AND T. PAWSON. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360: 689-692, 1992[Medline]. |
| 399. | RUBIN, K., L. TERRACIO, L. RÖNNSTRAND, C.-H. HELDIN, AND L. KLARESKOG. Expression of platelet-derived growth factor receptors is induced on connective tissue cells during chronic synovial inflammation. Scand. J. Immunol. 27: 285-294, 1988[Medline]. |
| 400. | RUBIN, K., A. TINGSTRÖM, G. K. HANSSON, E. LARSSON, L. RÖNNSTRAND, L. KLARESKOG, L. CLAESSON-WELSH, C.-H. HELDIN, B. FELLSTRÖM, AND L. TERRACIO. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet 1: 1353-1356, 1988[Medline]. |
| 401. |
RUPP, E.,
A. SIEGBAHN,
L. RÖNNSTRAND,
C. WERNSTEDT,
L. CLAESSON-WELSH, AND C.-H. HELDIN.
A unique autophosphorylation site in the platelet-derived growth factor receptor from a heterodimeric receptor complex.
Eur. J. Biochem.
225: 29-41, 1994[Medline].
|
| 402. | RUTHERFORD, C., W. MARTIN, M. CARRIER, E. E. ÄNGGÅRD, AND G. A. A. FERNS. Endogenously elicited antibodies to platelet derived growth factor-BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit. Int. J. Exp. Pathol. 78: 21-32, 1997[Medline]. |
| 403. | RUTHERFORD, C., W. MARTIN, M. SALAME, M. CARRIER, E. ÄNGGÅRD, AND G. FERNS. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor. Atherosclerosis 130: 45-51, 1997[Medline]. |
| 404. | RUTHERFORD, R. B., C. E. NIEKRASH, J. E. KENNEDY, AND M. F. CHARETTE. Platelet-derived and insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. J. Periodont. Res. 27: 285-290, 1992[Medline]. |
| 405. | SACHINIDIS, A., R. LOCHER, J. HOPPE, AND W. VETTER. The platelet-derived growth factor isomers, PDGF-AA, PDGF-AB and PDGF-BB, induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS Lett. 272: 95-98, 1990. |
| 406. | SANO, H., K. ENGLEKA, P. MATHERN, T. HLA, L. J. CROFFORD, E. F. REMMERS, C. L. JELSEMA, E. GOLDMUNTZ, T. MACIAG, AND R. L. WILDER. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J. Clin. Invest. 91: 553-565, 1993. |
| 407. | SASAHARA, A., J. N. KOTT, M. SASAHARA, E. W. RAINES, R. ROSS, AND L. E. WESTRUM. Platelet-derived growth factor B-chain-like immunoreactivity in the developing and adult rat brain. Dev. Brain Res. 68: 41-53, 1992[Medline]. |
| 408. | SASAHARA, M., S. AMANO, H. SATO, J. G. YANG, Y. HAYASE, M. KANEKO, I. SATO, M. SUZAKI, AND F. HAZAMA. Normal developing rat brain expresses a platelet-derived growth factor B chain (c-sis) mRNA truncated at the 5' end. Oncogene 16: 1571-1578, 1998[Medline]. |
| 409. | SASAHARA, M., J. W. U. FRIES, E. W. RAINES, A. M. GOWN, L. E. WESTRUM, M. P. FROSCH, D. T. BONTHRON, R. ROSS, AND T. COLLINS. PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model. Cell 64: 217-227, 1991[Medline]. |
| 410. | SATO, N., J. G. BEITZ, J. KATO, M. YAMAMOTO, J. W. CLARK, P. CALABRESI, AND A. R. FRACKELTON, JR Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am. J. Pathol. 142: 1119-1130, 1993[Abstract]. |
| 411. | SAWUTZ, D. G., D. C. BODE, G. M. BRIGGS, J. R. REID, P. CANNIFF, L. CALDWELL, C. R. FALTYNEK, D. MILLER, J. A. DUNN, L. DE GARAVILLA, J. W. GUILES, C. WEIGELT, W. MICHNE, A. M. TREASURYWALA, AND P. J. SILVER. In vitro characterization of a novel series of platelet-derived growth factor receptor tyrosine kinase inhibitors. Biochem. Pharmacol. 51: 1631-1638, 1996[Medline]. |
| 412. |
SCARPATI, E. M., AND P. E. DICORLETO.
Identification of a thrombin response element in the human platelet-derived growth factor B-chain (c-sis) promoter.
J. Biol. Chem.
271: 3025-3032, 1996 |
| 413. |
SCHATTEMAN, G. C.,
K. MORRISON-GRAHAM,
A. VAN KOPPEN,
J. A. WESTON, AND D. F. BOWEN-POPE.
Regulation and role of PDGF receptor -subunit expression during embryogenesis.
Development
115: 123-131, 1992[Abstract].
|
| 414. | SCHLESSINGER, J. How receptor tyrosine kinases activate Ras. Trends Biochem. Sci. 18: 273-275, 1993[Medline]. |
| 415. |
SCHNELLER, M.,
K. VUORI, AND E. RUOSLAHTI.
v 3-Integrin associates with activated insulin and PDGF receptors and potentiates the biological activity of PDGF.
EMBO J.
16: 5600-5607, 1997[Medline].
|
| 416. |
SCHÖLLMANN, C.,
R. GRUGEL,
D. TATJE,
J. HOPPE,
J. FOLKMAN,
D. MARMÉ, AND H. A. WEICH.
Basic fibroblast growth factor modulates the mitogenic potency of the platelet-derived growth factor (PDGF) isoforms by specific upregulation of the PDGF receptor in vascular smooth muscle cells.
J. Biol. Chem.
267: 18032-18039, 1992 |
| 417. |
SCHÖNHERR, E.,
H. T. JÄRVELÄINEN,
L. J. SANDELL, AND T. N. WIGHT.
Effects of platelet-derived growth factor and transforming growth factor- 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells.
J. Biol. Chem.
266: 17640-17647, 1991 |
| 418. |
SEIFERT, R. A.,
C. E. HART,
P. E. PHILIPS,
J. W. FORSTROM,
R. ROSS,
M. MURRAY, AND D. F. BOWEN-POPE.
Two different subunits associate to create isoform-specific platelet-derived growth factor receptors.
J. Biol. Chem.
264: 8771-8778, 1989 |
| 419. | SEIFERT, R. A., S. M. SCHWARTZ, AND D. F. BOWEN-POPE. Developmentally regulated production of platelet-derived growth factor-like molecules. Nature 311: 669-671, 1984[Medline]. |
| 420. |
SEJERSEN, T.,
C. BETSHOLTZ,
M. SJÖLUND,
C.-H. HELDIN,
B. WESTERMARK, AND J. THYBERG.
Rat skeletal myoblasts and arterial smooth muscle cells express the gene for the A chain but not the gene for the B chain (c-sis) of platelet-derived growth factor (PDGF) and produce a PDGF-like protein.
Proc. Natl. Acad. Sci. USA
83: 6844-6848, 1986 |
| 421. | SEYMOUR, L., AND W. R. BEZWODA. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res. Treat. 32: 229-233, 1994[Medline]. |
| 422. |
SHAMAH, S. M.,
C. D. STILES, AND A. GUHA.
Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.
Mol. Cell. Biol.
13: 7203-7212, 1993 |
| 423. | SHAWVER, L. K., D. P. SCHWARTZ, E. MANN, H. CHEN, J. TSAI, L. CHU, L. TAYLORSON, M. LONGHI, S. MEREDITH, L. GERMAIN, J. S. JACOBS, C. TANG, A. ULLRICH, M. E. BERENS, E. HERSH, G. McMAHON, K. P. HIRTH, AND T. J. POWELL. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin. Cancer Res. 3: 1167-1177, 1997[Abstract]. |
| 424. | SHIMOKADO, K., E. W. RAINES, D. K. MADTES, T. B. BARRETT, E. P. BENDITT, AND R. ROSS. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell 43: 277-286, 1985[Medline]. |
| 425. |
SHINBROT, E.,
K. G. PETERS, AND L. T. WILLIAMS.
Expression of the platelet-derived growth factor receptor during organogenesis and tissue differentiation in the mouse embryo.
Dev. Dyn.
199: 169-175, 1994[Medline].
|
| 426. |
SHULMAN, T.,
F. G. SAUER,
R. M. JACKMAN,
C. N. CHANG, AND N. F. LANDOLFI.
An antibody reactive with domain 4 of the platelet-derived growth factor receptor allows BB binding while inhibiting proliferation by impairing receptor dimerization.
J. Biol. Chem.
272: 17400-17404, 1997 |
| 427. |
SHULTZ, P. J.,
P. E. DECORLETO,
B. J. SILVER, AND H. E. ABBOUD.
Mesangial cells express PDGF mRNAs and proliferate in response to PDGF.
Am. J. Physiol.
255 (Renal Fluid Electrolyte Physiol. 24): F674-F684, 1988 |
| 428. | SHURE, D., R. M. SENIOR, G. L. GRIFFIN, AND T. F. DEUEL. PDGF AA homodimers are potent chemoattractants for fibroblasts and neutrophils, and for monocytes activated by lymphocytes or cytokines. Biochem. Biophys. Res. Commun. 186: 1510-1514, 1992[Medline]. |
| 429. | SIEGBAHN, A., A. HAMMACHER, B. WESTERMARK, AND C.-H. HELDIN. Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J. Clin. Invest. 85: 916-920, 1990. |
| 430. |
SILVER, B. J.,
F. E. JAFFER, AND H. E. ABBOUD.
Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens.
Proc. Natl. Acad. Sci. USA
86: 1056-1060, 1989 |
| 431. |
SILVERMAN, E. S.,
L. M. KHACHIGIAN,
V. LINDNER,
A. J. WILLIAMS, AND T. COLLINS.
Inducible PDGF A-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42): H1415-H1426, 1997 |
| 432. | SIMON, M.-P., F. PEDEUTOUR, N. SIRVENT, J. GROSGEORGE, F. MINOLETTI, J.-M. COINDRE, M.-J. TERRIER-LACOMBE, N. MANDAHL, R. D. CRAVER, N. BLIN, G. SOZZI, C. TURC-CAREL, K. P. O'BRIEN, D. KEDRA, I. FRANSSON, C. GUILBAUD, AND J. P. DUMANSKI. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genet. 15: 95-98, 1997[Medline]. |
| 433. |
SIROIS, M. G.,
M. SIMONS, AND E. R. EDELMAN.
Antisense oligonucleotide inhibition of PDGF- receptor subunit expression directs suppression of intimal thickening.
Circulation
95: 669-676, 1997 |
| 434. | SMITS, A., K. FUNA, F. S. VASSBOTN, M. BEAUSANG-LINDER, F. AF EKENSTAM, C.-H. HELDIN, B. WESTERMARK, AND M. NISTÉR. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am. J. Pathol. 140: 639-648, 1992[Abstract]. |
| 435. | SMITS, A., M. HERMANSON, M. NISTÉR, I. KARNUSHINA, C.-H. HELDIN, B. WESTERMARK, AND K. FUNA. Rat brain capillary endothelial cells express functional PDGF B-type receptors. Growth Factors 2: 1-8, 1989[Medline]. |
| 436. |
SMITS, A.,
M. KATO,
B. WESTERMARK,
M. NISTÉR,
C.-H. HELDIN, AND K. FUNA.
Neurotrophic activity of platelet-derived growth factor (PDGF): rat neuronal cells possess functional PDGF -type receptors and respond to PDGF.
Proc. Natl. Acad. Sci. USA
88: 8159-8163, 1991 |
| 437. |
SMITS, A.,
D. VAN GRIEKEN,
M. HARTMAN,
U. LENDAHL,
K. FUNA, AND M. NISTÉR.
Coexpression of platelet-derived growth factor and receptors on medulloblastomas and other primitive neuroectodermal tumors is consistent with an immature stem cell and neuronal derivation.
Lab. Invest.
74: 188-198, 1996[Medline].
|
| 438. | SNYDER, L. S., M. I. HERTZ, M. S. PETERSON, K. R. HARMON, W. A. MARINELLI, C. A. HENKE, J. R. GREENHECK, B. CHEN, AND P. B. BITTERMAN. Acute lung injury. Pathogenesis of intra-alveolar fibrosis. J. Clin. Invest. 88: 663-673, 1991. |
| 439. | SOMA, Y., V. DVONCH, AND G. R. GROTENDORST. Platelet-derived growth factor AA homodimer is the predominant isoform in human platelets and acute human wound fluid. FASEB J. 6: 2996-3001, 1992[Abstract]. |
| 440. |
SOMASUNDARAM, R., AND D. SCHUPPAN.
Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB).
J. Biol. Chem.
271: 26884-26891, 1996 |
| 441. |
SORIANO, P.
Abnormal kidney development and hematological disorders in PDGF -receptor mutant mice.
Genes Dev.
8: 1888-1896, 1994 |
| 442. |
SORIANO, P.
The PDGF receptor is required for neural crest cell development and for normal patterning of the somites.
Development
124: 2691-2700, 1997[Abstract].
|
| 443. |
SORKIN, A.,
B. WESTERMARK,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF -receptor.
J. Cell Biol.
112: 469-478, 1991 |
| 444. | SOUZA, P., M. KULISZEWSKI, J. WANG, I. TSEU, A. K. TANSWELL, AND M. POST. PDGF-AA and its receptor influence early lung branching via an epithelial-mesenchymal interaction. Development 121: 2559-2567, 1995[Abstract]. |
| 445. |
SOUZA, P.,
A. K. TANSWELL, AND M. POST.
Different roles for PDGF- and - receptors in embryonic lung development.
Am. J. Respir. Cell Mol. Biol.
15: 551-562, 1996[Abstract].
|
| 446. |
SOYOMBO, A. A., AND P. E. DICORLETO.
Stable expression of human platelet-derived growth factor B chain by bovine aortic endothelial cells. Matrix association and selective proteolytic cleavage by thrombin.
J. Biol. Chem.
269: 17734-17740, 1994 |
| 447. | SPARKOWSKI, J., M. MENSE, J. ANDERS, AND R. SCHLEGEL. E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16-kilodalton protein binding and platelet-derived growth factor receptor binding and phosphorylation. J. Virol. 70: 2420-2430, 1996[Abstract]. |
| 448. | SPRITZ, R. A., K. M. STRUNK, S. T. LEE, J. M. LU-KUO, D. C. WARD, D. LE PASLIER, M. R. ALTHERR, T. E. DORMAN, AND D. T. MOIR. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 22: 431-436, 1994[Medline]. |
| 449. | SPRUGEL, K. H., J. M. McPHERSON, A. W. CLOWES, AND R. ROSS. Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers. Am. J. Pathol. 129: 601-613, 1987[Abstract]. |
| 450. | STAEBLER, A., J. H. PIERCE, S. BRAZINSKI, M. A. HEIDARAN, W. Q. LI, R. SCHLEGEL, AND D. J. GOLDSTEIN. Mutational analysis of the beta-type platelet-derived growth factor receptor defines the site of interaction with the bovine papillomavirus type 1 E5 transforming protein. J. Virol. 69: 6507-6517, 1995[Abstract]. |
| 451. | STEED, D. L. THE DIABETIC ULCER STUDY GROUP. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J. Vasc. Surg. 21: 71-81, 1995[Medline]. |
| 452. | STEIN, D., J. WU, S. A. W. FUQUA, C. ROONPRAPUNT, V. YAJNIK, P. D'EUSTACHIO, J. J. MOSKOW, A. M. BUCHBERG, C. K. OSBORNE, AND B. MARGOLIS. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 13: 1331-1340, 1994[Medline]. |
| 453. |
STEPHENSON, D. A.,
M. MERCOLA,
E. ANDERSON,
C. WANG,
C. D. STILES,
D. F. BOWEN-POPE, AND V. M. CHAPMAN.
Platelet-derived growth factor -subunit gene (Pdgfra) is deleted in the mouse patch (Ph) mutation.
Proc. Natl. Acad. Sci. USA
88: 6-10, 1991 |
| 454. | STOKOE, D., AND F. McCORMICK. Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro. EMBO J. 16: 2384-2396, 1997[Medline]. |
| 455. | STÜRZL, M., H. BRANDSTETTER, C. ZIETZ, B. EISENBURG, G. RAIVICH, D. P. GEARING, N. H. BROCKMEYER, AND P. H. HOFSCHNEIDER. Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene 10: 2007-2016, 1995[Medline]. |
| 456. | SU, Y. C., J. HAN, S. XU, M. COBB, AND E. Y. SKOLNIK. NIK is a new Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/JNK cascade via a conserved regulatory domain. EMBO J. 16: 1279-1290, 1997[Medline]. |
| 457. | SUNDBERG, C., M. BRANTING, B. GERDIN, AND K. RUBIN. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma: transfer of platelet-derived growth factor-AB/BB to stromal cells. Am. J. Pathol. 151: 479-492, 1997[Abstract]. |
| 458. |
SUNDBERG, C.,
M. LJUNGSTRÖM,
G. LINDMARK,
B. GERDIN, AND K. RUBIN.
Microvascular pericytes express platelet-derived growth factor- receptors in human healing wounds and colorectal adenocarcinoma.
Am. J. Pathol.
143: 1377-1388, 1993[Abstract].
|
| 459. |
SUNDBERG, C., AND K. RUBIN.
Stimulation of 1 integrins on fibroblasts induces PDGF independent tyrosine phosphorylation of PDGF -receptors.
J. Cell Biol.
132: 741-752, 1996 |
| 460. |
SWAN, D. C.,
O. W. McBRIDGE,
K. C. ROBBINS,
D. A. KEITHLEY,
E. P. REDDY, AND S. A. AARONSON.
Chromosomal mapping of the simian sarcoma virus oncogene analogue in human cells.
Proc. Natl. Acad. Sci. USA
79: 4691-4695, 1982 |
| 461. | TAKIMOTO, Y., AND A. KURAMOTO. Mechanism of regulation of PDGF-A chain gene expression by serum and TPA. Biochim. Biophys. Acta 1260: 176-182, 1995[Medline]. |
| 462. |
TANAKA, S.,
T. OUCHI, AND H. HANAFUSA.
Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G.
Proc. Natl. Acad. Sci. USA
94: 2356-2361, 1997 |
| 463. | TANG, W. W., T. R. ULICH, D. L. LACEY, D. C. HILL, M. QI, S. A. KAUFMAN, G. Y. VAN, J. E. TARPLEY, AND J. S. YEE. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am. J. Pathol. 148: 1169-1180, 1996[Abstract]. |
| 464. | TAVERNA, D., B. GRONER, AND N. E. HYNES. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Cell Growth & Differentiation 2: 145-154, 1991[Abstract]. |
| 465. |
TERRACIO, L.,
L. RÖNNSTRAND,
A. TINGSTRÖM,
K. RUBIN,
L. CLAESSON-WELSH,
K. FUNA, AND C.-H. HELDIN.
Induction of platelet-derived growth factor receptor expression in smooth muscle cells and fibroblasts upon tissue culturing.
J. Cell Biol.
107: 1947-1957, 1988 |
| 466. |
TIESMAN, J., AND C. E. HART.
Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma.
J. Biol. Chem.
268: 9621-9628, 1993 |
| 467. | TODO, T., E. F. ADAMS, R. FAHLBUSCH, T. DINGERMANN, AND H. WERNER. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J. Neurosurg. 84: 852-858, 1996[Medline]. |
| 468. |
TSUKAMOTO, T.,
T. MATSUI,
H. NAKATA,
M. ITO,
T. NATAZUKA,
M. FUKASE, AND T. FUJITA.
Interleukin-1 enhances the response of osteoblasts to platelet-derived growth factor through the receptor-specific up-regulation.
J. Biol. Chem.
266: 10143-10147, 1991 |
| 469. | UCHIDA, K., M. SASAHARA, N. MORIGAMI, F. HAZAMA, AND M. KINOSHITA. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 124: 9-23, 1996[Medline]. |
| 470. |
UEBELHOER, M.,
B. BEWIG,
H. KREIPE,
D. NOWAK,
H. MAGNUSSEN, AND J. BARTH.
Modulation of fibroblast activity in histiocytosis X by platelet-derived growth factor.
Chest
107: 701-705, 1995 |
| 471. | UEDA, M., A. E. BECKER, N. KASAYUKI, A. KOJIMA, Y. MORITA, AND S. TANAKA. In situ detection of platelet-derived growth factor-A and -B chain mRNA in human coronary arteries after percutaneous transluminal coronary angioplasty. Am. J. Pathol. 149: 831-843, 1996[Abstract]. |
| 472. |
UHRBOM, L.,
G. HESSELAGER,
M. NISTÉR, AND B. WESTERMARK.
Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus.
Cancer Res.
58: 5275-5279, 1998 |
| 473. |
VALGEIRSDÓTTIR, S.,
A. ERIKSSON,
M. NISTÉR,
C.-H. HELDIN,
B. WESTERMARK, AND L. CLAESSON-WELSH.
Compartmentalization of autocrine signal transduction pathways in Sis-transformed NIH 3T3 cells.
J. Biol. Chem.
270: 10161-10170, 1995 |
| 474. |
VALGEIRSDÓTTIR, S.,
K. PAUKKU,
O. SILVENNOINEN,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF -receptor juxtamembrane and kinase insert domains.
Oncogene
16: 505-515, 1998[Medline].
|
| 475. | VAN DER GEER, P., M. HENKEMEYER, T. JACKS, AND T. PAWSON. Aberrant Ras regulation and reduced p190 tyrosine phosphorylation in cells lacking p120-Gap. Mol. Cell. Biol. 17: 1840-1847, 1997[Abstract]. |
| 476. | VANHAESEBROECK, B., S. J. LEEVERS, G. PANAYOTOU, AND M. D. WATERFIELD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22: 267-272, 1997[Medline]. |
| 477. |
VANHEE, D.,
P. GOSSET,
B. WALLAERT,
C. VOISIN, AND A. B. TONNEL.
Mechanisms of fibrosis in coal workers' pneumoconiosis. Increased production of platelet-derived growth factor, insulin-like growth factor type I, and transforming growth factor and relationship to disease severity.
Am. J. Respir. Crit. Care Med.
150: 1049-1055, 1994[Abstract].
|
| 478. |
VASSBOTN, F. S.,
O. K. HAVNEN,
C.-H. HELDIN, AND H. HOLMSEN.
Negative feedback regulation of human platelets via autocrine activation of the platelet-derived growth factor -receptor.
J. Biol. Chem.
269: 13874-13879, 1994 |
| 479. | VASSBOTN, F. S., A. ÖSTMAN, N. LANGELAND, H. HOLMSEN, B. WESTERMARK, C.-H. HELDIN, AND M. NISTÉR. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J. Cell. Physiol. 158: 381-389, 1994[Medline]. |
| 480. | VERSNEL, M. A., M. HAARBRINK, A. W. LANGERAK, L. P. DE, A. HAGEMEIJER, T. H. VAN DER KWAST, D. B.-B. L. VAN, AND P. I. SCHRIER. Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo. Cancer Genet. Cytogenet. 73: 60-64, 1994[Medline]. |
| 481. | VESALUOMA, M., A.-M. TEPPO, C. GRÖNHAGEN-RISKA, AND T. TERVO. Platelet-derived growth factor-BB (PDGF-BB) in tear fluid: a potential modulator of corneal wound healing following photorefractive keratectomy. Curr. Eye Res. 16: 825-831, 1997[Medline]. |
| 482. | VIGNAIS, M.-L., H. B. SADOWSKI, D. WATLING, N. C. ROGERS, AND M. GILMAN. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol. Cell. Biol. 16: 1759-1769, 1996[Abstract]. |
| 483. | VIGNAUD, J.-M., M. ALLAM, N. MARTINET, M. PECH, F. PLENAT, AND Y. MARTINET. Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstitial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene. Am. J. Respir. Cell. Mol. Biol. 5: 531-538, 1991. |
| 484. | VIKJAER, D., S. BLOM, E. HJØRTING-HANSEN, AND E. M. PINHOLT. Effect of platelet-derived growth factor-BB on bone formation in calvarial defects: an experimental study in rabbits. Eur. J. Oral Sci. 105: 59-66, 1997[Medline]. |
| 485. |
WAHL, M. I.,
S. NISHIBE,
J. W. KIM,
H. KIM,
S. G. RHEE, AND G. CARPENTER.
Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C- in intact HSC-1 cells.
J. Biol. Chem.
265: 3944-3948, 1990 |
| 486. |
WALKER, L. N.,
D. F. BOWEN-POPE,
R. ROSS, AND M. A. REIDY.
Production of PDGF-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury.
Proc. Natl. Acad. Sci. USA
83: 7311-7315, 1986 |
| 487. | WALSH, J., M. ABSHER, AND J. KELLEY. Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am. J. Respir. Cell. Mol. Biol. 9: 637-644, 1993. |
| 488. |
WANG, C., AND B. SONG.
Cell-type-specific expression of the platelet-derived growth factor receptor: a role for GATA-binding protein.
Mol. Cell. Biol.
16: 712-723, 1996[Abstract].
|
| 489. |
WANG, C., AND C. D. STILES.
Platelet-derived growth factor receptor gene expression: isolation and characterization of the promoter and upstream regulatory elements.
Proc. Natl. Acad. Sci. USA
91: 7061-7065, 1994 |
| 490. |
WANG, J.,
M. D. COLTRERA, AND A. M. GOWN.
Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study.
Cancer Res.
54: 560-564, 1994 |
| 491. |
WANG, Z. Y.,
S. L. MADDEN,
T. F. DEUEL, AND F. J. RAUSCHER III.
The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene.
J. Biol. Chem.
267: 21999-22002, 1992 |
| 492. |
WANG, Z.-Y.,
N. MASAHARU,
Q.-Q. QIU,
Y. TAKIMOTO, AND T. F. DEUEL.
An S1 nuclease-sensitive region in the first intron of human platelet-derived growth factor A-chain gene contains a negatively acting cell type-specific regulatory element.
Nucleic Acids Res.
22: 457-464, 1994 |
| 493. | WEINMASTER, G., AND G. LEMKE. Cell-specific cyclic AMP-mediated induction of the PDGF receptor. EMBO J. 9: 915-920, 1990[Medline]. |
| 494. | WESTERMARK, B., AND Å. WASTESON. A platelet factor stimulating human normal glial cells. Exp. Cell Res. 98: 170-174, 1976[Medline]. |
| 495. |
WHITE, M. F.,
S. E. SHOELSON,
H. KEUTMANN, AND C. R. KAHN.
A cascade of tyrosine autophosphorylation in the -subunit activates the phosphotransferase of the insulin receptor.
J. Biol. Chem.
263: 2969-2980, 1988 |
| 496. | WIESMANN, C., G. FUH, H. W. CHRISTINGER, C. EIGENBROT, J. A. WELLS, AND A. M. DE VOS. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91: 695-704, 1997[Medline]. |
| 497. | WILCOX, J. N., K. M. SMITH, L. T. WILLIAMS, S. M. SCHWARTZ, AND D. GORDON. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J. Clin. Invest. 82: 1134-1143, 1988. |
| 498. |
WOLSWIJK, G., AND M. NOBLE.
Cooperation between PDGF and FGF converts slowly dividing O-2A adult progenitor cells to rapidly dividing cells with characteristics of O-2A perinatal progenitor cells.
J. Cell Biol.
118: 889-900, 1992 |
| 499. |
WONG, L.,
G. YAMASAKI,
R. J. JOHNSON, AND S. L. FRIEDMAN.
Induction of -platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture.
J. Clin. Invest.
94: 1563-1569, 1994.
|
| 500. |
XIE, J.-F.,
J. STROUMZA, AND D. T. GRAVES.
IL-1 down-regulates platelet-derived growth factor- receptor gene expression at the transcriptional level in human osteoblastic cells.
J. Immunol.
153: 378-383, 1994[Abstract].
|
| 501. |
XU, J., AND R. A. F. CLARK.
Extracellular matrix alters PDGF regulation of fibroblast integrins.
J. Cell Biol.
132: 239-249, 1996 |
| 502. | YAN, X.-Q., G. BRADY, AND N. N. ISCOVE. Platelet-derived growth factor (PDGF) activates primitive hematopoietic precursors (pre-CFCmulti) by up-regulating IL-1 in PDGF receptor-expressing macrophages. J. Immunol. 150: 2440-2448, 1993[Abstract]. |
| 503. | YANG, M., L. M. KHACHIGIAN, C. HICKS, C. N. CHESTERMAN, AND B. H. CHONG. Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. Thromb. Hemostasis 78: 892-896, 1997[Medline]. |
| 504. |
YAO, R., AND G. M. COOPER.
Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor.
Science
267: 2003-2006, 1995 |
| 505. | YARDEN, Y., J. A. ESCOBEDO, W.-J. KUANG, T. L. YANG-FENG, T. O. DANIEL, P. M. TREMBLE, E. Y. CHEN, M. E. ANDO, R. N. HARKINS, U. FRANCKE, V. A. FRIEND, A. ULLRICH, AND L. T. WILLIAMS. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323: 226-232, 1986[Medline]. |
| 506. | YARDEN, Y., W.-J. KUANG, T. YANG-FENG, L. COUSSENS, S. MUNEMITSU, T. J. DULL, E. CHEN, J. SCHLESSINGER, U. FRANCKE, AND A. ULLRICH. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6: 3341-3351, 1987[Medline]. |
| 507. | YEH, H.-J., K. G. RUIT, Y.-X. WANG, W. C. PARKS, W. D. SNIDER, AND T. F. DEUEL. PDGF A-chain gene is expressed by mammalian neurons during development and in maturity. Cell 64: 209-216, 1991[Medline]. |
| 508. |
YEH, H. J.,
S. I. SILOS,
Y. X. WANG,
R. J. GEORGE,
W. D. SNIDER, AND T. F. DEUEL.
Developmental expression of the platelet-derived growth factor alpha-receptor gene in mammalian central nervous system.
Proc. Natl. Acad. Sci. USA
90: 1952-1956, 1993 |
| 509. | YEH, J., AND R. OSATHANONDH. Expression of messenger ribonucleic acids encoding for basic fibroblast growth factor (FGF) and alternatively spliced FGF receptor in human fetal ovary and uterus. J. Clin. Endocrinol. Metab. 77: 1367-1371, 1993[Abstract]. |
| 510. | YI, E. S., H. LEE, S. YIN, P. PIGUET, I. SAROSI, S. KAUFMANN, J. TARPLEY, N.-S. WANG, AND T. R. ULICH. Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am. J. Pathol. 149: 539-548, 1996[Abstract]. |
| 511. |
YOKOTE, K.,
U. HELLMAN,
S. EKMAN,
Y. SAITO,
L. RÖNNSTRAND,
Y. SAITO,
C.-H. HELDIN, AND S. MORI.
Identification of Tyr-762 in the platelet-derived growth factor -receptor as the binding site for Crk proteins.
Oncogene
16: 1229-1239, 1998[Medline].
|
| 512. |
YOKOTE, K.,
B. MARGOLIS,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Grb7 is a downstream signaling component of platelet-derived growth factor - and -receptors.
J. Biol. Chem.
271: 30942-30949, 1996 |
| 513. |
YOKOTE, K.,
S. MORI,
A. SIEGBAHN,
L. RÖNNSTRAND,
C. WERNSTEDT,
C.-H. HELDIN, AND L. CLAESSON-WELSH.
Structural determinants in the platelet-derived growth factor -receptor implicated in modulation of chemotaxis.
J. Biol. Chem.
271: 5101-5111, 1996 |
| 514. | YOSHIMURA, A., K. GORDON, C. E. ALPERS, J. FLOEGE, P. PRITZL, R. ROSS, W. G. COUSER, D. F. BOWEN-POPE, AND R. J. JOHNSON. Demonstration of PDGF B-chain mRNA in glomeruli in mesangial proliferative nephritis by in situ hybridization. Kidney Int. 40: 470-476, 1991[Medline]. |
| 515. |
YU, J.-C.,
M. A. HEIDARAN,
J. H. PIERCE,
J. S. GUTKIND,
D. LOMBARDI,
M. RUGGIERO, AND S. A. AARONSON.
Tyrosine mutations within the platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signal transduction.
Mol. Cell. Biol.
11: 3780-3785, 1991 |
| 516. |
YU, J. C.,
D. MAHADEVAN,
W. J. LAROCHELLE,
J. H. PIERCE, AND M. A. HEIDARAN.
Structural coincidence of -PDGFR epitopes binding to platelet-derived growth factor-AA and a potent neutralizing monoclonal antibody.
J. Biol. Chem.
269: 10668-10674, 1994 |
This article has been cited by other articles:
![]() |
C. Sundberg, T. Friman, L. E. Hecht, C. Kuhl, and K. R. Solomon Two Different PDGF {beta}-Receptor Cohorts in Human Pericytes Mediate Distinct Biological Endpoints Am. J. Pathol., July 1, 2009; 175(1): 171 - 189. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Zemskov, E. Loukinova, I. Mikhailenko, R. A. Coleman, D. K. Strickland, and A. M. Belkin Regulation of Platelet-derived Growth Factor Receptor Function by Integrin-associated Cell Surface Transglutaminase J. Biol. Chem., June 12, 2009; 284(24): 16693 - 16703. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Schneider, C.-M. Stock, P. Dieterich, B. H. Jensen, L. B. Pedersen, P. Satir, A. Schwab, S. T. Christensen, and S. F. Pedersen The Na+/H+ exchanger NHE1 is required for directional migration stimulated via PDGFR-{alpha} in the primary cilium J. Cell Biol., April 6, 2009; 185(1): 163 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Deaton, Q. Gan, and G. K. Owens Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1027 - H1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukushima, I. Matsumura, S. Ezoe, M. Tokunaga, M. Yasumi, Y. Satoh, H. Shibayama, H. Tanaka, A. Iwama, and Y. Kanakura FIP1L1-PDGFR{alpha} Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells J. Biol. Chem., March 20, 2009; 284(12): 7719 - 7732. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Cai, J.-H. Wu, S. T. Exum, M. Oppermann, R. T. Premont, S. K. Shenoy, and N. J. Freedman Reciprocal Regulation of the Platelet-Derived Growth Factor Receptor-{beta} and G Protein-Coupled Receptor Kinase 5 by Cross-Phosphorylation: Effects on Catalysis Mol. Pharmacol., March 1, 2009; 75(3): 626 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sparwel, M. Vantler, E. Caglayan, K. Kappert, J. W.U. Fries, H. Dietrich, M. Bohm, E. Erdmann, and S. Rosenkranz Differential effects of red and white wines on inhibition of the platelet-derived growth factor receptor: impact of the mash fermentation Cardiovasc Res, March 1, 2009; 81(4): 758 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jurek, K. Amagasaki, A. Gembarska, C.-H. Heldin, and J. Lennartsson Negative and Positive Regulation of MAPK Phosphatase 3 Controls Platelet-derived Growth Factor-induced Erk Activation J. Biol. Chem., February 13, 2009; 284(7): 4626 - 4634. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Cina, P. Patel, J. C. Bethune, J. Thoma, J. C. Rodriguez-Lecompte, C. M. Hoff, L. Liu, and P. J. Margetts Peritoneal morphological and functional changes associated with platelet-derived growth factor B Nephrol. Dial. Transplant., February 1, 2009; 24(2): 448 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sabuda-Widemann, B. Grabensee, C. Schwandt, and C. Blume Mycophenolic acid inhibits the autocrine PDGF-B synthesis and PDGF-BB-induced mRNA expression of Egr-1 in rat mesangial cells Nephrol. Dial. Transplant., January 1, 2009; 24(1): 52 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Davies and N. W. Morrell Molecular Mechanisms of Pulmonary Arterial Hypertension: Role of Mutations in the Bone Morphogenetic Protein Type II Receptor Chest, December 1, 2008; 134(6): 1271 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Basciani, G. De Luca, S. Dolci, M. Brama, M. Arizzi, S. Mariani, G. Rosano, G. Spera, and L. Gnessi Platelet-Derived Growth Factor Receptor {beta}-Subtype Regulates Proliferation and Migration of Gonocytes Endocrinology, December 1, 2008; 149(12): 6226 - 6235. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yang, H. Chrisman, and C. J. Weijer PDGF signalling controls the migration of mesoderm cells during chick gastrulation by regulating N-cadherin expression Development, November 1, 2008; 135(21): 3521 - 3530. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhang, M. V. Shah, J. Yang, S. B. Nyland, X. Liu, J. K. Yun, R. Albert, and T. P. Loughran Jr. Network model of survival signaling in large granular lymphocyte leukemia PNAS, October 21, 2008; 105(42): 16308 - 16313. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Venkatesan, N. Ghosh-Choudhury, F. Das, L. Mahimainathan, A. Kamat, B. S. Kasinath, H. E. Abboud, and G. G. Choudhury Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B FASEB J, October 1, 2008; 22(10): 3469 - 3482. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ogawa, A. L. Firth, W. Yao, L. J. Rubin, and J. X.-J. Yuan Prednisolone inhibits PDGF-induced nuclear translocation of NF-{kappa}B in human pulmonary artery smooth muscle cells Am J Physiol Lung Cell Mol Physiol, October 1, 2008; 295(4): L648 - L657. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Ho, C. D. Owens, T. Longo, X. X. Sui, C. Ifantides, and M. S. Conte C-reactive protein and vein graft disease: evidence for a direct effect on smooth muscle cell phenotype via modulation of PDGF receptor-{beta} Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1132 - H1140. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamamoto, E. Fukumoto, K. Yoshizaki, T. Iwamoto, A. Yamada, K. Tanaka, H. Suzuki, S. Aizawa, M. Arakaki, K. Yuasa, et al. Platelet-derived Growth Factor Receptor Regulates Salivary Gland Morphogenesis via Fibroblast Growth Factor Expression J. Biol. Chem., August 22, 2008; 283(34): 23139 - 23149. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al. Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib Blood, August 15, 2008; 112(4): 1346 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, F. Tanaka, Y. Yoshikawa, K. Mimori, H. Inoue, K. Yanaga, and M. Mori PDGF-BB is a Novel Prognostic Factor in Colorectal Cancer Ann. Surg. Oncol., August 1, 2008; 15(8): 2129 - 2136. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Biswas, Y. Zhao, A. Nagalingam, T. W. Gardner, and L. Sandirasegarane PDGF- and Insulin/IGF-1-Specific Distinct Modes of Class IA PI 3-Kinase Activation in Normal Rat Retinas and RGC-5 Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3687 - 3698. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pang, Z. Gao, J. Yin, J. Zhang, W. Jia, and J. Ye Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E313 - E322. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De Donatis, G. Comito, F. Buricchi, M. C. Vinci, A. Parenti, A. Caselli, G. Camici, G. Manao, G. Ramponi, and P. Cirri Proliferation Versus Migration in Platelet-derived Growth Factor Signaling: THE KEY ROLE OF ENDOCYTOSIS J. Biol. Chem., July 18, 2008; 283(29): 19948 - 19956. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Schilder, M. W. Sill, R. B. Lee, T. J. Shaw, M. K. Senterman, A. J. Klein-Szanto, Z. Miner, and B. C. Vanderhyden Phase II Evaluation of Imatinib Mesylate in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study J. Clin. Oncol., July 10, 2008; 26(20): 3418 - 3425. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ammoun, C. Flaiz, N. Ristic, J. Schuldt, and C. O. Hanemann Dissecting and Targeting the Growth Factor-Dependent and Growth Factor-Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma Cancer Res., July 1, 2008; 68(13): 5236 - 5245. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perros, D. Montani, P. Dorfmuller, I. Durand-Gasselin, C. Tcherakian, J. Le Pavec, M. Mazmanian, E. Fadel, S. Mussot, O. Mercier, et al. Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 81 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jin, E. M. Hansson, S. Tikka, F. Lanner, C. Sahlgren, F. Farnebo, M. Baumann, H. Kalimo, and U. Lendahl Notch Signaling Regulates Platelet-Derived Growth Factor Receptor-{beta} Expression in Vascular Smooth Muscle Cells Circ. Res., June 20, 2008; 102(12): 1483 - 1491. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Gong and L. E. Niklason Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs) FASEB J, June 1, 2008; 22(6): 1635 - 1648. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes & Dev., May 15, 2008; 22(10): 1276 - 1312. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Petti, E. C. Ricciardi, H. J. Page, and K. A. Porter Transforming signals resulting from sustained activation of the PDGF{beta} receptor in mortal human fibroblasts J. Cell Sci., April 15, 2008; 121(8): 1172 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pinkas, B. Fisch, G. Rozansky, C. Felz, G. Kessler-Icekson, H. Krissi, S. Nitke, A. Ao, and R. Abir Platelet-derived growth factors (PDGF-A and -B) and their receptors in human fetal and adult ovaries Mol. Hum. Reprod., April 1, 2008; 14(4): 199 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.S. AI-Aql, A.S. Alagl, D.T. Graves, L.C. Gerstenfeld, and T.A. Einhorn Molecular Mechanisms Controlling Bone Formation during Fracture Healing and Distraction Osteogenesis Journal of Dental Research, February 1, 2008; 87(2): 107 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Pickett, G. S. Olsen, and M. D. Tallquist Disruption of PDGFR{alpha}-initiated PI3K activation and migration of somite derivatives leads to spina bifida Development, February 1, 2008; 135(3): 589 - 598. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Werth, D. Stuhlmann, B. Cat, H. Steinbrenner, L. Alili, H. Sies, and P. Brenneisen Stromal resistance of fibroblasts against oxidative damage: involvement of tumor cell-secreted platelet-derived growth factor (PDGF) and phosphoinositide 3-kinase (PI3K) activation Carcinogenesis, February 1, 2008; 29(2): 404 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Oganesian, L. C. Armstrong, M. M. Migliorini, D. K. Strickland, and P. Bornstein Thrombospondins Use the VLDL Receptor and a Nonapoptotic Pathway to Inhibit Cell Division in Microvascular Endothelial Cells Mol. Biol. Cell, February 1, 2008; 19(2): 563 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Croce Oncogenes and Cancer N. Engl. J. Med., January 31, 2008; 358(5): 502 - 511. [Full Text] [PDF] |
||||
![]() |
A. Siegbahn, M. Johnell, A. Nordin, M. Aberg, and T. Velling TF/FVIIa Transactivate PDGFR to Regulate PDGF-BB Induced Chemotaxis in Different Cell Types: Involvement of Src And PLC Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 135 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Floege, F. Eitner, and C. E. Alpers A New Look at Platelet-Derived Growth Factor in Renal Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 12 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nakata, N. Fujita, Y. Kitagawa, R. Okamoto, H. Ogita, and Y. Takai Regulation of Platelet-derived Growth Factor Receptor Activation by Afadin through SHP-2: IMPLICATIONS FOR CELLULAR MORPHOLOGY J. Biol. Chem., December 28, 2007; 282(52): 37815 - 37825. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Azuma, Y. Nishioka, Y. Aono, M. Inayama, H. Makino, J. Kishi, M. Shono, K. Kinoshita, H. Uehara, F. Ogushi, et al. Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1243 - 1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mottet, A. Bellahcene, S. Pirotte, D. Waltregny, C. Deroanne, V. Lamour, R. Lidereau, and V. Castronovo Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis Circ. Res., December 7, 2007; 101(12): 1237 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Qin, E. M. Rezler, V. Gokhale, D. Sun, and L. H. Hurley Characterization of the G-quadruplexes in the duplex nuclease hypersensitive element of the PDGF-A promoter and modulation of PDGF-A promoter activity by TMPyP4 Nucleic Acids Res., December 3, 2007; 35(22): 7698 - 7713. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Huang, J. B. DuHadaway, G. C. Prendergast, and L. D. Laury-Kleintop RhoB Regulates PDGFR- Trafficking and Signaling in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2597 - 2605. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Piccaluga, C. Agostinelli, A. Califano, A. Carbone, L. Fantoni, S. Ferrari, A. Gazzola, A. Gloghini, S. Righi, M. Rossi, et al. Gene Expression Analysis of Angioimmunoblastic Lymphoma Indicates Derivation from T Follicular Helper Cells and Vascular Endothelial Growth Factor Deregulation Cancer Res., November 15, 2007; 67(22): 10703 - 10710. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Xu, C. M. Kitchen, H.-K. G. Shu, and T. J. Murphy Platelet-derived Growth Factor-induced Stabilization of Cyclooxygenase 2 mRNA in Rat Smooth Muscle Cells Requires the c-Src Family of Protein-tyrosine Kinases J. Biol. Chem., November 9, 2007; 282(45): 32699 - 32709. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ali, Y. Lin, M. M. Gharibo, M. K. Gounder, M. N. Stein, T. F. Lagattuta, M. J. Egorin, E. H. Rubin, and E. A. Poplin Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors Clin. Cancer Res., October 1, 2007; 13(19): 5876 - 5882. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. U. Magnusson, C. Looman, A. Ahgren, Y. Wu, L. Claesson-Welsh, and R. L. Heuchel Platelet-Derived Growth Factor Receptor-{beta} Constitutive Activity Promotes Angiogenesis In Vivo and In Vitro Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2142 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Zemskov, I. Mikhailenko, D. K. Strickland, and A. M. Belkin Cell-surface transglutaminase undergoes internalization and lysosomal degradation: an essential role for LRP1 J. Cell Sci., September 15, 2007; 120(18): 3188 - 3199. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Dhillon, F. Peng, R. M. Ransohoff, and S. Buch PDGF Synergistically Enhances IFN-{gamma}-Induced Expression of CXCL10 in Blood-Derived Macrophages: Implications for HIV Dementia J. Immunol., September 1, 2007; 179(5): 2722 - 2730. [Abstract] [Full Text] [PDF] |
||||